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This study examines how firms learn from corporate venture capital (CVC) 
investments. A firm's CVC investments can shape its ability to explore and exploit 
new knowledge. Applying the exploration–exploitation framework of organizational 
learning in the context of CVC investments, I hypothesize that the key determinants 
of this learning process are (1) market diversification of investments (2) technological 
relatedness and (3) market relatedness between the CVC investors and investees. 
Moreover, stronger ties between corporate investors and investees are likely to 
enhance the explorative and exploitative learning benefits. Based on a sample of 516 
investor-investee pairs in the biotechnology and semiconductor industries from 1978 
to 2002, I find that investment diversification has a positive impact on explorative 
learning. The effect on this learning benefit is stronger when the duration of tie 
between the investors and investees increases. The findings suggest that both 
technological relatedness and market relatedness have a positive impact on a firm’s 
exploitative learning, and that a moderate level of technological relatedness enhances 
a corporate investor’s knowledge exploration as well. Moreover, investors and 
investees with longer duration ties benefit more from exploitative learning when 
investing in related ventures. The finding of this study provides evidence for the role 
of corporate venture capital investment in enhancing a firm’s knowledge exploration 
and exploitation.  
                   vi
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CHAPTER 1. INTRODUCTION 
 
1.1. OVERVIEW & MOTIVATION 
In most industries, a constant stream of new technologies, together with 
changing environments, globalized markets, and fierce competition produce a 
competitive environment that is best characterized by its increasing pace of change. 
Firms are faced with a transformation of existing markets and the emergence of 
completely new business opportunities. In this challenging environment, firms need 
to renew themselves by constantly absorbing new knowledge and developing 
capabilities. 
Researchers have examined a number of ways in which firms may seek external 
knowledge to acquire and develop valuable resources and capabilities for continuous 
growth. For instance, strategic alliances, mergers and acquisitions (M&A), 
university-industry partnerships and joint ventures are all different mechanisms for 
accessing external knowledge. However, investing in corporate venture capital (CVC), 
an important source of external knowledge, has only received scant attention in the 
literature. 
CVC investment refers to established firms’ participation in the private equity 
market by providing start-ups with funding in return for equity positions (Gompers 
and Lerner, 1998). During the past two decades, many large corporations have turned 
to CVC activities as a way to learn about new technologies and markets, to promote 
innovation, and to spur continuous growth (Silver, 1993; McNally, 1997; Chesbrough, 
2002; McKinsey & Co, 2003). According to the National Venture Capital Association 
(NVCA), at its peak in the year 2000, there were over 200 corporations with CVC 
investments, reaching $17 billion and representing 16% of all VC investment. 
CVC activity can be understood as a process for developing new business 
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opportunities and a process of renewal which includes recognition, understanding, and 
exploitation of new opportunities. In other words, the firm needs to explore new 
knowledge and capabilities and exploit the exiting ones. For example, the declared 
goal of Nokia Ventures, the CVC program of Nokia is to “fuel future growth and to 
boost new product and long-term business development” (Business Wire, 1998). 
Lucent Technologies CEO Rich McGinn stated that Lucent Venture Partners “will 
give us early insight into the technologies, products and companies developing 
outside Lucent's walls that can help support our current competence and future 
growth" (Lucent Technologies, 1998). 
While many companies have participated in CVC investment with the objectives 
to explore and/or exploit knowledge, some fundamental questions about how firms 
learn from CVC investment remain unanswered. Thus, this study tries to answer the 
question and is motivated by the increasing trend of CVC investment activity and its 
role in organizational learning and corporate strategy. Specifically, this study intends 
to answer the following two questions: 
1. How do different relationship characteristics relate to explorative and 
exploitative learning in the context of CVC investment? 
2. How is learning from CVC investment enhanced through its social 
network? 
The concept of explorative and exploitative learning (March, 1991) contrasts two 
types of learning activities: explorative learning emphasizes the entrepreneurial search 
for new opportunities and knowledge, while exploitative learning is more adaptive 
and risk-averse and it usually leverages existing knowledge and resources. 
Exploration activities include search, variation, risk taking, experimentation, play, 
flexibility, discovery, or innovation (March, 1991). Knowledge generated by such 
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activities is often distant from the existing knowledge base of the firm (Katila, 2002). 
Exploitative learning is a directed search emphasizing limiting variety (McGrath, 
2001), and its activities include refinement, choice, production, efficiency, selection, 
implementation, and execution (March, 1991). Organizations search by using 
knowledge that is closely related to their pre-existing knowledge bases (Helfat, 1994; 
Stuart and Podolny, 1996).  
CVC investments can promote both explorative and exploitative learning. By 
investing in new ventures, firms can explore new business opportunities and acquire 
new knowledge about emerging technologies and markets that is different from their 
existing knowledge bases. At the same time, by accessing the knowledge that their 
portfolio companies possess, firms can put the related knowledge into immediate use 
to promote the utilization and exploitation of existing capabilities. In this study, I 
develop and test hypotheses concerning the determinants of knowledge exploration 
and exploitation in CVC investments. 
 
1.2. BACKGROUND OF CVC 
1.2.1. What is CVC? 
The domain of corporate venturing can be categorized as internal venturing and 
external venturing (Sharma and Chrisman, 1999). Sharma and Chrisman defined 
internal venturing as “corporate venturing activities that result in the creation of 
organizational entities that reside within an organizational domain”. CVC investment, 
as a boundary spanning operation, belongs to another category that is labeled as 
external venturing. Sharma and Chrisman defined external venturing as “corporate 
venturing activities that result in the creation of semi-autonomous or autonomous 
organizational entities that reside outside the existing organizational domain.”  
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According to the framework of corporate venturing proposed by Keil (2001), 
external venturing activities can be further categorized into three groups: corporate 
venture capital, venturing alliances, and other agreements such as acquisitions and 
spin-offs (see Figure 1.1). CVC investments resemble the operations of traditional 
venture capital firms in regards to programs that reside at the various levels of 
corporations where investments are made in independent external companies 
(Chesbrough, 2000). CVC investment can be made directly into ventures or indirectly 
through dedicated funds or pooled funds that are managed by external venture capital 
firms (Sykes, 1990; McNally, 1997; Aernoudt and San Jose, 2003). A recent survey 
(Ernst & Young, 2002) has found that the direct investment through self-managed 
funds seems to be the most common approach and is used by 86% of companies 
surveyed. This type of CVC investment is common amongst firms seeking to enhance 
their competitive position by facilitating the acquisition and the transfer of technology, 
resources and capabilities from external sources. The process can be relatively 
informal, comprising of just a team of individuals searching for entrepreneurial and 
innovative opportunities in the market or more formal, involving the setting up of a 
dedicated unit (Ernst & Young, 2002). 
Figure 1.1. CVC as an External Corporate Venturing Mode 
 
 
Source: Keil (2001) 
Corporate Venturing 
Internal Venturing 
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In this study, I define CVC investments as an equity-link (typically minority) 
investment of corporate funds directly into start-up companies that are executed and 
controlled by a non-financial corporation1. This definition excludes investments made 
through an external fund managed by a third party, even if the investment vehicle is 
funded by and specifically designed to meet the objectives of a single investing firm. 
The definition does however include investments made in start-ups that a company 
has already spun off as independent businesses. In CVC the only limited partner is a 
corporation. Alternatively, a CVC fund can be a subsidiary of a corporation. The focus 
of this study is highlighted in the Figure 1.1. 
1.2.2. The History of CVC Investment 
Three different waves of CVC activity have been identified (Gompers and Lerner, 
1998). First, in the late 1960s, corporations participated in CVC in order to gain a 
“window of technology”. More than 25% of the Fortune 500 corporations were 
engaged in CVC in the late 1960s and early 1970s. Following the collapse in the 
market for IPO in 1973, the return on venture capital rapidly declined and most of the 
CVC programs were quickly dissolved. The second wave of CVC activity took place 
in the 1980s when it was used as a diversification tool. This wave peaked in 1986, 
when 12% of the total VC investment was managed by CVC programs. However, 
only a small number of CVC programs were successful and most of them were again 
dissolved after the crash of the stock market at the end of the 1980s. During the latter 
half of the 1990s CVC emerged again, this time in a much larger scale than ever 
before. However, following a peak in 2000, the volume of CVC investments rapidly 
declined due to the economic slowdown since 2001. The development of CVC from 
                                             
1 Detailed definition of “non-financial corporation” would be described in the research design part. 
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1995 until the first two quarters of 2004 is reported in Table 1.1. Table 1.2 lists the top 
US corporate investors in the venture capital market in the year of 2001 and 2002. 







































1995 427 8,373 5% 133 1,949 7% 124 1,613 8% 
1996 711 11,886 6% 221 2,731 8% 204 2,183 9% 
1997 1,011 15,484 7% 365 3,296 11% 332 2,645 13% 
1998 1,839 21,847 8% 538 3,781 14% 498 3,083 16% 
1999 8,555 56,144 15% 1,339 5,731 23% 1,174 4,575 26% 
2000 17,042 107,714 16% 2,170 8,294 26% 1,981 6,582 30% 
2001 5,019 42,887 12% 1,017 4,854 21% 958 4,005 24% 
2002 1,876 21,776 9% 567 3,109 18% 528 2,616 20% 
2003 1,216 18,924 6% 450 2,884 16% 424 2,383 18% 
1H04 660 10,709 6% 245 1,449 17% 235 1,364 17% 
TOTAL 38,491 320,034 12% 7,119 39,347 18% 6,527 32,068 20% 
Source: NVCA (PricewaterhouseCoopers/Thomson Venture Economics/National Venture Capital Association 
MoneyTreeTM Survey) 
 























Source: Ernst & Young Corporate Venture Capital Report (2002) 
 
2001 
Corporate Investor Name  Number of Deals  
Intel Corporation  75  
GE Capital, Equity Capital Group  41  
Johnson & Johnson Development  20  
Mitsui & Co. Venture Partners  19  
Mitsubishi  19  
Cisco Systems  18  
AOL Time Warner Ventures  17  
Texas Instruments  13  
2002 
Corporate Investor Name  Number of Deals  
Intel Corporation  24  
GE Capital, Equity Capital Group  13  
Cisco Systems  8  
Johnson & Johnson Development  6  
Dell Ventures  6  
Texas Instruments  6  
Sun Microsystems  5  
Accenture Technology Ventures  5  
Lucent Venture Partners  4  
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1.3. CONTRIBUTION 
This thesis makes three main contributions. First, this study extends our 
understanding of CVC activity by examining corporate investor’s learning benefits 
from an inter-organizational learning perspective. Previous studies on CVC have 
mainly either focus on financial returns to investing firms (e.g. Gompers and Lerner, 
1998) or examine the benefits such as IPO value from the venture’s perspective (e.g. 
Maula and Murray, 2001). Few studies have examined the learning benefits from the 
corporate investor’s perspective. Second, it contributes to inter-organizational learning 
literature by empirically examining the determinants of explorative versus 
exploitative learning outcomes in the context of CVC. Previous studies have 
examined various forms of inter-organizational learning activities such as strategic 
alliances, joint ventures and M&As, yet few studies have made a distinction between 
explorative and exploitative learning, nor rigorously investigated what factors have an 
impact on explorative versus exploitative learning outcomes. Third, this study 
enriches the literature on learning through CVC investment by integrating multiple 
perspectives from both strategic management and social network literature.  
1.4. STRUCTURE 
This study has seven chapters. Following this chapter, Chapter two provides a 
review of core literature areas that underlie the theoretical arguments of this study. In 
the third chapter I propose the research model and develop the corresponding 
hypotheses. Chapter four describes the research design including research setting, 
sources of data, measures and statistical models. Chapter five presents statistical 
analysis results and main research findings. In chapter six I discuss the findings and 
their implications. I close in chapter seven with some concluding remarks.
Chapter 2 Literature Review 
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CHAPTER 2.  LITERATURE REVIEW 
 
This chapter reviews several streams of research that underlie the key concepts 
and theoretical arguments for developing a framework of learning from CVC 
investment activities. First, I will present a literature review on CVC investment and 
its learning objective. Then, I discuss how we can extend organizational learning 
theories to establishing the learning mechanisms in corporate investment activities. 
Finally, I identify several factors that might influence the learning outcome of CVC 
investments by integrating the relevant literature on business diversification, strategic 
alliances and social network theory. The overall discussion in this chapter will provide 
the basis of hypotheses development in Chapter 3. 
 
2.1. CVC INVESTMENT AND ITS LEARNING OBJECTIVE 
2.1.1 Strategic Objectives of CVC Investment 
Extensive studies have examined the motivations for firms to form 
inter-organizational relationships. Inter-firm cooperation is motivated not only by cost 
minimization (e.g. Glaister and Buckley, 1996), access to resources (e.g. Dyer and 
Singh, 1998), and strategic positioning (Mitchell and Singh, 1992), but also driven by 
knowledge acquisition and learning (e.g. Hamel, 1991; Powell et al, 1996; Stuart, 
2000). Like other forms of inter-firm relationships, these motives are also applicable 
for firms engaging in corporate investment relationship. 
Most firms involving in CVC investment are driven by the strategic objectives 
rather than financial objectives. As the mission statement of Intel Capital declared:  
“We invest with strategic intent, aiming to create and expand new markets for 
Intel’s products. We want to stimulate growth in the internet, computing and 
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communications to grow the total internet infrastructure now and in the future. While 
financial returns are not our primary goal, we are seeking companies that can 
succeed and have an impact on their market segment.” (Intel capital, 1990) 
The literature on CVC investment is relatively scant. Previous studies have 
shown that the main reason for firms to engage in CVC activity is to achieve their 
strategic objectives rather than financial gains. For instance, Seigel et al. (1998) found 
that exposure to new technologies and markets is one of the important objectives of 
CVC investment. Sykes (1990) found that identifying new opportunities and 
developing business relationships were the most important goals for corporations 
investing directly. Similarly, Silver (1993) found in his survey that getting exposure to 
new markets, acquisition targets, adding new products to existing distribution 
channels, externalizing R&D, and utilizing excess plant space, time, and people were 
the most important objectives. McNally (1997) surveyed U.K. corporations and found 
that identifying new markets, exposure to new technologies, financial return, 
identifying new products, and developing business relationships were the five most 
important corporate objectives for direct CVC. Bannock Consulting (2000) found in 
their survey of 150 European corporations that on average 62% had strategic goals, 
and 27% had financial goals, as their primary motivations for CVC investments, while 
many had several goals. Based on seven in-depth case studies of external corporate 
venturing activities of information and communications technology corporations, Keil 
(2001) identified four primary strategic objectives: monitoring of markets, learning of 
markets and new technologies, option building, and market enactment.  
2.1.2. Learning in CVC Investment 
Motivated by the above strategic objectives, CVC plays a critical role in 
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acquiring external knowledge. CVC investment can be understood as a process of 
identifying new business opportunities as well as a process of understanding and 
exploiting the opportunities. In other words, the investing firm needs to explore new 
knowledge and capability while exploiting the existing knowledge and capability. The 
nature of exploration and exploitation in learning through CVC activity can also be 
summarized from the existing literature. 
One prevailing aspect of learning in CVC is that it allows the firm to search a 
broader space for new business opportunities. Established firms can learn from 
constantly monitoring the new ventures and, therefore, being exposed to 
developments of new technologies, markets and business models (Sykes, 1990; Silver, 
1993; McNally, 1997; Keil, 2001; Ferrary, 2003). 
As mentioned by Vadasz, Senior Vice President of Intel Capital about Intel’s 
motive to engage in CVC investment (Lane, 2000): 
“A step (we have taken) is the realization that corporate venture capital 
investment can be a good way to understand new technologies that are not today’s 
concern in the business units, but might become important in the future.” 
Corporate investors also realize their learning benefit by an indirect learning 
process from CVC activity. CVC investment has been used to change corporate 
culture and to learn about venture capital (Sykes, 1990; McNally, 1997), to support 
development of internal venturing processes (Winters and Murfin, 1988; Keil, 2001), 
and to provide contacts with related actors like investment banks, scientists and 
venture capitalists (Winters and Murfin, 1988). All these indirect learning processes 
provide the investing firm with new business opportunities. 
Besides exploration of new business opportunities, learning benefits in CVC 
investment is also realized via the exploitation of existing knowledge and capabilities 
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through three mechanisms. First, CVC allows firms to leverage their internal 
resources. For instance, corporate investors are able to utilize their existing recourses 
to develop new technologies with their invested ventures without acquiring new 
recourses (Keil, 2001). Firms can also use CVC to stimulate demands for their 
technologies and products by sponsoring companies using and applying them 
(McKinsey & Co, 1998). In addition, firms can use CVC to proactively shape markets, 
and steer and promote the development of de-facto standards around their 
technologies by supporting favorable companies (Keil, 2001).  
The objective of leveraging and exploitation in CVC investment is well 
described in the General Electric (GE) Equity’s mission statement:  
“To be a global equity provider that creates value for its customers by leveraging 
the GE system. The objective is to combine investee performance with their 
request/need and our skills and knowledge.” 
Secondly, CVC provides access to complementary capabilities that may be 
necessary to facilitate a firm’s entry into new markets or new technological fields 
(McNally, 1997) with existing resources. Also, some corporations use CVC as a form 
of external R&D to develop their knowledge bases, competencies, technologies, 
products and processes (Silver, 1993; Rice et al, 2000; Ferrary, 2003). This type of 
exploitation often requires closer collaborations and frequent communications with 
portfolio companies (Sykes, 1990; Keil, 2001; Ferrary, 2003).  
Lastly, CVC can create options to acquire the investee company for rapid entry 
into new markets or technologies. Often, the viability of competing technologies or 
the potential of markets are difficult to assess in advance. CVC provides options to 
acquire investees that enable the use of existing resources more efficiently while 
enabling the building of new capabilities more rapidly (McNally, 1997; Bannock 
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Consulting, 2000; Chesbrough, 2002). One CVC manager explains the logic of this 
acquisition activity like this (Keil, 2001): 
Over time you might want to do acquisitions to add some of the capabilities to 
your portfolio. We have done exactly this through the acquisitions of (venture 1 and 
venture 2). These were third parties that were doing something we thought was 
becoming fundamentally important to what we are doing. So we transformed that 
from being part of our value web to being part of our organization.” 
From the above review, we can conclude that learning in CVC investment can 
serve two broad functions (see Table 2.1). It allows firms to broaden their search for 
business opportunities by monitoring new technological and market development. At 
the same time, CVC investment facilitates the rapid exploitation of emerging 
opportunities. Although previous studies on CVC have provided insights on potential 
learning benefits from CVC activities, the existing literature has not provided much 
understanding about how firms learn from CVC or what factors have impact on a 
corporate investor’s learning outcome. Thus, this study intends to fill this gap in this 
aspect. 
 
Table 2.1. Learning in CVC Investment 
 
Learning Benefits Study Example 
Exposure to /forging a link with new 
technologies, markets & business 
models to spur innovation 
Winters & Murfin 1988, Silver 1993, 
McNally 1997, Bannock Consulting 
2000 





Leveraging internal resources McKinsey & Co 1998,  Keil 2001 
Access to complementary capabilities McNally 1997, Sykes 1990, Silver 1993, Rice et al 2000, Ferrary, 2003 Exploitation (Rapid Entry) 
Options to acquire companies/to enter 
new markets 
Winters & Murfin 1988, Siegel et al. 
1988, McNally 1997, Chesbrough 
2002 
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2.2. ORGANIZATIONAL LEARNING 
2.2.1. Explorative and Exploitative Learning 
Organizational learning has been defined primarily through its results, such as a 
quantifiable improvement in activities, increased available knowledge for decision 
making or sustainable competitive advantage. Organizational learning can also be 
characterized based on the various processes involved, such as the ways companies 
build routines or socialize employees into a corporate culture (Miller, 1996). Not all 
organizational learning however is the same. Two different types of organizational 
learning are commonly discussed in the literature: explorative learning and 
exploitative learning (March, 1991).  
The first type of learning is explorative learning. March (1991) described 
exploration as “experimentation with new alternatives” which involves questioning 
existing boundaries, searching and experimenting with new technologies or 
entrepreneurial opportunities for wealth creation and above average returns. 
Exploration involves innovation, basic research, invention, risk taking, building new 
capabilities, and entering new lines of business (Koza and Lewin, 1998). This type of 
learning is referred to under labels such as “double loop” (Argyris and Schön, 1996), 
“generative” (Senge, 1990), “strategic” (Coopey, 1996), “second-order” 
(Fox-Wolfgramm et al. 1998), “revolutionary”, “frame-breaking”, “proactive” (Weick 
and Westley, 1996), and “radical” (Miner and Mezias, 1996). 
The second type of learning is exploitative learning, which is defined as “the 
refinement and extension of existing competencies, technologies, and paradigms” 
(March, 1991). It is characterized as routine learning which adds to the existing 
knowledge and competencies of a firm without changing the nature of its activities 
(Hagedoorn and Duysters, 2002). Exploitation is associated with increasing the 
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productivity of employed capital and assets, standardization, and systematic cost 
reduction. It is described in the literature as “‘single-loop” (Argyris and Schön, 1996), 
“adaptive” (Senge, 1990), “operational” (Coopey, 1996), “first-order” 
(Fox-Wolfgramm et al., 1998), “evolutionary”, “frame-taking”, “reactive” (Weick and 
Westley, 1996), and “incremental” (Miner and Mezias, 1996). 
The explorative–exploitative learning framework developed by March (1991) 
highlights the different nature of learning. In comparison with exploitation, 
exploration is more experimental in nature, long-term oriented, and highly uncertain. 
However, both types of learning are believed to enhance the competitive ability of an 
organization. Levinthal and March (1993) argued that the survival of the firm is 
dependent upon the firm’s ability to “engage in enough exploitation to insure the 
organization current viability and engage in enough exploration to insure its future 
viability”. 
By applying March’s framework, the learning outcome in CVC investment (as 
described in Section 2.1) could be categorized into explorative learning and 
exploitative learning as well. Since this thesis aims to examine what are the 
determinants of the explorative and exploitative learning in CVC investment, the 
following sections review the related literature on factors influencing learning 
outcome. 
2.2.2. Absorptive Capacity  
Learning involves both transfer and assimilation of new knowledge. One of the 
most frequently discussed factors affecting knowledge transfer and assimilation in 
organizational learning is the absorptive capacity of the firm that tries to learn. Cohen 
and Levinthal (1989, 1990, and 1994) found that the ability to absorb external 
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knowledge and technologies is related to a firm’s internal research and development 
(R&D) activities in related areas. Creating related knowledge through internal R&D 
helps to identify appropriate knowledge to assimilate it and to apply it. Internal R&D 
efforts perform two functions within this process. On the one hand, the understanding 
of the knowledge is supported by related internal efforts during the search, 
assimilation, and application of knowledge. On the other hand, the R&D can create 
complementing knowledge that is necessary in order to exploit external knowledge 
(Granstrand et al, 1992).  
In particular, Cohen and Levinthal (1990) identified that the relatedness of the 
knowledge produced by the internal R&D activities affects the ease of internalizing 
external knowledge. The more related knowledge of the firm is to the knowledge to 
be assimilated, the higher the capability of the firm to understand and integrate the 
external knowledge. Researchers have reported that firms with an expertise in a given 
research domain exhibit higher levels of knowledge absorption from external sources 
(Pisano, 1991; Veugelers, 1997). The position is that in seeking and applying relevant 
knowledge, a firm needs to possess a knowledge base in the same or similar areas. It 
is only through such similarities that a firm can achieve an understanding of the new 
knowledge and its applicability to the firm’s unique circumstances.  
While Cohen and Levinthal (1990) stressed the firm-specific component of 
absorptive capacity, Lane and Lubatkin (1998), as well as Dyer and Singh (1998), 
focused on the relationship-specific component. They pointed out that firms are not 
uniformly able to develop effective knowledge assimilation with all partners. 
Partner-specific absorptive capacity may be partially a function of effective 
knowledge sharing routines between the partners. It may also be a function of similar 
or dissimilar knowledge structures within the organization (Lam, 1997). Lane and 
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Lubatkin (1998) argued that in a dyad relationship, a firm’s ability to learn from 
another firm depends on the similarity of both firms along three dimensions. These 
dimensions are firms’ knowledge bases, the organizational structures and policies, and 
the dominant logic. The authors found the similarity of the partner’s basic knowledge, 
lower management formalization, research centralization, compensation practices, and 
research communities related to inter-organizational learning. 
 
2.3. BUSINESS DIVERSIFICATION  
Literature on business diversification has examined a number of mechanisms 
through which the diversification could influence a firm’s performance, and learning 
is one of the mechanisms. Since learning involves search of new knowledge, business 
diversification could serve as a form to broaden a firm’s knowledge search scope and 
to expand its knowledge domains, and therefore enhance the firm’s learning outcome 
and performance.  
The prevailing theory of diversification draws heavily on the resource based 
view (RBV) of firms. According to the RBV, firms attempt to accumulate valuable, 
rare, inimitable and non-substitutable resources and use them in value-creating 
strategies to attain a sustainable competitive advantage (Eisenhardt and Martin 2000).  
Empirical tests have provided support for the positive relationship between 
diversification and a firm’s performance. For example, researchers found that there is 
a positive relationship between international market diversification and firm 
innovation (e.g. Hitt et al, 1997). Many other studies also have shown evidence that 
product/market diversification provide benefit to a firm’s performance (e.g. Pandya 
and Rao, 1998).  
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2.4. STRATEGIC ALLIANCES  
One significant stream of research on strategic alliances has examined the impact 
of the partnership on firms’ learning benefits and innovative performance. The 
fundamental argument is that learning involves exploration and acquisition of new 
knowledge by the organization (Kumar and Nti, 1998). By forming inter-firm 
collaboration, firms can access external knowledge and resource that are necessary for 
its development and growth.  
Many empirical studies have provided evidence of the role of alliances in firms’ 
learning benefits and performance. For instance, Kogut (1988) argued that alliances 
are formed because they help the transfer of tacit knowledge that is not easily 
transferred in arms-length relationships. Shan et al (1994) analyzed alliances of 85 
biotechnology firms finding a positive relationship between the number of strategic 
alliances and a firm’s research productivity. Later, Deeds and Hill (1996) analyzed 
alliances of 132 entrepreneurial biotechnology firms and found a curvilinear (inverted 
U shape) relationship between a start-up’s strategic alliances and its new product 
development. Hagedoorn and Schakenraad (1994) and Ahuja (2000) indicated that 
knowledge from innovative alliance partners may spillover and positively affect the 
innovativeness of a firm. Stuart (2000) showed that a firm’s patenting rates increase 
the more technologically advanced are its alliance partners. The number of strategic 
alliance not only has impact on a start-up’s learning and performance, but also has an 
impact on incumbent firms. The curvilinear relationship between an incumbent’s 
strategic alliances with providers of the new technology and the incumbent’s new 
product development is further confirmed by Rothaermel (2001). 
Baum et al. (2000), by studying the start-ups’ innovative performance in 
Canadian biotechnology, also demonstrated that alliance network composition has a 
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positive effect on biotechnology start-ups performance. Their analysis, from the 
perspective of the startup firm rather than the established firm, empirically validates 
the impact of inter-organizational arrangements on the learning benefits. Nevertheless, 
they also acknowledged that there are limitations to the usefulness of collaborative 
agreements. Specifically, the larger the number of a firm’s collaborative partners, the 
higher the risk of redundancy (i.e. the risk that different partners provide access to the 
same information or complementary knowledge; Burt, 1992; Gomes-Casseres, 1994). 
Therefore, Baum et al. (2000) came to the conclusion that it is not the amount of 
collaborative partners per se, but rather the diversity of the firm’s alliance network 
that is influencing the knowledge acquisition and innovative performance of the firm. 
Recently, researchers have started to make a distinction between the different 
kinds of inter-firm relationships by looking at the learning objectives of the 
collaborations. Applying March’s (1991) dichotomy of exploration and exploitation, 
researchers have made a distinction between explorative and exploitative alliances 
(Koza and Lewin, 1998; Rothaermel, 2001, Rothaermel and Deeds, 2004). In this way, 
it is emphasized that the firm’s choice to enter into a collaboration can be 
distinguished in terms of its motivation to exploit an existing capability with focus on 
leveraging existing skills and knowledge or to explore new opportunities (Koza and 
Lewin, 1998).  
Exploitative alliances are those partnerships where firms pool their existing 
complementary resources to generate benefits for both firms involved. The most 
common form of an exploitation alliance involves the joint maximization of 
complementary assets by sharing in the residual returns from a business activity 
(Koza and Lewin, 1998). Examples will be upstream and downstream outsourcing 
agreements, joint manufacturing, and shared distribution or service (Yoshino and 
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Rangan, 1995). Quite often efficiency and value adding is the major goal of carrying 
out the activity via an exploitative alliance (Yoshino and Rangan, 1995). Explorative 
alliances are set up to create new knowledge that can later be applied or manufactured 
by the partners either jointly or separately, or even by a third-party. Examples will be 
firms forging alliances with aims to develop new technologies or products, adopt new 
business models, and enter new market segments. Innovation and knowledge creation 
is the major goal in explorative partnerships. 
The above literature review indicates that strategic alliance plays an important 
role in a firm’s learning outcome. Therefore, when examining the determinants of 
learning in CVC investment, alliance is a necessary factor that needs to be 
incorporated to rule out the alternative explanations. 
 
2.5. SOCIAL NETWORKS  
Apart from the above strategic management perspectives, another perspective of 
examining the determinants of inter-firm learning is from the social network theory. 
In the most general terms, the concept of social networks is about the value of 
connections. The existing literature on social networks implies two basic opposing 
mechanisms of how network structure might affect an organization’s ability to 
mobilize and acquire information through one’s networks.  
The first of these is the strength of weak ties perspective associated with 
Granovetter (1973) and Burt (1992), emphasizing the opportunities to access 
information stemming from having a central brokering position within the flow of 
information. According to this view, large networks composed of heterogeneous and 
transient ties are especially valuable, because they provide organizations with a wide 
range of information and are more likely to introduce the decision makers to 
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fundamentally new and foreign ideas and insights (Granovetter, 1973; Rogers, 1995). 
A second alternative view emphasizes the strength of strong ties associated with 
Coleman (1990) and Uzzi (1996). The strong tie view argues that having a densely 
knit network makes it easier to gain support and get those who have the information 
to actually share it. Strong network ties have three defining characteristics. These are: 
(1) frequent interaction, (2) an extended history, and (3) intensity or “mutual 
confiding” (Granovetter, 1982) between the parties in the relationship (Krackhardt, 
1992). As noted, networks composed predominantly of strong ties provide less 
diverse or novel information. However, they are more likely to promote in-depth, 
two-way communications and to facilitate the exchange of detailed information 
between organizations (Uzzi, 1996). In addition, the trust and mutual identification, 
that are likely to exist when ties are strong, make it more likely that both 
organizations will share valuable information with one another and that the 
information provided will be taken into account and acted upon (Uzzi, 1996). 
Empirical research has indicated that strong tie and frequent social interaction 
are factors facilitating the knowledge transfer and learning process. For instance, 
Mowery et al. (1996) found in their analysis of 792 alliances that strong ties (i.e. 
equity joint ventures) are more likely to be used to transfer complex capabilities than 
weak ties (i.e. contract-based alliances). They also found that strong ties (i.e. bilateral 
contracts) are more effective than weaker ties (i.e. unilateral contracts) for knowledge 
transfer. Dyer and Singh (1998) indicated that social interaction facilitates the 
exchange of information and the identification of opportunities for cooperation. 
Similarly, Kale et al. (2000) found in their research on alliances of 278 U.S. 
companies that relational social capital is positively related to learning from the 
alliance partner. Examining knowledge acquisition in key customer relationships of 
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180 technology-based new firms, Yli-Renko et al (2001) found that social capital 
embedded in the key customer relationship greatly facilitates the knowledge 
acquisition from key customers. By studying the networks around managers in a large 
American electronics company, Burt (2004) also found that people connected across 
groups (i.e. having a brokerage position in the networks) tend to get new and good 
ideas. 
The existing literature on social networks implies that social networks could 
affect an organization’s ability to mobilize and acquire information and thus enhance 
its learning outcome. Therefore, we could expect this social network effect in the 
CVC investment relationship as well. Stronger ties between corporate investors and 




Existing literature on CVC investment has identified learning from new ventures 
and other investee companies as one of the most important strategic objectives for 
corporate investors. Several other streams of research such as business diversification, 
strategic alliances and social network theory have also discussed how different 
organizational factors may drive the learning outcomes stemming from an inter-firm 
relationship. However, few empirical studies on CVC investment have examined 
rigorously how corporate investors can benefit from the learning activities established 
with their investee companies. Existing studies which investigated the learning 
activities of CVC investment also did not make a distinction between knowledge 
exploration and exploitation, both of which are important learning mechanisms that 
form the knowledge base of the firm. Therefore, in the next chapter, to enhance our 
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understanding of how corporate investors learn from their investee companies, I will 
integrate multiple perspectives of factors that drive such learning process and develop 
hypotheses that establish their impact on explorative and exploitative learning 
outcome. 
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CHAPTER 3. HYPOTHESES 
 
This chapter presents the main hypotheses of this study as summarized in Figure 
3.1 below. Based on the literature review in Chapter 2, these hypotheses establish the 
causal relationships between different relational characteristics of investor-invested 
firms and explorative/exploitative learning from CVC investments. 
Figure 3.1. Hypotheses 
The following are the primary components of the hypotheses that explain 
explorative and exploitative learning from CVC investment: market diversification of 
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CVC investments, technological relatedness and market relatedness between investors 
and investee ventures, and tie strength between the investors and investees. These 
factors and their corresponding hypotheses are identified based on strategic 
management literature and social network theory reviewed in the previous chapter.  
 
3.1. DIVERSIFICATION OF CVC INVESTMENTS 
3.1.1. Investment Diversification and Explorative-exploitative Learning. 
Most CVC programs start with a specific budget that limits the scope of 
investments. Firms can choose to invest in many different industries with multiple 
investee companies in their portfolio, or to invest in one or few industries with limited 
investees. The market diversification in a firm’s investment portfolio is not only 
associated with its financial ability but also has an impact on corporate investor’s 
learning benefits from CVC investments. 
One of the main reasons for established firms to undertake CVC activities is to 
have a window to new technologies, markets and business models (e.g. McNally, 
1997; McKinsey & Co, 1998; Chesbrough, 2002). In order to realize this strategic 
objective, corporate investors could choose to diversify their investments by investing 
in different markets to gain broader exposure of opportunities that leads to more 
explorative learning. Market diversification of investments could provide corporate 
investors a larger body of new knowledge to search and acquire. Since start-ups 
operating in different markets do not have the same knowledge base, investing in 
multiple markets allows firms to have a wider knowledge space and explore a more 
diverse set of emerging technologies and markets. In addition, by diversifying the 
investments incumbents can reduce the risks associated with the experimental nature 
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of exploration, while at the same time maintain an option for learning especially about 
emerging and radically new technologies. Hence, I hypothesize: 
Hypothesis 1a: The more diverse the CVC investments 
(diversification as measured by the different industries 
invested in the portfolio), the more explorative learning 
takes place in investing firms. 
While market diversification of investments could enhance explorative learning 
in CVC, it could hamper investing firm’s exploitative learning. Investing into 
different industries might challenge the number of knowledge domains a firm can 
cover or master. Firms might have difficulties in absorbing different sources of 
knowledge they obtain from multiple industries because of a lack of absorptive 
capacity (Cohen & Levinthal, 1990) in multiple areas. Therefore, investing into 
different industries might decrease the ability of a firm to apply and exploit the 
knowledge in a given area. Further, when managing a large number of CVC 
investments in multiple industries, the firm cannot dedicate its resources to any single 
invested company or to any particular industry. This could limit the firm’s interactions 
with startups, delaying the flow of incoming knowledge that fosters exploitative 
learning. 
Hypothesis 1b: The more diverse the CVC investments 
(diversification as measured by the different industries 
invested in the portfolio), the less exploitative learning takes 
place in investing firms.  
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3.1.2. Moderating Effect of Tie Strength 
Previously, it is argued that diversification of investments has different impact on 
a firm’s explorative and exploitative learning from CVC investment. However, the 
existence of diverse investees in a portfolio alone is not enough for the realization of 
the potential learning benefits. The extent to which a firm can acquire external 
knowledge from others will also depend on the ability to recognize and assess the 
value of knowledge, on the willingness to share information, and on the patterns of 
interaction with partners (Dyer and Singh, 1998; Lane and Lubatkin, 1998).  
One of the biggest challenges for knowledge acquisition and learning processes 
concerns the transfer barriers between the source and the recipient. Researchers have 
summarized such barriers as the ignorance of where to identify knowledge, a lack of 
motivation, obstacles to the effective search for knowledge, lack of trust, and 
unfavorable access to knowledge (Rivkin, 2001). Additionally, scholars consider 
knowledge as experts’ cognitions distributed in certain social networks (Hansen, 
2002), and emphasize the nature of embeddedness in knowledge transfer. The fact that 
knowledge is embedded, not only in practice but also in dynamic interactions between 
people and their social context, raises another barrier to knowledge acquisition and 
learning. 
These barriers of knowledge transfer and acquisition could be eased by the high 
level of social interaction between parties involved in this transfer process. Thus I 
contend that the amount of knowledge acquisition and learning benefits a corporate 
investor realized from CVC investment depends on the level of social interaction 
between investors and investees in the investment portfolio. Social interaction refers 
to the extent of social relationships between the firms, or in other words, the tie 
strength as defined by Granovetter (1973). Specifically, I argue that the duration of 
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the ties, the frequency of the interactions, and the intensity level between investors 
and investees could lower the knowledge acquisition barrier and enable firms to gain 
more learning benefits. 
The first dimension of tie strength that can lower the barriers is the duration of 
ties. Firstly, longer duration of a relationship can reduce the difficulty of recognizing 
and valuing external knowledge. Longer engagement of relationships should assist in 
the identification of opportunities for cooperation (Dyer and Singh, 1998) and 
enhance the ability of investing firms to evaluate the pertinent knowledge of the 
investees. Secondly, social interactions develop over time in dyadic relationships as 
exchange partners become more comfortable with each other’s competence and 
reliability in economic exchange (Larson, 1992; Ring and Van de Ven, 1994). 
Therefore, stronger ties with longer duration of relationships can not only promote 
trust but also reduce unethical behavior (Gulati, 1995; Uzzi, 1996). By this means, the 
barriers of lack of motivation to transfer knowledge could also be lowered. 
The second social factor of lowering knowledge acquisition barriers is the 
frequency of interaction. Previous studies have shown that social interaction 
facilitates the exchange of information (Tsai and Ghoshal, 1998; Hansen, 2002) and 
as more social interactions build, a greater intensity and breadth of information can be 
exchanged (Yli-Renko et al, 2001). Prior studies on CVC have also reported that 
frequency of communication between investors and investees is one of the 
determinants of successful CVC investment program (Sykes 1990). In addition, direct 
frequent interactions also induce more trust and improve the willingness of 
individuals to share knowledge (Tsai and Ghoshal, 1998, Zahra et al 2000). When the 
communication efficiency is enhanced through repeated social interactions, both 
parties have a relatively greater incentive to invest more in knowledge-sharing 
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routines. By intensifying knowledge-sharing activities, social interaction serves to 
increase the relative capacity and effectiveness of an investing firm in recognizing and 
adapting external knowledge from the investees. Therefore, through frequent 
interactions with each other, the barriers of both explorative and exploitative learning 
process are reduced. 
In addition to duration and frequency of interaction, the intensity level of social 
ties is another dimension of tie strength to facilitate learning processes. One of the 
methods to establish intense and intimate relationships among organizations is to 
create ties through a member of one organization sitting on the board of another (often 
called board interlocks). From an information perspective, scholars have seen board 
interlocks as a means by which organizations reduce uncertainties and share 
information about acceptable and effective corporate practices (e.g. Haunschild, 1993; 
Gulati and Westphal, 1999; Westphal et al, 2001). The intensity of ties established 
through board interlock would allow a CVC investor to have a more direct monitor of 
the investee, a more direct communications channel, as well as a greater exposure to 
the technologies and practices of the venture. Moreover, this intensity of ties could 
provide a mechanism to reduce the problem of information asymmetry that investors 
sometimes incur. High levels of intensity in interaction also enables a firm to get close 
enough to acquire not just the observable components of knowledge, but the deeper 
tacit components of knowledge as well (Kogut and Zander 1996). As a result, CVC 
investors can have greater access to their ventures and enhance both their explorative 
and exploitative learning from the start-ups in relation to firms without a board 
interlock. 
In summary, I argue that stronger ties (longer duration of investment 
relationships, more frequency of interactions, and higher level of intensity) between 
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investors and investees tend to lower the barriers of the knowledge acquisition and 
transfer in both explorative and exploitative learning processes in an CVC investment 
relationship. In particular, when the diversification of investment might have a 
negative impact on the investing firm’s exploitative learning (as hypothesized in 1b), 
a stronger ties between the two firms could help to weaken this negative relationship 
by enhancing their knowledge exchange and acquisition through longer duration of 
investment relationship, more frequency of interactions and high level of intensity.  
Thus, I hypothesize: 
Hypothesis 2a:  The positive relationship between 
investment diversification and explorative learning from 
CVC activities will be strengthened by a stronger tie 
between the investor and the investees in the investor’s 
portfolio. 
Hypothesis 2b:  The negative relationship between 
investment diversification and exploitative learning from 
CVC activities will be weakened by a stronger tie between 
the investor and the investees in the investor’s portfolio. 
 
3.2. RELATEDNESS 
3.2.1. Relatedness and Explorative-exploitative Learning 
Previous research on corporate venturing have studied relatedness mainly for 
internal ventures, focusing mostly on the impact of business relatedness on a venture’s 
financial performance. The results of these studies have been mixed (Thornhill and 
Amit, 2001). Some authors found a positive relationship between relatedness and 
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performance (e.g. Dougherty, 1995), while others found a negative relationship (e.g. 
Ginsberg & Hay, 1994) or no relationship at all (Sorrentino and Willianms, 1995).  
The impact of business relatedness on learning in the context of CVC activity 
has not been given the same level of attention. However, arguments can be derived 
from the relevant strategic management literature. For example, study shows that a 
corporation might be able to generate new technologies through combining research 
and development resources in a related acquisition (Hagedoorn and Duysters, 2002). 
In the joint ventures, the higher the relatedness between the parents and their joint 
ventures, the higher the perceived performance of the joint ventures (Lane et al, 2001). 
Besides literature on acquisitions and joint ventures, some arguments of relatedness 
have focused on underlying characteristics of knowledge and learning. For instance, 
Kogut and Zander (1992) argued that elements of similar knowledge facilitate the 
integration of the partners’ knowledge bases. Common skills and similar cognitive 
structures enable the partners to communicate and learn from each other (Lane and 
Lubatkin, 1998; Nahapiet and Ghoshal, 1998). 
In the context of CVC investment, by business relatedness, I refer to those 
investments in which investing firms and invested ventures conduct similar research 
and development activities, employ similar production technologies, serve similar 
markets and use similar distribution systems (Rumelt, 1974). Thus, I categorize 
business relatedness into two sub-groups: technological relatedness and market 
relatedness. 
Technological relatedness. Previous studies have examined technological 
relatedness as an influencing factor of the amount of learning in inter-organizational 
relationships such as alliances (Lane and Lubatkin, 1998), joint ventures (Shenkar and 
Li, 1999), and acquisitions (Ahuja and Katila, 2001). It is argued that a firm’s 
Chapter 3 Hypotheses 
                                    31
previous related knowledge can facilitate the identification, interpretation, and 
digestion of external knowledge (Cohen and Levinthal, 1990). Therefore, if the 
knowledge bases of the two partners are similar, learning benefits should increase 
among the partners (Lane and Lubatkin, 1998). 
The above arguments would suggest a linear positive relationship between 
technological relatedness and explorative learning. However, if the knowledge bases 
of two firms are too closely related, little learning might take place (Ahuja & Katila, 
2001). In other words, relatedness can negatively affect learning outcome since once 
an optimal point is achieved, similar knowledge bases might reduce the learning 
benefit. The diminishing returns of learning from closely related technological 
knowledge base could bring negative impact at some point due to the rigidity and 
limitation of knowledge search space. In the context of CVC investment, one of the 
main learning objectives for corporate investors is to be exposed to and to forge a link 
with new technological knowledge (Winters and Murfin, 1988, Silver 1993, McNally 
1997, Bannock Consulting, 2000). Such explorative learning benefits would be 
dampened if the investor and investee share a knowledge base that is too similar, 
which leads to no new knowledge exploration. Therefore, although the similarity of 
knowledge would be necessary to increase explorative learning benefit at first, too 
much similarity would reduce the exposure of experimenting and new knowledge, and 
results in negative effect on the explorative learning outcome. 
Exploitative learning, however, is more likely to take place within very closely 
related knowledge bases. Firstly, since both parties share most of each other’s 
knowledge, knowledge transfer is likely to be refining or incrementally extending the 
exiting knowledge base of the firm. Secondly, if the investor and the investee have 
similar technology know-how, the investing firm would be more likely to leverage its 
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own capabilities via acquiring knowledge from the investee, because the elements of 
similar knowledge facilitate the integration of the partners’ knowledge bases (Kogut 
and Zander, 1992), In addition, the prior knowledge would be relevant enough to 
facilitate learning processes and knowledge exploitation. Therefore, I hypothesize: 
Hypothesis 3a: Technological relatedness between investors 
and investees in CVC activities is curvilinearly related 
(inverted U) with explorative learning that takes place in 
investing firms. 
Hypothesis 3b: The more technological related between 
investors and investees in CVC activities, the more 
exploitative learning takes place in investing firms. 
 
Market relatedness. Apart from technological relatedness, there is also market 
relatedness affecting the learning benefit from CVC investments. Corporate investors 
can invest in ventures that operate in the same or similar markets or in markets they 
are not familiar with. Related markets share important characteristics that support 
incremental learning and make explorative learning less likely. In other words, the 
more related the markets are, the more we expect learning to be incremental, building 
and refining of existing knowledge; the less related the markets are, the more likely 
the explorative learning would take place. 
If a corporate investor and its investee operate in similar markets, this similarity 
should allow two firms to exchange knowledge more easily and consequently to 
enhance operation in exiting markets. Similarities in business logic and cognitive 
framework makes two firms more likely to share the same views on the future 
evolution of markets and technologies and will search for knowledge in similar places 
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(Silverman, 1999). In this way firms are more likely to explore opportunities in new 
markets as well as to exploit their capital, assets and capability in the exiting markets.  
While market relatedness can help firms obtain new knowledge, too much 
market relatedness might make a firm less likely to have an opportunity to acquire 
knowledge of new markets and to explore new business opportunities. When the 
investor and investee operate in very similar or completely the same markets, they are 
more likely to focus on how to compete with each other and exploit from the partner 
instead of to explore new knowledge and business opportunities. 
Hypothesis 4a: Market relatedness between investors and 
investees in CVC activities is curvilinearly related (inverted 
U) with explorative learning that takes place in investing 
firms. 
Hypothesis 4b: The more market related between investors 
and investees in CVC activities, the more exploitative 
learning takes place in investing firms. 
 
3.2.2. Moderating Effect of Tie Strength 
Previously, it is argued that technological relatedness and market relatedness 
between an investor and an investee have impact on the investor’s learning benefits 
from CVC investments. Here it is further hypothesized that the relationship between 
the relatedness and learning outcome is influenced by the tie strength between the two 
firms. 
As discussed in the section 3.1.2, close social interaction could facilitate 
knowledge transfer and acquisition (e.g. Mowery et al.,1996; Yli-Renko et al, 2001). 
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Through interacting with the investee on a long, frequent and intense level, an 
investing firm should be better able to absorb the technological and market knowledge 
provided by the invested company. This strengthening effect of a strong tie is 
especially true when the corporate investor invests in unfamiliar technologies and 
markets. Moreover, a lasting, repeated and close relationship also helps to foster more 
trust between the two parties and willingness to share knowledge between the 
individuals (Tsai and Ghoshal, 1998, Zahra et al 2000). Therefore, the stronger ties 
between the investors and investees play the enhancing role in the relationship 
between the relatedness and knowledge exploration/exploitation. Thus, I hypothesize 
that:  
Hypothesis 5a:  The positive relationship between 
technological relatedness and explorative learning from 
CVC activities will be strengthened the stronger the tie is 
between the investor and the investee. 
Hypothesis 5b:  The positive relationship between market 
relatedness and explorative learning from CVC activities 
will be strengthened the stronger the tie is between the 
investor and the investee. 
 
Hypothesis 6a:  The positive relationship between 
technological relatedness and exploitative learning from 
CVC activities will be strengthened the stronger the tie is 
between the investor and the investee. 
Hypothesis 6b:  The positive relationship between market 
relatedness and exploitative learning from CVC activities 
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will be strengthened the stronger the tie is between the 
investor and the investee. 
 
3.3. SUMMARY 
The primary components of the hypotheses that explain explorative and exploitative 
learning from CVC investment are: market diversification of CVC investments, 
technological relatedness and market relatedness between investors and investees, and 
tie strength between investors and investees. These factors and their corresponding 
hypotheses are summarized in the table below. 
 
Table 3.1. Hypotheses Summary 
 
Variables  Proposed signs  Hypotheses
Explorative learning (DV)   
Market diversification of CVC investments + H1a 
Market diversification * Tie strength between investor-investee  + H2a 
Technological relatedness between investor-investee +/- (inverted U) H3a 
Market relatedness between investor-investee +/- (inverted U) H4a 
Technological relatedness * Tie strength between investor-investee + H5a 
Market relatedness * Tie strength between investor-investee + H6a 
   
Exploitative learning (DV)   
Market diversification of CVC investments - H1b 
Market diversification * Tie strength between investor-investee  + H2b 
Technological relatedness between investor-investee + H3b 
Market relatedness between investor-investee + H4b 
Technological relatedness * Tie strength between investor-investee + H5b 
Market relatedness * Tie strength between investor-investee + H6b 
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CHAPTER 4. METHODOLOGY 
 
In this chapter, I discuss about the research methods used to test the proposed 
hypotheses made in the prior chapter. I will first describe the data sources and sample 
selection process. Then I will present measures of all the variables used in the study. 
The third section specifies the models to be used in testing the hypotheses and 
describes the statistical methods. 
 
4.1. DATA 
The research setting of this study is CVC investment activities in high-tech 
industries. The reason for choosing high-tech industries as the setting is based on the 
following two considerations. First, according to the NVCA (2004), over 90% of 
CVC investment deals since the 1970’s are in the high-tech industries. Secondly, the 
fast growing, technologically intensive nature of high-tech industries stimulates 
creation of new knowledge to a degree where “learning” within established firms 
varies measurably: an essential consideration for this study. 
To be specific, I choose two high-tech industries, the biotechnology and 
semiconductor industry as the research setting. The emergence of biotechnology can 
be interpreted as a radical process innovation that reduces the barriers of entry into 
the pharmaceutical industry, among other industries (Pisano, 1990). The 
commercialization of biotechnology is characterized by extensive inter-firm 
co-operations including the mode of CVC. Since the early 1970’s about 1600 new 
biotechnology firms have emerged to commercialize this technological breakthrough 
(Rothaermal and Deeds, 2004). Another industry in the sample is the semiconductor 
industry. Like the biotechnology industry, entrepreneurial start-ups and inter-firm 
relationships also play important roles in the evolution of the semiconductor industry 
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(Almaida and Kogut, 1999). Considering the extensive new knowledge generation 
and widely used inter-firm cooperation, the biotechnology and semiconductor 
industry provide a good setting for this study. 
Data of corporate investors and portfolio companies in CVC activities comes 
from the Thompson Financial SDC Platinum database. The “VentureXpert” database 
in SDC Platinum contains a comprehensive coverage of investment, exit, and 
performance in the private equity industry from the 1970’s to present. It provides 
information about firm/fund profiles for both investors and portfolio ventures and 
information of deal details relevant to this study.  
The samples are selected from the SDC Platinum database according to the 
following three criteria: First, the type of investing firms is “non-financial 
corporate/affiliate/subsidiary”2. They will be referred to as “firms” subsequently. The 
second criterion is that the fund type is “direct investment”. The third criterion is the 
invested companies (which will be referred to as “companies” subsequently) belong 
to either biotechnology or semiconductor industry. Based on these three criteria, the 
database identifies 337 CVC deals (or called “investment rounds”) in the 
biotechnology industry with 99 firms and 201 companies from 1978 to 2002. In the 
semiconductor industry, there are 409 CVC deals from 1978 to 2002, with 142 firms 
and 217 companies. 
I choose to use panel data to analyze longitudinal changes of learning outcome 
                                             
2 Other types of firm/fund in VentureXpert database include: Private Firm Investing Own Capital; 
Private Equity Advisor or Fund of Fund Manager; Investment/Merchant Bank Subsidiary or 
Affiliate; Commercial Bank Affiliate or Subsidiary; Bank Group; Investment Management/ 
Finance Consulting; Affiliate/Subsidiary of Other Financial Institution; Insurance Firm Affiliate 
or Subsidiary; Pension Fund, Public; Pension Fund, Corporate; Profit Sharing Fund; 
Endowment; Foundation; Incubator; University Affiliated Program; Business Development 
Fund; State Govt Affiliated Not Elsewhere Classified; Federal Govt Affiliated Not Elsewhere 
Classified; Government Program Not Elsewhere Classified; MESBIC Not Elsewhere Classified; 
SBIC Not Elsewhere Classified; Individuals; Investment or Angel Network; Management 
Consulting Firm; Venture Consulting Firm; Accounting Firm; Placement Agent; Law Firm; 
Other Service Provider; Other Not Elsewhere Classified 
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taking place in established firms resulting from CVC investment activities. Based on 
the information of investment exit or start-up IPO provided in the SDC database, the 
final panel dataset includes a total of 2666 observations with 516 firm-company pairs. 
Table 4-1 summarizes the total number of observations with firm-company pairs in 
each industry type in the sample. Figure 4-1 describes the distribution of these 
observations in each year from 1978 to 2002. The name of the investing firms and 
investee companies are listed in Appendix 1. 
 
 











Biotechnology 1265 237 99 201 
Semiconductor 1401 279 142 217 
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Figure 4.1. Distribution of Observations (1978-2002) 
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Source: “VentureXpert” database, SDC Platinum 
4.2. MEASURES 
In this section, measures of variables are discussed. I will first discuss the two 
dependent variables of the study: explorative learning and exploitative learning. 
Independent and control variables are introduced next. Unless otherwise noted, all 
variables of the study are annual values collected yearly ranging from 1978 to 2002. 
To aid the reader, all variables, the proposed measures and corresponding data sources 











Chapter 4 Methodology 
   40
Table 4.2. Key constructs, Measures & Data Source 
 
Key Constructs Measures Data Sources 
Explorative/exploitative 
learning 
EXPLORE: patent counts in “explorative classes” 




of investment (H1) 
DIVERSE: number of different industries (SIC of 





TECHREL_1: 0, 0.25, 0.5 or 1 depending on the number 
of publication/conference proceedings sharing same 
keyword (s) 
TECHREL_2*: 0, 0.25, 0.5 or 1 depending on the overlap 
between international patent classifications.  






Market relatedness (H4) 
MKTREL: 0, 0.25, 0.5,0.75, or 1 depending on the 






Moderating effect of tie 




(H2, H5 & H6) 
Pair level: 
DUR: investment duration (in years) 
FQY: number of cumulative investment round 
ITY: dummy coded as 1 with board interlock, otherwise 0. 
 
Portfolio level: 
DUR_AVG: average duration of investment in the 
portfolio  
FQY_AVG: average investment round in the portfolio 













SIZE: firm annual total assets  
FIRM_AGE: based on year of foundation 
R&D: firm annual R&D disbursement  
SALES: firm annual sales amount 
ALLIANCE_2* & ALLIANCE_3: number of cumulative 
alliances a firm has formed in the prior 2 or 3 years  
NETWORK: number of cumulative co-investors 
INDUSTRY: dummy (biotech=1, semiconductor =0) 
COM_AGE1: based on company first publication year 
COM_AGE2: based on company first patent application 
year 
WRDS; SDC; 




The dataset used 
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4.2.1 Dependent Variables 
Explorative learning & Exploitative learning (EXPLORE & EXPLOIT). 
Yearly patent counts from NUS patent database3 are used to derive the two dependent 
variables—explorative learning and exploitative learning. Although researchers have 
pointed out that patents as innovative output have limitation (e.g. Griliches, 1990; 
Trajtenberg, 1990), patent data has been widely used to as a proxy for technological 
capabilities, learning and innovativeness (Cockburn and Henderson, 1998; Stuart and 
Podlony, 1996; Stuart, 2000; Ahuja and Katila, 2001).  
Technological profiles of all firms are computed to find out whether a patent in a 
particular year has to be categorized as “exploitative” or “explorative”. This 
categorization is based on the international patent class of each patent provided by the 
NUS patent database. Each international patent class is a hierarchical seven-digit code 
comprising combined symbols representing the section, class, subclass and group4. 
Based on the classification, a firm’s technological profiles can be created by adding 
up the patents that a firm received in each patent class during the five years prior to a 
given year. A moving window of 5 years is the appropriate time frame for assessing 
the technological impact (Podolny and Stuart, 1995; Stuart and Podolny, 1996; 
Henderson and Cockburn, 1996; Ahuja, 2000). Studies about R&D depreciation 
(Griliches, 1984) have suggested that knowledge capital depreciates sharply, losing 
most of its economic value within 5 years. As a result, a 5-year period is appropriate 
to assess the technological profile of a firm.  
These technology profiles allow us to make a distinction between exploitative 
and explorative technology classes. Classes where a firm had not received a patent in 
                                             
3 NUS patent database (http://patents.nus.edu/) contains all US patents issued between 1976 and 2004 
by US Patent Office. Technological classes, citation counts, and inventor and assignee details are 
included. 
4 For example, A 01 B 2/34 is an international patent class. A--section, 01--class, B--subclass, 
2/34--group/subgroup. 
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the prior five years but did receive a patent in the year of observation is considered as 
“explorative” patent classes. I choose the year when the firm filed for the patent rather 
than the year when it was granted because the learning benefits for the firm would 
have been realized as of the filing. All the classes where a firm had successfully 
applied for a patent in the previous five years and successfully applied for a patent in 
the year of observation is considered “exploitative” patent classes. 
The dependent variable EXPLORE is then calculated by adding up all the patents 
applied for in the year of observation in the “explorative” patent classes. In other 
words, explorative learning is considered to take place when a firm first applies a 
patent in a new class in which it had not patented in the previous five years. The same 
is done for the dependent variable EXPLOIT. By adding up the patents in the 
“exploitative” classes, we can obtain a measure for exploitative learning. 
Considering that learning from another organization and then integrating that 
knowledge into a firm’s own routines or technologies are time consuming processes 
(Stuart, 2000), I assume a two year lag between the regressors and dependent 
variables to address the time lag effect of the CVC investment on learning outcome. 
In other words, I examine the association between last two-year’s value of 
independent variable and this year’s EXPLORE and EXPLOIT value. 
I do not exclude firms without patents in the sample. Instead, I keep all the 2666 
observations and if the firm does not have any explorative or exploitative patent count, 
I give the value of zero (0) for the observation.  
4.2.2. Independent Variables 
Diversification of investment (DIVERSE). Empirical studies on diversification 
have commonly used Herfindahl-based measure to measure market diversification 
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(e.g. Hitt et al, 1997). Such measure is based on data of segment market shares. In the 
context of CVC investment activities however, so far there is no available data source 
which is able to provide the break-downed information on each firm’s investment 
shares in different industries/markets.    
Given the above, diversification of investment in this study is measured by the 
number of different industries the firm invests in its portfolio. The classification of 
industry is based on the first three digits of the 4-number US Standard Industry Code 
(SIC) of each investee in the portfolio. In other words, the market diversification of 
investment is measured as the number of different 3-digit SIC of the investees in the 
portfolio each year. The source of SIC code is from the VentureXpert database in 
SDC Platinum, CorpTech database5 and Osiris database6. 
Tie strength. Prior social network studies have employed several different 
measures of “strength of ties” (Marsden and Campbell, 1984). In this study, I 
introduce three widely used constructs to measure tie strength: duration of ties, 
frequency of ties, and intensity level of ties. There are two sets of measures for tie 
strength in this study: the tie strength between each pair of investor and investee, and 
the overall tie strength between the investor and investees on the portfolio level.  
For tie strength on the pair level, the duration of ties (DUR) is measured by the 
investment duration in terms of years between each firm-company pair, i.e. the 
duration between the year of the firm making its first investment and the year of 
observation. For the second construct frequency of ties (FQY) I use the number of 
cumulative investment rounds that a venture receives from the investor in the year of 
observation as a proxy7. Intensity level of ties (ITY) is measured as a dummy variable. 
                                             
5 CorpTech (www.corptech.com) provides business information of over 95,000 public and private hi-tech 
companies. 
6 Osiris database covers over 90 countries and includes over 22,000 publicly listed companies. 
7 Investment rounds could also be a proxy of commitment level to an area where the investing firms want 
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It is coded as one (1) if the firm and its investee have board interlock, i.e. a member of 
one organization sitting on the board of another. Otherwise, it is coded as zero (0). All 
the data for these three constructs are collected from the VentureXpert database in 
SDC Platinum. Accordingly, the corresponding measures of tie strength on the 
portfolio level are the average value of DUR, FRY and ITY in the investor’s portfolio. 
Technological relatedness (TECHREL). I use two measures for the 
technological relatedness between firms and companies. The first measure 
“Techrel_1” is based on science publication and conference information of the 
investor and investee. Based on the number of publications or conference proceedings 
sharing the same keyword(s), I give values of 0, 0.25, 0.5, or 1 to each 
investor-investee pair. Techrel_1 is coded as 0 if the investor firm and investee 
company do not have any publication or conference proceedings that share keywords 
within their abstracts during the year of observation. The two firms are treated as 
technologically unrelated. The technological relatedness receives a value of 0.25 if the 
pair has one or two publications or conference proceedings that share keyword(s) in 
their abstracts. Techrel_1 is coded as 0.5 if the pair has more than two but less than 
five publications or conference proceedings that share keyword(s). If they have five or 
more publications or conference proceedings that share keyword(s), it is coded as 1, 
meaning these two firms are highly technologically related to each other. I use 
databases like Web of Science, BIOSIS Review and ISI Proceedings to get 
publication/proceeding data for each firm and company. 
Considering the fact that publication is only one aspect that reflects a firm’s 
technological status (which might cause a bias if the construct is solely based on it), I 
use the second alternative measure “Techrel_2” based on patent information provided 
                                                                                                                               
to exploit with the investee companies. A more accurate measure would be first-hand data on 
communication frequency in the CVC investment relationship. However, such data is not available due to 
data source and collection constrain. Therefore investment rounds is used as an alternative proxy here. 
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by NUS patent database. The database provides information of international patent 
classification for each issued patent. As mentioned before, an international patent 
class is a hierarchical code comprising combined symbols representing section, class, 
subclass and group. In order to test the effects of the relatedness, a method similar to 
the first measure is used: the firm-company pairs are divided into four groups: 
Unrelated (coded as 0), moderately related (0.25), closely related (0.5) and highly 
related (1). The Techrel_2 variable is coded as 0 if the investee has no patent that falls 
in the same class of its investing firm’s patent stock. The variable is coded as 0.25 if 
the venture has patents that share the same classes as the firm’s patents. Similarly, it is 
coded as 0.5 when they have the same subclasses. When there are patents of the 
venture having the same main group or subgroup coding as the investing firm’s 
patents, this variable is coded as 1. Following Jaffe (1986), a continue construct of 
technological relatedness based on patent information is also derived from the above 
mention patent profiles of both investing firms and invested companies. This 
continuous measure is used in the sensitivity tests. 
Market relatedness (MKTREL). The most common technique to assess market 
similarity relies on SIC codes (Chatterjee and Blocher 1992). SIC-based measures of 
relatedness mainly measure product-market similarities between different business 
lines. In my samples, firm-company pairs operating in the same or similar industries 
are considered to serve similar markets. Therefore, I construct the variable market 
relatedness based on the overlaps of 4-digit Standard Industry Codes (SIC) of the 
investors and investees. By comparing the SIC codes of each investor-investee pair, 
this construct has face validity.  
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The variable receives values 1, 0.75, 0.5 or 0.25 if the firm and company have 
the same SIC code on four, three, two or one digit level, respectively. If the firm and 
company have totally different SIC code, then it receives a value of zero (0).  Similar 
measures based on number of matching digit of primary SIC codes have been used to 
measure market relatedness in prior research (e.g. Finkelstein and Haleblian, 2002; 
Villalonga and McGahan, 2003). Appendix B lists the SIC codes and business 
description for all the investor-investee pairs. The data sources are from the SDC, 
CorpTech, Osiris, Dun & Bradstreet8, and SEC9 databases.  
 
4.2.3. Control Variables 
Firm size (SIZE). I include eight control variables in my regression models. 
Firstly, larger firms may have greater scope of technological opportunities, enabling 
firms to leverage their resources for successful explorative and exploitative learning. I 
measure a firm’s size using a natural logarithm of the total firm assets (in millions of 
dollars). Each firm’s total assets data are obtained from the CRSP/COMPUSTAT 
merged database provided by WRDS10.  
Firm age (FIRM_AGE). Secondly, firms with more experience are more likely 
to identify successful investment opportunities and possess a greater ability to acquire 
external knowledge that allows the firm to gain more learning benefits than those with 
less experience. Firm experience is measured as a firm’s age based on its year of 
foundation. SDC database provides information of firms’ foundation year.  
Research & Development expenditure (R&D). The third control variable is the 
                                             
8 www.selectory.com  
9 www.sec.gov 
10 WRDS: Wharton Research Data Services.  
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natural logarithm of annual R&D expenditure. Firms with a larger disbursement in 
their R&D activities are typically able to acquire more knowledge and learning 
benefits. Data of annual R&D expenditure (in millions of dollar) is obtained from the 
CRSP/COMPUSTAT merged database provided by WRDS. 
Sales Amount (SALES). The fourth control variable is the natural logarithm of 
a firm’s annual sales amount. Firms with a larger sales amount possess larger 
financial resources, which could have an impact on their motivation and ability to 
acquire knowledge from outside sources. Data of annual sales amounts (in millions of 
dollar) are obtained from CRSP/COMPUSTAT merged database provided by WRDS. 
Alliances of firms (ALLIANCE). Prior studies have shown that firms could 
enhance their learning and innovative performance by collaborating with strategic 
alliance partners (e.g. Stuart, 2000; Ahuja and Katila, 2001). To rule out the 
alternative explanation for learning benefits, I include the fifth control variable that 
measures a firm’s alliances. This variable is measured by the number of cumulative 
alliances a firm has formed in the three years prior to the year of observation 
(Alliance_3). For sensitivity tests, I also use the number of alliances that a firm has 
formed in the prior two years as an alternative measure for this construct (Alliance_2). 
Alliance data in the biotechnology industry is obtained from the Recombinant Capital 
(Recap) alliances database11. For alliances in the semiconductor industry, I use a 
dataset containing alliances information in the information technology and 
communication (ITC) industry12. 
Co-investor networks (NETWORK). Social networks can enhance a firm’s 
both explorative and exploitative learning outcome. Networks are vital to the 
                                             
11 Recap (www.recap.com) provides detailed information on alliances, earned alliance revenues, product 
sales, employment agreements, company profiles and capitalization in the biotechnology industry. 
12 The dataset was used in: Soh & Roberts, 2003. Networks of Innovators: A Longitudinal Perspective. 
Research Policy, 32 (9): 1537-1717  
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discovery of new entrepreneurial opportunities (Burt, 1992), as well as to exchange 
high-quality and fine-grained information and to establish trust-based governance (Uzzi, 
1997). In the context of CVC investment, networks can be formed when several firms 
invest in a same venture, i.e. the relationship of being a co-investor. As a co-investor 
of the venture, a firm would be able to access a broader spectrum of information that 
the network provides. The breadth and heterogeneity of an organization’s direct and 
indirect ties within the network could provide it additional sources of information. 
Thus, a firm can improve its ability to recognize and respond to new technological 
and market opportunities in the investment process and consequently enhance its 
explorative learning. At the same time, networks are also able to enhance firms’ 
exploitative learning from CVC. By engaging in repeated formal and informal 
interactions within the network, firms are able to better absorb information and have a 
deeper understanding of applying specific technological and market knowledge. 
Therefore, co-investor networks have an impact on both explorative and exploitative 
learning from CVC investment.  
Co-investor networks are measured by the number of cumulative co-investors a 
focal corporate investor has in the year of observation. Information on co-investment 
relationships is obtained from the SDC database.  
Investment industry (INDSUTRY). The industry that a firm operates in is 
related with its innovation behavior (Nobel and Birkinshaw, 1998). Some 
innovation-related factors, such as technological opportunity and the availability of 
critical complementary assets, are strongly associated with industry sectors. This can 
directly affect the learning benefits a firm gains from CVC investments. I use a 
dummy variable to control this industry effect. The variable is coded as one (1) if the 
investment deal is in the biotechnology industry. For investments in the 
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semiconductor industry, the dummy variable is coded as zero (0).   
Company age (COM_AGE). Lastly, the age of invested companies could affect 
an investing firm’s learning outcome as well. Ventures in different stages possess 
different amounts of resources, knowledge bases and capabilities which would have 
impact on a firm’s knowledge exploration and exploitation from the investments. To 
measure company ages, I collect data from the Web of Science/BIOSIS Review/ISI 
Proceedings to get each company’s first scientific publication year, which is regarded 
as age one for the company. The corresponding value of company age for each 
observation (COM_AGE1) is based on this year. A second measure (COM_AGE2) is 
also developed for sensitivity tests. It is based on the application year of the first 
patent applied by the company. Similarly, the age value is then assigned to each 
observation based on this year. 
 
4.3. METHOD 
The hypotheses developed in Chapter 3 identify two dependent variables: 
explorative learning and exploitative learning. Hypotheses 1-6 predict how the 
relationship characteristics between investors and investees affect the explorative and 
exploitative learning benefits from CVC investments. I examine a sample of 516 
firm-company pairs in the period from 1978 to 2002. Empirical validation of the 
hypotheses is done through a cross-sectional time series model.  
A regression approach is used to test these hypotheses. In each regression model 
the dependent variable is regressed against a vector of explanatory variables including 
both hypothesized effects and control variables. A longitudinal research design is used, 
which pools the sample over firm-company pairs (i) and over time (t). As mentioned 
before, all independent variable are lagged by two years. The regression model 
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Given the dependant variables (Explore & Exploit) are integer numbers based on 
patent counts in a given year, a Poisson model is selected to address the discrete 
nature of the dependant variables. One of the important assumptions for Poisson 
distribution is that the mean and variance are equal. By checking each independent 
variable’s mean and variance, I did not find severe violation of this assumption. A 
likelihood ratio test also showed that the data did not violate the Poisson regression 
model assumptions. Therefore, using the Poisson model to test the hypotheses is 
appropriate in this study. To test the robustness, I also include alternative measures of 
some key variables in the model to verify the sensitivity of the results. 
I test my hypotheses with hierarchical regression analysis to determine the 
amount of additional variance that is explained by the independent variables after 
controls. I enter control variables in step one and then add independent variables one 
by one until the full model is reached. 
In summary, I adopt a Poisson model with lagged independent variables to test 
my hypotheses using a cross-sectional time series dataset with hierarchical regression 
analysis. For the sensitivity tests, I also adopt alternative measures for some key 
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constructs in the model. Stata 8.2, a statistical software package, is used for testing all 
the regression models. In the next chapter, I will report the results of these tests. 
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CHAPTER 5. RESULTS 
 
In this chapter I report the results of the hypotheses testing. First, I report the 
descriptive statistics and second, I present the results of hierarchical regression 
analysis using Poisson models. The third section presents the sensitivity tests by 
reporting results using alternative key measures. The last section summarizes the key 
results of the statistical tests. 
 
5.1. DESCRIPTIVE STATISTICS  
Table 5.1 reports descriptive statistics and the correlation matrix for all variables. 
On average, the sample firms applied for approximately nine patents each year under 
new patent classes compared to the previous five years (the mean of “Explore” is 
8.83). For “exploitative” patents, the firms introduced about thirty-seven patents 
under old patent classes for each year (the mean of “Exploit” is 37.26).  
In the correlation matrix, the correlations between independents variables are not 
deemed high enough to warrant the problem of multicollinearity (except in the case of 
two pairs of measurements: Alliance_2& Alliance 3; Techrel1 & Techrel2). Since in 
the regression models only one measure is used, the high correlations would not 
create severe problems. 
5.2. RESULTS OF REGRESSION ANALYSIS 
In this section, I first present the results of hierarchical regression predicting 
explorative learning. Followed by the results on explorative learning, the results on 
exploitative learning are presented. All results are based on Poisson models. 
In each table of regression results, Model 1 is the base model only including 
control variables. Model 2 to 6 test the hypotheses of main effects (i.e. Hypothesis 1, 
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3, and 4). Model 7 to 15 include the interaction terms and test Hypothesis 2, 5 and 6. 
The rest of the models add main effects and interaction terms one by one until the full 
model is reached. The same reporting patterns are used in the sensitivity tests in the 
next section. 
5.2.1. Results on Explorative Learning 
Table 5.2 presents the Poisson regression models predicting explorative learning. 
In baseline Model 1, firm size, firm age, R&D expense, sales, number of alliances, 
co-investor network, industry dummy and company age are included as control 
variables. Among these control variables, two of them are significant (“Alliance” with 
coefficient of 0.002, p<0.05; and “Network” with coefficient of 0.367, p<0.001).As 
expected, the more alliances the corporate investors have and the larger the 
co-investor networks, the more explorative learning benefits the firm gains.  
Model 2 tests Hypothesis 1a, predicting the more market diverse CVC 
investment is the more explorative learning benefits an investor firm gains. After 
including control variables as applied in the baseline model, the positive and 
significant coefficient of the variable “Diverse” β=0.151, p<0.01) provides strong 
support for Hypothesis 1a.  
Model 3 and 4 test Hypothesis 3a, which predicts an inverted U relationship 
between technological relatedness and explorative learning benefits a firm gains. The 
results of Model 3 show that the coefficient of technological relatedness is at a 
significant level with a positive sign (β=0.189, p<0.01), indicating that more 
explorative learning takes place when the investing firm is more technologically 
related to the invested company. However, the results of Model 4 suggest that after a 
certain point, the relationship becomes a negative one, supported by the significant 
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negative sign of the square term of technological relatedness (β= -0.476, p<0.01). The 
results suggest an inverted U relationship and therefore Hypothesis 3a is supported. 
Hypothesis 4a predicts the same inverted U relationship between market 
relatedness and explorative learning. Model 5 and 6 test this hypothesis, and the 
results do not support it. Rather, the positive sign in Model 5 (coefficient of “Mktrel” 
is 0.384, p<0.01) suggests that more explorative learning takes place when the 
markets are closely related. 
Hypothesis 2a proposes a positive moderating effect of tie strength on the 
relationship between investment diversification and explorative learning. In other 
words, the positive relationship between market diversification and explorative 
learning will be strengthened the stronger the tie strength is. Measuring tie strength in 
three different dimensions (duration, frequency and intensity), I test Hypothesis 2a in 
model 7, 8, and 9. The results of Model 7 suggests that the duration of investment has 
a positive moderating effect on explorative learning, but the effect is not significant. 
In Model 8 I use frequency as the tie strength measure. The results suggest that the 
frequency itself has a significant positive relationship with explorative learning (β= 
0.151, p<0.01). However, its moderating effect is negative (coefficient of 
“Diverse*Fqy” is -0.016, p<0.01) . In Model 9 the results suggest that the intensity 
level of tie strength between the investor and investee has a significant positive 
moderating effect on explorative learning (coefficient of “Diverse*Ity” is 0.270, 
p<0.01). Therefore, the results of model 7 to 9 provide partial support for Hypothesis 
2a.  
The results of Hypothesis 5a, which predicts the enhancing effect of tie strength 
on the relationship between technological relatedness and explorative learning, are 
presented in Model 10, 11 and 12. The results of Model 11 suggest the frequency of 
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tie strength has a negative moderating effect on explorative learning (β=-0.060, 
p<0.01). Model 10 and 12 do not provide support to the hypothesis either. 
The results of the moderating effect of tie strength on market relatedness and 
explorative learning (Hypothesis 6a) are shown in Model 13 to 15. Overall, the results 
do not provide support for the enhancing role of tie strength as hypothesized. Again, 
Model 14 suggests that there is a negative moderating effect of frequency on 
explorative learning (β=0.070, p< 0.01). 
Model 16 through 20 add the variable of each main effect hypothesis and 
interaction terms one by one. Model 16 provides support for Hypothesis 1a (a positive 
relationship between investment diversification and explorative learning) and 
Hypothesis 3a (an inverted U relationship between technological relatedness and 
explorative learning). Model 17 presents the full model for all the main effect 
hypotheses. It confirms the above results and a positive relationship between market 
relatedness and explorative learning (Hypothesis 4a). Based on the full model for all 
the main effect hypotheses, Model 18 to 20 add the interaction terms between main 
effect and tie strength. Model 18 and 19 provide partial support for Hypothesis 2a but 
no support for Hypothesis 5a, suggesting the moderating effect of duration and 
intensity level of ties on the relationship between market diversification and 
explorative learning. In addition, it also suggests a negative moderating effect of the 
frequency of ties. Finally, Model 20 includes all the hypotheses, whose results are 
consistent with the previous models, yet provide no support for Hypothesis 6a 
(moderating effect of tie strength on market relatedness and explorative learning). 
5.2.2. Results on Exploitative Learning 
The Poisson regression models predicting exploitative learning are reported in 
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Table 5.3. Model 1 reports the baseline model where control variables are included. 
The positive and significant coefficient of firm size (β=0.286, p<0.01), firm age 
(β=0.005, p<0.1), sales (β=0.295, p<0.01), number of alliances (β=0.008, p<0.01) and 
co-investor network (β=0.165, p<0.01)are as expected. Interestingly, the negative sign 
of R&D expenses indicates that more R&D expenses would not necessarily bring 
more exploitative learning benefits to the firm. 
Hypothesis 1b proposes that more market diversification in CVC investments 
would lead to less exploitative learning benefits for the investing firm. Model 2 tests 
this hypothesis, and its significant positive sign provides (β=-0.007, p<0.1) support 
for the hypothesis.  
Hypothesis 3b predicts that an investing firm gains more exploitative learning 
benefits from a company that is more technologically related. The positive and 
significant sign in Model 3 supports this hypothesis (β=1.095, p<0.01). Moreover, the 
results of Model 4 indicate there is no inverted U relationship as in the explorative 
learning. 
Hypothesis 4b focuses on the role of market relatedness to exploitative learning. 
Model 5 tests this hypothesis and the positive and significant sign of the coefficient 
(β=2.571, p<0.1) provides support to Hypothesis 4b. Model 6 further confirms this 
result.  
Model 7 to 9 test Hypothesis 2b, which predicts that the negative relationship 
between investment diversification and exploitative learning is weakened by a 
stronger tie between the two firms. Results from Model 7 suggest that the relationship 
between diversification and exploitative learning is negative as hypothesized (the 
coefficient of “Diverse” is -0.025, p<0.01), and that investment duration weakens this 
relationship (the coefficient of “Diverse*Dur” is 0.003, p<0.01). This result provides 
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support for H2b. However, Model 8 and 9 indicate the frequency and intensity of ties 
do not have a hypothesized moderating effect on the relationship. Rather, the results 
suggest that stronger ties strengthen the negative relationship between investment 
diversification and exploitative learning. Overall, the results of these three models 
provide partial support for Hypothesis 2b. 
The results of Hypothesis 5b, which predicts an enhancing effect of tie strength 
on the relationship between technological relatedness and exploitative learning, are 
presented in Model 10, 11 and 12. The positive and significant sign of the interaction 
term (duration of tie) in Model 10 provides support for H5b (β=0.029, p<0.01). When 
using frequency of tie as in Model 11, the results suggest the moderating effect is 
negative. 
With regard to the moderating effect on market relatedness and exploitative 
learning (Hypothesis 6b), the results are shown in Model 13 to 15. Overall, these 
results are the same as with technological relatedness. Model 13 provides support for 
the enhancing role of longer duration of ties as hypothesized (β=0.011, p<0.05). 
Model 14 indicates a negative moderating effect on exploitative learning when using 
the frequency of tie as the tie strength measure. 
Model 16 to 20 add the variable of each main effect hypothesis and interaction 
terms one by one. Model 17 presents the full model for all the main effect hypotheses 
of exploitative learning. Consistent with previous results, Hypothesis 1b 
(diversification of investment), Hypothesis 3b (technological relatedness) and 
Hypothesis 4b (market relatedness) are supported. Finally, based on the full model for 
all the main effect hypotheses, Model 18 to 20 add interaction terms between main 
effects and tie strength. Model 18 provides partial support for Hypothesis 2b, 
suggesting a moderating effect of duration of ties on the relationship between market 
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diversification and exploitative learning benefit. Model 19 also suggests the duration 
of ties can strengthen the positive relationship between technological relatedness and 
exploitative learning. Finally, Model 20 includes all the hypotheses and its results are 
consistent with the previous models. The results, however, provide no support for 
Hypothesis 6b (the moderating effect of tie strength on market relatedness and 
exploitative learning). 
 
5.3. RESULTS OF SENSITIVITY TESTS  
The robustness of the results is tested in this section. I use several alternative 
measures of the key variables to test the sensitivity of the results. For the control 
variable “Alliance”, I use the number of alliances a firm has formed in the previous 
two years in the sensitivity tests (compared with alliances in prior three years in the 
original tests). For the age of companies, I use the alternative measure based on patent 
information (compared with publication information). Besides, I also include one key 
independent variable “technological relatedness”, using its alternative continuous 
measures based on patent data instead of publication data.  
Table 5.4 presents the sensitivity test results on explorative learning. Overall, the 
results based on the alternative measures exhibit a very similar pattern to the original 
results reported in the Table 5.2. Model 2 to 6 test the main effect hypotheses. The 
results are consistent with the previous results, providing support for Hypothesis 1a (a 
positive relationship between market diversification and explorative learning), 
Hypothesis 3a (an inverted U relationship between technological relatedness and 
explorative learning), and suggesting a positive relationship between market 
relatedness and explorative learning (Hypothesis 4a). In the models from Model 7 to 
Model 15, which include the interaction terms, the results are consistent with the 
Chapter 5             Results 
 
   59
original results too. They confirm the moderating effect of tie strength (as in duration 
of tie and intensity of tie) on the relationship between market diversification and 
explorative learning, providing partial support for Hypothesis 2a. These results are 
further confirmed in Model 16 to 20 which include both the main hypotheses and 
interaction terms.  
Results of sensitivity tests on exploitative learning are reported in Table 5.5. 
Overall, the pattern is similar to the original results in Table 5.3. Model 2 provides 
support for Hypothesis 1b, suggesting a negative relationship between market 
diversification and exploitative learning. Model 3 and 4 provide support for 
Hypothesis 3b (a positive relationship between technological relatedness and 
exploitative learning), and Model 5 and 6 for Hypothesis 4b (a positive relationship 
between market relatedness and exploitative learning). Finally, in models including 
the interaction terms, consistent with previous results, the results provide partial 
support for Hypothesis 2b, 5b and 6b, suggesting the duration of ties has a positive 
moderating effect on exploitative learning. 
 
5.4. SUMMARY  
Table 5.6 (presented at the end of this chapter) summarizes all the hypotheses 
and the corresponding results from the statistical analysis. Similarly, Figure 5.1 
reports the hypotheses model of this study with the statistic results. Hypothesis 1 
predicts that the market diversification of CVC investments has a positive relationship 
with explorative learning, but a negative relationship with exploitative learning. The 
results of the regression models support both hypothesis 1a and hypothesis 1b. 
Hypothesis 2 proposes a moderating effect of tie strength on the relationship 
between investment diversification and learning benefits. The regression results show 
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a positive moderating effect of tie strength on both explorative learning and 
exploitative learning when using the duration of ties as the measurement. In other 
words, it provides support that the longer duration of ties between the 
investor-investee, the more learning benefits the investing firm would gain from 
investing in diverse markets. Therefore, hypothesis 2a and hypothesis 2b are partially 
supported. 
Hypothesis 3 predicts that technological relatedness has an inverted U 
relationship with explorative learning, but a positive relationship with exploitative 
learning. The results provide support for both hypothesis 3a and hypothesis 3b. 
Hypothesis 4 further predicts the effect of market relatedness on knowledge 
exploration and exploitation. The results do not provide support for hypothesis 4a, i.e. 
an inverted U relationship between market relatedness and explorative learning. 
Rather, the results suggest the relationship is positive. However, the predicted positive 
relationship with exploitative learning is confirmed and therefore hypothesis 4b is 
supported. 
Finally, Hypothesis 5 and 6 predict the moderating effect of tie strength on the 
relationship between technological/market relatedness and the learning benefits. The 
results provide partial support for Hypothesis 5b and Hypothesis 6b, suggesting a 
stronger tie could enhance the exploitative learning benefits gained from investing in 
ventures that are technologically and market related. However, the results do not 
provide support for Hypothesis 5a or Hypothesis 6a. The moderating effect of tie 
strength is not found on the relationship between relatedness and explorative learning. 
 
Chapter 5                     Results 
 
   61
Table 5.1. Descriptive Statistics and Correlation Matrixa,b,c 
 
 Mean S.D. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31.
1. Explore 8.83 14.17 1                                
2. Exploit 37.26 110.25 .762 1                               
3. Size 16239.66 28456.24 .234 .205 1                              
4. Firm_Age 10.97 13.07 -.007 .010 .194 1                             
5. R&D 926.84 1306.70 .165 .041 .541 .278 1                            
6. Sales 105.74 194.66 .081 .015 .277 .234 .813 1                           
7. Alliance_2 12.50 30.59 .056 .009 .089 .144 .410 .279 1                          
8. Alliance_3 15.95 39.81 .059 .008 .091 .147 .412 .278 .996 1                         
9. Network 0.55 0.98 .798 .554 .162 -.016 .196 .153 -.069 -.064 1                        
10. Industry 0.47 0.50 -.048 -.072 -.103 -.015 -.088 -.111 .346 .344 -.267 1                       
11.Com_age1 4.48 2.97 -.009 -.009 -.058 .147 -.080 -.108 .022 .034 .039 -.019 1                      
12.Com_age2 4.23 3.34 -.052 -.045 -.124 .139 -.129 -.124 .006 .014 .028 -.030 .857 1                     
13. Diverse (DVS) 2.99 1.98 .634 .377 .133 .059 .280 .175 .381 .381 .452 .270 -.038 -.078 1                    
14. Duration(DUR)  3.66 2.33 .038 .040 -.078 .060 -.115 -.127 .007 .017 .060 .030 .661 .287 .003 1                   
15.Frequency (FQY) 1.96 1.44 .206 .187 -.145 -.036 -.059 -.035 .189 .190 .139 .352 .209 .045 .349 .370 1                  
16. Intensity (ITY) 0.03 0.16 -.025 -.032 .077 .027 .088 .053 .065 .063 -.015 -.060 -.051 -.025 -.007 -.056 -.048 1                 
17.Dur_Avg 3.66 2.02 .042 .046 -.089 .065 -.134 -.148 .007 .018 .056 .047 .580 .240 .011 .863 .361 -.013 1                
18.Fqy_Avg 1.95 1.34 .214 .199 -.159 -.036 -.074 -.045 .182 .183 .157 .358 .183 .048 .380 .337 .935 -.053 .385 1               
19.ITY_Avg 0.03 0.11 -.040 -.045 .117 .051 .140 .083 .110 .112 -.036 -.043 -.028 -.029 .009 -.018 -.075 .661 -.021 -.078 1              
20. Techrel_1 0.23 0.33 .477 .457 -.027 -.095 -.046 -.006 .085 .080 .425 .188 .029 -.051 .420 .083 .466 -.057 .098 .495 -.074 1             
21. Techrel_2 0.29 0.36 .515 .515 -.029 -.100 -.063 -.007 .082 .079 .463 .250 .000 -.042 .462 .107 .525 -.060 .125 .545 -.067 .880 1            
22. Mktrel 0.28 0.35 .251 .267 -.154 -.051 -.102 -.059 .168 .169 .222 .202 .072 .109 .276 .087 .318 -.026 .121 .357 -.039 .403 .479 1           
23. DVS*Dur_Avg 11.00 9.56 .519 .325 .045 .074 .105 .020 .297 .304 .378 .234 .296 .070 .745 .483 .527 -.012 .566 .568 -.001 .412 .462 .322 1          
24. DVS*Fqy_Avg 6.84 8.65 .456 .290 -.043 -.025 .083 .048 .275 .274 .363 .373 .060 -.030 .753 .179 .749 -.040 .210 .806 -.049.525 .562 .383 .757 1         
25.DVS*Ity_Avg 0.08 0.32 .016 -.041 .128 .063 .238 .156 .321 .326 -.013 .055 .001 -.025 .208 -.008 -.057 .514 -.010 -.054 .795 -.061 -.059 .017 .130 .033 1       
26.TR_1*DUR 0.89 1.66 .391 .365 -.036 -.053 -.060 -.042 .073 .075 .365 .149 .258 .053 .338 .425 .542 -.063 .357 .546 -.056 .806 .709 .368 .559 .522 -.048 1      
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27.TR_1*FRQ 0.66 1.36 .331 .331 -.071 -.057 -.020 .006 .153 .152 .286 .299 .100 -.004 .393 .194 .742 -.067 .201 .740 -.080 .820 .720 .393 .488 .718 -.077 .795 1     
28.TR_1*ITY 0.00 0.04 .033 .036 .014 -.011 .044 .071 .000 -.002 .069 -.026 -.030 -.014 .019 -.040 -.044 .432 .015 -.014 .165 .084 .062 .051 .021 -.007 .219 .016 -.002 1    
29.MR*DUR 1.11 1.87 .223 .221 -.126 -.012 -.085 -.058 .136 .142 .225 .151 .330 .199 .221 .484 .440 -.047 .412 .449 -.036 .355 .412 .772 .468 .397 .006 .574 .440 .015 1    
30.MR*FRQ 0.72 1.35 .255 .260 -.122 -.034 -.056 -.021 .178 .179 .223 .288 .136 .071 .348 .233 .722 -.049 .251 .727 -.066 .484 .545 .757 .480 .669 -.041 .541 .689 -.007 .765 1   
31.MR*ITY 0.01 0.07 .020 .001 -.005 .005 .029 .016 .051 .054 .041 -.009 -.018 -.019 .054 -.045 -.036 .562 .008 -.015 .306 .011 .015 .116 .045 .008 .352 -.008 -.026 .568 .043 .021 1 
 
a. All descriptive statistics reported from non-transformed values. 
b. For Mean and S.D, number of observation N=2666, except Size (2178), R&D (1908), Sales (1900), Com_age1 (2417), Com_age2 (1120), 
Techrel_2 (2145). 
c. Significant at the 0.001 level (two-tailed test) when coefficients of pairwise correlation > |0.072|. 
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Table 5.2. Poisson Regression Model Predicting Explorative Learning a,b,c, 
Variables Model  



















































































































































































































































































































































































                      












   




































   
-0.476***
(0.140)  
        


































     
0.107 
(0.213) 
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Tie strength                      
Duration 
























(Ity)            
-0.245 
(0.231) 
  -0.580 
(0.284) 






      
-0.040***
(0.014) 
     








       
0.151***
(0.021) 
    








        
-1.289***
(0.401) 
   







Interactions                      
Diverse*Dur 
(H2a)        
0.003 
(0.002) 
     








(H2a)        
-0.016***
(0.003) 
    








(H2a)         
0.270***
(0.091) 
   




























(H5a)            
0.241 
(0.398) 






(H6a)             
-0.020**
(0.010) 




(H6a)             
 -0.070***
(0.025) 




(H6a)             
  0.846 
(0.558) 
    0.286  
(0.448) 
 
                      
Log-likelihood -4497.08 -4295.50 -4490.68 -4484.95 -4485.77 -4485.65 -4291.17 -4268.66 -4290.44 -4488.75 -4486.03 -4490.13 -4482.30 -4481.01 -4483.94 -4276.35 -4268.61 -4235.62 -4215.97 -4215.06  
Wald 
chi-square 
1267.70 1697.32 1285.45 1308.47 1380.15 1380.62 1701.79 1789.29 1716.10 1291.48 1300.72 1287.95 1316.85 1316.48 1318.77 1777.61 1829.06 1944.60 2022.86 2027.87  
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Note: 
 
a. *p<0.1; **p<0.05; ***p<0.01, all two-tailed tests. 
b. Cell entries are coefficient estimates. Numbers in parentheses are standard errors. 
c. No.of observation = 1731; No. of groups = 315. 
d. Logarithmic transformation. 
e. Used Alliance_3 (number of cumulative alliances a firm formed in the prior 3 years). 
f. Used Com_age1 (based on publication data). 
g. Used Techrel_1 (based on publication data). 
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Table 5.3. Poisson Regression Model Predicting Exploitative Learning a,b,c, 
Variables Model  



















































































































































































































































































































































































                      












   




































   
1.008*** 
(0.084) 
        
    
     
Mktrel (H4a) 






















     
-0.080 
(0.166) 
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Tie strength                      
Duration 
























(Ity)            
-0.500 
(0.404) 
  -0.493 
(0.593) 






      
0.006***
(0.007) 
     








       
0.384***
(0.010) 
    








        
0.647 
(0.434) 
   







Interactions                      
Diverse*Dur 
(H2a)        
0.003***
(0.001) 
     








(H2a)        
-0.020***
(0.002) 
    








(H2a)         
-0.308***
(0.109) 
   




























(H5a)            
-0.136 
(0.320) 






(H6a)             
0.011** 
(0.005) 




(H6a)             
 -0.043***
(0.013) 




(H6a)             
  -0.333 
(1.351) 
    -0.185  
(0.957) 
 
                      
Log-likelihood -10848.81 -10847.07-10145.03 -10072.56-9687.62 -9687.50 -10831.08-9710.88 -10824.86-10094.36-9402.77 -10143.78-9647.70 -9098.08 -9686.57 -10144.77-9186.01 -8506.08 -8426.01 -8393.08  
Wald 
chi-square 
1693.55 1696.00 3005.52 3139.47 3815.21 3816.84 1725.81 3733.46 1737.04 3124.25 4313.28 3008.53 3871.86 4890.72 3818.84 3004.59 4770.19 5982.40 6176.75 6227.99  
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Note:  
 
a. *p<0.1; **p<0.05; ***p<0.01, all two-tailed tests. 
b. Cell entries are coefficient estimates. Numbers in parentheses are standard errors. 
c. No.of observation = 1731; No. of groups = 315. 
d. Logarithmic transformation. 
e. Used Alliance_3 (number of cumulative alliances a firm formed in the prior 3 years). 
f. Used Com_age1 (based on publication data). 
g. Used Techrel_1 (based on publication data). 
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Table 5.4. Sensitivity Tests Predicting Explorative Learning a,b,c, 
Variables Model  































































































































































































































































































































































































   




































   
0.064 
(0.465)  
        


































     
-0.451 
(0.421) 
      









Tie strength                      
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Duration 
























(Ity)            
0.312 
(0.540) 
  -0548 
(0.708) 






      
-0.035**
(0.022) 
     








       
0.211***
(0.034) 
    








        
-1.272 
(0.927) 
   







Interactions                      
Diverse*Dur 
(H2a)        
0.011***
(0.004) 
     








(H2a)        
-0.019***
(0.005) 
    








(H2a)         
0.297 
(0.215) 
   




























(H5a)            
-0. 793 
(2.402) 






(H6a)             
0.026 
(0.023) 




(H6a)             
 -0.016 
(0.047) 




(H6a)             
  0.992 
(1.108) 
    1.639  
(1.457) 
 
                      
Log-likelihood -1325.26 -1296.01 -1320.44 -1320.43 -1318.40 -1317.84 -1291.94 -1275.92 -1295.02 -1319.53 -1316.40 -1320.26 -1317.23 -1316.58 -1318.00 -1290.57 -1279.22 -1252.69 -1245.03 -1242.78  
Wald 
chi-square 
341.56 402.02 355.07 354.92 366.79 367.39 412.38 484.98 404.66 355.60 375.40 355.98 369.93 376.84 368.93 419.16 472.13 595.20 644.19 661.67  
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Note: 
a. *p<0.1; **p<0.05; ***p<0.01, all two-tailed tests. 
b. Cell entries are coefficient estimates. Numbers in parentheses are standard errors. 
c. No.of observation = 487; No. of groups = 129. 
d. Logarithmic transformation. 
e. Used Alliance_2 (number of cumulative alliances a firm formed in the prior 2 years). 
f. Used Com_age2 (based on patent data). 
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Table 5.5. Sensitivity Tests Predicting Exploitative Learning a,b,c, 
Variables Model  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  20  






























































































































































































































































































































































































   




































   
0.258 
(0.301) 
        
    
     
Mktrel (H4a) 






















     
0.546 
(0.502) 
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Duration 
























(Ity)            
-0.708 
(0.780) 
  0.113 
(1.483) 






      
0.174***
(0.013) 
     








       
0.489***
(0.017) 
    








        
-0.717 
(0.954) 
   







Interactions                      
Diverse*Dur 
(H2a)        
-0.020***
(0.002) 
     








(H2a)        
-0.040***
(0.003) 
    








(H2a)         
-0.113 
(0.241) 
   




























(H5a)            
8.052***
(1.227) 






(H6a)             
0.098*** 
(0.014) 




(H6a)             
 0.150***
(0.028) 




(H6a)             
  -0.513 
(2.625) 
    2.553 
(2.682) 
 
                      
Log-likelihood -3399.23 -3262.80 -3339.85 -3339.49 -3008.77 -2947.71 -3158.75 -2825.35 -3236.51 -3323.51 -2981.29 -3317.29 -2983.84 -2694.73 -3008.74 -3222.09 -2933.92 -2537.93 -2463.50 -2456.60  
Wald 
chi-square 
392.53 657.15 502.76 504.38 1096.75 1139.67 870.37 1488.39 711.71 529.70 1224.60 543.34 1134.75 1715.17 1097.31 733.42 1241.98 1989.08 2171.62 2191.45  
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Note: 
a. *p<0.1; **p<0.05; ***p<0.01, all two-tailed tests. 
b. Cell entries are coefficient estimates. Numbers in parentheses are standard errors. 
c. No.of observation =487; No. of groups = 129. 
d. Logarithmic transformation. 
e. Used Alliance_2 (number of cumulative alliances a firm formed in the prior 2 years). 
f. Used Com_age2 (based on patent data). 
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Table 5.6. Proposed Effects and the Results 
 
Variables Proposed signs Results Hypotheses 
Explorative learning    
H1a Diversification of investment + + Supported 
H2a Diversification * Tie strength  + + (Duration of ties) Partially supported
H3a Technological relatedness +/- (inverted U) +/- (inverted U) Supported 
H4a Market relatedness +/- (inverted U) + Rejected 
H5a Technological relatedness * Tie strength + / Not supported 
H6a Market relatedness * Tie strength + / Not supported 
    
Exploitative learning    
H1b Diversification of investment - - Supported 
H2b Diversification * Tie strength  + + (Duration of ties) Partially supported
H3b Technological relatedness + + Supported 
H4b Market relatedness + + Supported 
H5b Technological relatedness * Tie strength + + (Duration of ties) Partially supported
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Figure 5.1. Hypotheses and Results
H5b (+) (β=0.029, p<0.01) 
H6b (+) (β=0.011, p<0.05) 
H3b (+) (β=1.095, p<0.01) 
H4b (+) (β=2.571, p<0.01) 
H5a (+) H6a (+) 
H3a (+/-) (β=0.189, p<0.01; β=-0.476, p<0.01) 
H4a (+/-) 
H2b (+) (β=0.003, p<0.01)
H1b (-) (β=-0.007, p<0.1) 
H1a (+) (β=0.151, p<0.01) 
Relatedness between 
investors-investees 
- Technological  




of CVC investments   
Market diversification 
of CVC investments 
Relatedness between 
investors-investees 
- Technological  
- Market  
H2a (+) (β=0.003, p<0.01)
 Tie strength between 
investors-investees 
Tie strength between 
investors-investees 
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CHAPTER 6. DISCUSSION  
 
6.1. DISCUSSION & IMPLICATION 
In this study, I examined the determinants of knowledge exploration and 
exploitation in CVC investment. This section discusses the findings of the study and 
provides insights concerning the determinants as well as the implications for investing 
firms. 
The results in the previous chapter highlighted the impact of market 
diversification of investments, relatedness between the investor and investee, and tie 
strength on the investing firm’s learning benefits. I will discuss each determinant one 
by one as follows. 
6.1.1. Market Diversification of Investments 
The results of the regression models suggest that the CVC investments in more 
diverse markets lead to more explorative learning in the investing firm. Moreover, the 
results also indicate that investing in a large number of different industry domains 
could decrease the exploitative learning benefits for the corporate investors. So 
overall, there is a tradeoff between explorative and exploitative learning outcome 
when corporate investors diversify the markets in their investment portfolio.  
This finding provides evidence for some previous literature suggesting that the 
main strategic objective of CVC investment for corporate investors is to gain a 
window of new technologies and business models (e.g. McNally, 1997; McKinsey & 
Co, 1998; Chesbrough, 2002). By investing in multiple industries, corporate investors 
are exposed to different industry domains with different knowledge bases. This allows 
corporate investors to have a larger knowledge space and to explore a more diverse 
set of emerging technologies and markets.  
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According to this finding, the implication for the corporate investors is that the 
degree of market diversification of CVC investments should depend on the type of 
learning objective they have. On the one hand, if the corporate investor aims to 
explore knowledge, it is better to diverse their investment portfolio by investing in 
ventures operating in different industry domains, so that the corporate can have a 
larger body of new knowledge to search and acquire. Through a wide range of 
knowledge exposure, the investing firm can better absorb the related knowledge and 
create new knowledge that it was previously not familiar or expertized in. On the 
other hand, if the primary objective is to exploit the existing technologies or markets, 
the firm should not invest in too many different ventures operating in different 
industries. In addition, if the firm wants to both explore and exploit knowledge from 
investing in new ventures, in order to find a balance between these two types of 
learning objectives, it is beneficial for the firm to find an optimal level of market 
diversification in its CVC investments.  
6.1.2. Relatedness 
The results show that technological relatedness between the investing firm and 
invested company has an inverted U relationship with explorative learning and a 
positive relationship with exploitative learning. The results also indicate that market 
relatedness has a positive relationship with both exploitative learning and explorative 
learning benefits. 
Theoretically, this finding supports the argument that similar knowledge 
facilitates the integration of each partner’s knowledge base (e.g. Kogut and Zander, 
1992) and provides evidence that similarity in knowledge bases can increase the 
learning benefits among partners (Lane and Lubatkin, 1998). Moreover, the finding 
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also provides support for the argument that if the knowledge of two parties is too 
closely related, little learning might take place (Ahuja & Katila, 2001). 
The findings suggest that it is highly valuable to invest in companies that are 
technologically related to the investors if the firm wants to explore and exploit 
knowledge. By investing in a company that has the similar technological knowledge 
base, the investing firm is more likely to gain both explorative and exploitative 
learning benefits from the investment. However, the firm should be aware that if the 
two knowledge bases are too similar with each other, it could hinder the firm’s ability 
to explore new knowledge. Therefore, the investing firm needs to have a moderate 
level of technological relatedness with the investee in order to balance both 
explorative and exploitative learning. For market consideration, it is beneficial for a 
firm to invest in another company that is operating in a similar market, so that the 
corporate investor would be able to better explore and exploit knowledge from this 
investment relationship. 
6.1.3. Tie Strength and Social Networks 
In addition to investment diversification and relatedness, I also investigated the 
impact of tie strength (duration, frequency and intensity of ties) between investors and 
investees on the learning outcome from CVC investment. I found that the duration of 
ties can enhance both the explorative and exploitative learning benefits obtained from 
diverse investments. In addition, longer duration of investment relationships also 
strengthen the exploitative learning benefit obtained from related investments.  
The results do not provide support for the role of frequency of ties as in 
enhancing learning benefits. Rather, they suggest the frequency of ties has a negative 
impact on the relationship between relatedness and learning outcome. Considering I 
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use investment rounds to measure frequency of ties, this result might indicate that 
corporate investors who continually invest in ventures with financial needs are not 
likely to gain learning benefits through CVC investments. 
For the level of intensity of ties (as measured by board interlock), the results do 
not provide support for a positive moderating effect either. This could be due to the 
reason of lack of data variation. Of 2666 observations in the sample, only 74 of them 
have board interlock and are given a value of one (1) and the remaining receive a 
value of zero (0). Another possible explanation is that the data reported in the SDC 
platinum database may not be up-to-date and complete. 
Apart from examining the impact of tie strength, I also included the co-investor 
networks in the controls. As expected, the results suggest that firms gain more 
learning benefits from larger co-investor networks. 
From the network perspective on inter-organizational learning, the above finings 
provide evidence that closer social interaction is an important facilitator of knowledge 
transfer (Bresman et al., 1999; Yli-Renko et al. 2001). In addition, they also support 
the notion that organizations can produce more innovative knowledge if they occupy a 
central network position (Tsai, 2001).  
The implication of these findings is clear: it is valuable for a corporate investor 
to maintain a close interaction level with the invested company. Since social 
interaction serves to increase the relative capacity and effectiveness of the corporate 
in recognizing and adapting external knowledge from the investees, longer duration of 
the investment relationship allows the corporate investor to gain additional learning 
benefits from the CVC investment activities.  
Further, the findings also suggest that a corporate investor would more likely to 
gain learning benefits by syndicating its CVC investment with other investors. A 
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larger co-investor network provides opportunities to access information stemming 
from having a central brokering position beyond what the firm could acquire if being 
the only investor. Therefore, the firm is more likely to gain insights of other firm’s 
investment experiences and thus gain learning benefits from the investment activities. 
 
6.2. LIMITATION & FUTURE RESEARCH 
Several limitations of this thesis indicate avenues for future research. First, this 
thesis only investigates a limited number of determinants of knowledge exploration 
and exploitation in the context of CVC investment. Future research should further 
explore other determinants and examine other influencing factors that might have an 
impact on learning from CVC investments. For example, there could be more 
dimensions in relatedness other than the technological and market relatedness that this 
study examined.  
Secondly, the measures of some variables can be improved to better test the 
robustness of my findings. In particular, other measures could be developed for 
technological relatedness besides using information on patents and scientific 
publications. For market relatedness, this study uses SIC code for proximity. However, 
an industry code is not sufficient to measure the market relatedness between two firms. 
Future research should develop other measures that could more precisely measure the 
market relatedness. In addition, future research needs to develop better measures of tie 
strength in terms of frequency and intensity of ties. 
Thirdly, this study only tests hypotheses on the sample of two industries: the 
biotechnology and the semiconductor industry. In particular, it does not include the 
computer related industries, which comprise about 50% of the total CVC deals since 
the 1970’s (NVCA, 2005). Therefore, future research should expand the research 
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scope to other industries to have a better understanding of how firms learn from CVC 
investments. 
Finally, another area for future improvement of research on CVC investment is 
the methodology. This study mainly uses secondary data sources to test the 
hypotheses, which may introduce noise to the tests because of the possible existence 
of inaccurate data. Future research should be encouraged to use hybrid methodologies 
such as the combination of case studies, questionnaire surveys and secondary 
databases. 
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CHAPTER 7. CONCLUSION 
7.1. MAIN FINDINGS 
This thesis investigates the determinants of knowledge exploration and 
exploitation in CVC investment. I create a research model comprised of various 
relational factors in the CVC activities, and examine the effects of these influencing 
factors on corporate investor’s explorative and exploitative learning benefits. 
The findings of this thesis provide evidence that market diversification of 
investment, relatedness between investor-investee and network effects have impact on 
learning outcomes from CVC investments. I found that the more diverse the CVC 
investment scope, the more explorative learning benefits a corporation gains. In 
explaining the effect of technological and market relatedness on corporate learning, I 
found that both help increase knowledge exploration and exploitation for corporate 
investors. However, too much technological relatedness may have a negative impact 
on explorative learning for the investing firm. 
Further, by examining the tie strength and network effect on learning from CVC, 
I found that longer investment relationships tend to enhance the learning benefit from 
diverse investments. Also, a longer duration of ties helps to enhance the positive 
relationship between relatedness and exploitative learning benefits. Moreover, the 
explorative and exploitative learning for an investing firm increases with the size of 
its co-investor network.  
One particular interesting finding here is that the same determinant with different 
degree could lead to different learning outcome in terms of being explorative and 
exploitative. The results suggest that the CVC investments in more diverse markets 
lead to more explorative learning in the investing firm. However, the results also 
indicate that investing in a large number of different industry domains could decrease 
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the exploitative learning benefits for the corporate investors. Similar tradeoff also 
exists between the technological relatedness and learning benefits. The results show 
that technological relatedness between the investing firm and invested company has 
an inverted U relationship with explorative learning and a positive relationship with 
exploitative learning. In other words, when there is too much technological overlap 
between the investing firm and the investee company, the relatedness does not help 
the corporate investor to explore knowledge. 
In summary, this thesis is an empirical test on the determinants of corporate 
learning in the context of CVC investment. The findings provide evidence of the 
effects of investment diversification, relatedness between investor-investee, and 
network effect on knowledge exploration and exploitation from CVC investments.  
 
7.2. CONTRIBUTION 
This thesis has four main contributions. First, it extends our understanding of 
CVC activities by examining corporate investor’s learning outcome from an 
inter-organizational learning perspective. Previous studies on CVC mainly focused on 
either financial returns to investing firms (e.g. Gompers and Lerner, 1998) or 
examined the benefits such as IPO value from the invested venture’s perspective (e.g. 
Maula and Murray, 2001). Few studies have examined the learning benefits from the 
corporate investor’s perspective. 
Second, by applying explorative-exploitative learning framework, it contributes 
to learning literature by examining the determinants of explorative versus exploitative 
learning outcomes in the context of CVC. Previous studies have examined various 
forms of inter-organizational learning activities such as strategic alliances, joint 
ventures and mergers & acquisitions, yet few studies have made a distinction between 
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explorative and exploitative learning, nor rigorously investigated what factors have an 
impact on explorative versus exploitative learning outcomes. In addition, this study 
also examines the tradeoff effect of the certain determinants on different learning 
outcomes. 
Third, this thesis enriches the literature on how firm learn through CVC 
investment by integrating multiple perspectives from both strategic management and 
social network theory. By drawing from relevant literatures such as organizational 
learning, business diversification, strategic alliances and social network theory, this 
study provides insights for how different organizational factors may drive the 
different learning outcomes stemming from CVC investment relationship. 
Finally, from an empirical standpoint, this thesis provides managerial 
implications for corporations participating in CVC activities. CVC investment 
managers who plan to make investments in new ventures and those who have already 
engaged in CVC activities can benefit from understanding how the determinants of 
knowledge exploration and exploitation have an impact on corporate learning benefits. 
Categorization of learning outcomes and the corresponding investment strategies can 
help corporate investors to better harvest their investment benefits, and maintain a 
relationship with the invested ventures that is conducive to knowledge exploration 
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APPENDIX A 
 
A-1. LIST OF INVESTING FIRMS: 
 
No. Firm Name No. Firm Name 
    
1 3Com Ventures  42 Control Data Corporation 
2 Abbott Laboratories  43 Cooper Development Co. 
3 Acma Australia Pty Ltd.  44 Cowen Biotech Ltd. 
4 ADC Telecommunications, Inc. 45 CP Ventures Inc. 
5 Affymetrix, Inc.  46 CPC International Inc. 
6 AlliedSignal, Inc. 47 CPT Holdings Inc. 
7 Altera Corporation 48 Crossroad Systems 
8 Amena-Retevision Movil SA  49 Crystal Systems Solutions Ltd. 
9 American Cyanamid  50 Cypress Semiconductor Corp. 
10 American Express 51 Data General Corporation 
11 American Hospital Supply Corp. 52 Dekalb Agriresearch 
12 American Linen Supply Co. 53 Diagnostic Products Corp. 
13 Ameritech Development Corp. 54 Digital Equipment Corp. 
14 Renaissance Tech. 55 The Walt Disney Co. 
15 Analog Devices Enterprises  56 Dow Chemical Company, The 
16 Analogic Corp.  57 DU Pont 
17 Anschutz Investment Company  58 Eastman Kodak Co, Inc. 
18 Asachi Keiki Co. Ltd. 59 Elan Corporation PLC 
19 Asahi Chemical Industry Co., Ltd. 60 Electro-Science Corp. 
20 AT&T 61 Electrolux Corporation 
21 August Systems Corp. 62 ELF Technologies 
22 Banner Industries  63 Eli Lilly & Company 
23 Becton, Dickinson & Co.  64 Elron Technologies 
24 BIOMEC Inc. 65 Cabletron Systems, Inc. 
25 BMW Technologies Inc. 66 Ericsson Business Innovation AB.
26 Boehringer Mannheim Corp  67 Evans and Sutherland 
27 Borg-Warner Security Corp. 68 Exxon Enterprises 
28 Bristol-Myers Company 69 Fairchild Camera and Instrument 
29 British Petroleum  70 Farley Inc. 
30 BRM Capital 71 Fenwick & West LLP 
31 BSI Industries 72 Flextronics International Ltd. 
32 C. Itoh & Co. Ltd. 73 Foster Industries, Inc. 
33 Canon, Inc.  74 Fuji Bank, Limited 
34 Cendant Corporation 75 Fujitsu Ltd. 
35 Centocor Corporation 76 G.D. Searle Division 
36 ChevronTexaco Venture Equities  77 Genentech Corporatio 
37 CIBC Bank, CIBC Resourcing  78 General Atom/Toshiba Corp. 
38 Cisco Systems, Inc.   79 General Electric Credit Corp. 
39 Comcast Interactive Capital 80 General Instrument Corporation 
40 Comstellar Technologies, Inc.  81 General Motors 
41 Conexant Systems, Inc. 82 General Signal Corporation 
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83 Getty OIL Company 130 Monsanto Corp. 
84 Gillette Co 131 National Bank of Canada 
85 DAMAC Ventures 132 National Distillers 
86 Glyko Biomedical, Ltd. 133 National Iron and Steel Mill 
87 Gould Inc. 134 National Semiconductor 
88 Guidant Corporation 135 Neoplux Capital 
89 Harris Corp. (Semiconductor Division 136 Nissho Electronics 
90 Heizer Corporation 137 Norsk Hydro 
91 Hewlett-Packard  138 Nortel Networks Corporation 
92 Compaq Computer Corp.   139 Northern Pacific Capital Corp. 
93 Hillman  140 Northern Telecom Ltd. 
94 Hoechst Celanese Corporation 141 NYNEX Technology Investments 
95 Hybritech Incorporated 142 Olin Corporation 
96 Hyundai Venture Investment Corp. 143 Oracle Venture Fund 
97 IBM Corporation 144 Otsuka Pharmaceutical Co 
98 Infotechnology 145 Oxford Instruments Group PLC 
99 Innova Corp 146 Pacific Telecom 
100 Institution of Immunology 147 Pacnat Company 
101 Integrated Device Technology Inc. 148 Pernovo Corp. (Perstorp 
102 Intelligent Systems Corporation 149 Pfizer Inc 
103 Invacare Corporation 150 Philips Venture Capital Fund B.V. 
104 Itochu Corporation 151 Polaroid Corporation 
105 Johnson & Johnson  152 Proctor & Gamble 
106 Kanematsu-Gosho Ltd. 153 Purdue Pharma L.P. 
107 Kebo LAB AB 154 Questec Enterprises, Inc.  
108 Kimball Manufacturing 155 Raychem Corporation 
109 Kopvenco Inc. ( Koppers Co.) 156 RCA 
110 Kyocera International, Inc. 157 RCT BioVentures NE LLC 
111 LG Electronics 158 Repligen Corp. 
112 Litton Industries 159 Rhone Poulenc 
113 Lotus Development Corporation 160 Rockwell International 
114 LSI Logic Corporation 161 Rodal Corp. 
115 Lubrizol Business Development Co. 162 Rohm and Haas Company. 
116 Manufacturers Life Insurance Co. 163 SAIC Venture Capital Corp. 
117 Marion Merrill Dow 164 Sandoz Ltd. 
118 Martin Marietta Investments, Inc. 165 Schering-Plough Corp. 
119 Marubeni Corporation 166 Schlumberger Limited 
120 Matsushita Electric Corporation 167 Seagate Technology Inc 
121 MCM Capital Group, Inc. 168 Sensormatic Electronics Corp. 
122 MedImmune  169 Sepracor Inc. 
123 Medtronic, Inc. 170 Shanghai Industrial Holdings Ltd. 
124 Merck & Co. 171 Shanghai Land Holdings Ltd. 
125 Microsoft Corporation 172 Sharp Corporation 
126 Microwave Technology 173 Shaw Ventures Ltd. 
127 Minnesota Mining & Manufacturing 174 Shinsho Corporation 
128 Mitsui & Co.  175 Siemens Corporation 
129 Molex, Inc. 176 Siemens Venture Capital GmbH 
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177 Sigma Resources   
178 SISIR International Pte Ltd.   
179 Smith Kline Beecham Corp.   
180 Sony Corporation   
181 Standard Microsystems Corp.   
182 Standard OIL    
183 Standard OIL of California   
184 Sumitomo Cement Company, Ltd.   
185 Sumitomo Corporation   
186 Sumitomo Metal Industries   
187 Sun Microsystems, Inc.   
188 Syntex Corporation   
189 Sysorex   
190 Tandem Computers, Inc.   
191 Tata Enterprises    
192 Taub-Tech Ventures   
193 TDK Corporation   
194 Technology Asia Ventures Sdn Bhd   
195 Teck Research Inc.   
196 Tektronix Development Co   
197 Telefonica   
198 Tellabs Inc.   
199 Tenax Corporation   
200 TI Ventures   
201 Time, Inc.   
202 Tosco Corporation   
203 Trident Microsystems, Inc.   
204 TRW Inc.   
205 TVI Corporation   
206 Ultramar PLC   
207 United Computer and Technology   
208 Velocity Capital Management LLC   
209 VentureBank@PNC   
210 Votorantim Venture Capital Ltd   
211 Wang Development and Investment 
Corp. 
  
212 Weston Investment Co.   
213 Williams Communications Group   
214 WorldCom Ventures   
    
    
    
    
    
    
    
    
    
 
  Appendix A    
   97
A-2. LIST OF INVESTED COMPANIES: 
 
No. Company Name No. Company Name 
    
    
1 360networks, Inc.  42 Applied Molecular Evolution, Inc. 
2 Accelrys, Inc.  43 Applied Optoelectronics Technology 
3 Acelo Semiconductor, Inc.  44 Applied Superconetics 
4 Aclara BioSciences Inc.  45 ARC International PLC  
5 Acorda Therapeutics, Inc. 46 Argonaut Technologies, Inc. 
6 Actel Corporation  47 Aronex Pharmaceuticals, Inc. 
7 Adaptive Silicon, Inc 48 Array Biopharma, Inc 
8 Advanced Genetic Sciences, Inc  49 Ashvattha Semiconductor, Inc. 
9 Advanced Power Technology, Inc 50 Associated Biomedic Systems, Inc. 
10 Advanced Tissue Sciences, Inc 51 Asyst Technologies, Inc. 
11 Advancell 52 ATEQ Corp. 
12 Aerie Networks, Inc 53 Athena Neurosciences, Inc. 
13 Aetna Communication Laboratories  54 AtheroGenics, Inc. 
14 Agensys, Inc. 55 Atheros Communications, Inc 
15 Agile Therapeutics, Inc.  56 Athersys Inc. 
16 Agility Communications, Inc.  57 Austek Microsystems, Ltd. 
17 Agilix Corporation  58 AuthenTec, Inc. 
18 Agouron Pharmaceuticals, Inc. 59 Vector Pharmaceuticals, Inc. 
19 Agricultural Genetics Company 60 Axsun Technologies, Inc 
20 Agridyne Technologies, Inc.  61 BaySpec, Inc. 
21 Alchemia Pty., Ltd. 62 Be Here Corporation 
22 Alellyx Applied Genomics 63 Benchmarq Microelectronics, Inc. 
23 Alien Technology Corporation  64 Benzing Technologies, Inc. 
24 Allos Therapeutics, Inc.  65 Berlex Biosciences  
25 AltaRex Corp.  66 Bermai, Inc.  
26 Altera Corporation 67 Besco Inc. 
27 Altus Corporation  68 Beyond Genomics, Inc. 
28 Alvesta Corporation 69 BI, Inc. 
29 AmberWave Systems Corporation  70 Bio-Diagnostics, Inc. 
30 American Bionetics, Inc. 71 Bio Logicals, Inc. 
31 Amgen, Inc.  72 Biogen, Inc. 
32 Analog Devices, Inc.  73 BioMarin Pharmaceutical, Inc. 
33 Anamartic Ltd. 74 Biomedical Diagnostics 
34 Angenics, Inc. 75 Biopure Corporation 
35 APEX Semiconductor, Inc. 76 Biotechnology Development Corp. 
36 Aphton Corporation 77 Bipolar Integrated Technology Inc. 
37 Apollon, Inc.  78 Blaze Network Products, Inc. 
38 Applied Biosystems, Inc. 79 British Bio-Technology Group PLC 
39 Applied Biotechnology, Inc. 80 C.P. Clare Corporation 
40 Applied Micro Circuits Corp. 81 Calient Networks 
41 Applied Microsystems Corp. 82 California Micro Devices, Inc. 
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83 Caliper Technologies Corp. 130 DNA Research Innovations, Ltd. 
84 Cambridge BioTech Corporation 131 Dolch American Instruments 
85 Cambridge Biotechnology 132 Ecogen, Inc. 
86 Candescent Technologies Corp. 133 Electron Beam Corp. 
87 Canji, Inc. 134 Electronic Systems Products, Inc. 
88 CardioFocus, Inc. 135 Embrex, Inc 
89 Celetronix  136 Energy Conversion Devices, Inc 
90 Celgene Corporation 137 Engenics, Inc. 
91 Cellontech Co Ltd 138 EntoMed SA 
92 CENiX, Inc. 139 Environmental Processing Inc 
93 CentrePath  140 Enzo Biochem 
94 Cepheid, Inc. 141 Enzytech, Inc 
95 Cetus Corporation 142 Eos Biotechnology, Inc. 
96 Chameleon Systems, Inc. 143 Eotec Corporation 
97 Chemgen, Inc. 144 Epicyte Pharmaceutical, Inc. 
98 Chromatis Networks, Inc. 145 Epid 
99 ChromaVision Medical Systems Inc. 146 Erndex 
100 Cidra Corporation 147 Exelixis, Inc. 
101 Circe Biomedical, Inc. 148 Fairchild Semiconductor Int’l Inc. 
102 Clinical Sciences, Inc. 149 FiberNet Telecom Group, Inc. 
103 Clinicor, Inc. 150 Flight Dynamics, Inc. 
104 Codata Systems Corporation 151 Focus Company Ltd. 
105 Collaborative Research, Inc 152 Focus Semiconductor Systems, Inc. 
106 Compulaser, Inc. 153 FormFactor, Inc. 
107 Contrex, Inc. 154 FST Inc. (FKA: Fine Semiconduc 
108 Corixa Corporation 155 Gain Electronics 
109 Creative BioMolecules, Inc. 156 Galileo Pharmaceuticals, Inc. 
110 Credence Systems Corp. 157 GE Novasensor Inc. 
111 Critical Therapeutics, Inc. 158 Gen-Probe, Inc.  
112 Crop Genetics International Corp. 159 Genaissance Pharmaceuticals, Inc. 
113 Cross-Check Technology, Inc. 160 Genelabs Technologies, Inc. 
114 Crystal Semiconductor Corp 161 GeneMedix PLC 
115 Crystalvision Inc. 162 Genentech, Inc. 
116 Crysteco, Inc. 163 General Ionex Corporation 
117 Cybernetic Data Products, Inc. 164 Genetic Systems Diagnostics Partners 
118 Cyrano Sciences, Inc. 165 Genetics Institute, Inc. 
119 Cytogen Corporation 166 Genex Corporation 
120 Cytotech, Inc. 167 Genoa Corporation 
121 Daehan Bio Link Company, Ltd. 168 Genome Networks, Inc. 
122 Dallas-Semiconductor Corp 169 Genomics Collaborative, Inc. 
123 Datavision, Inc. 170 Genomine, Inc. 
124 Dialog Semiconductor GmbH 171 Genoptix, Inc. 
125 DigiLens, Inc.  172 GES Pharmaceutical Inc 
126 Dionex Corporation 173 GigaBit Logic, Inc. 
127 Dixy Company Ltd. 174 GLC Associates 
128 DNA Link, Inc. 175 Gliatech, Inc. 
129 DNA Plant Technology 176 Glycan Pharmaceuticals Inc 
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177 Glycomed, Inc. 224 LightLogic, Inc. 
178 Graffinity Pharmaceutical Design GmbH 225 Lightwave Technologies, Inc. 
179 Graviton, Inc. 226 Lineo, Inc. 
180 Greyhawk Systems, Inc. 227 LipoGen, Inc.  
181 Harwal Electrical Industries Pty Ltd 228 LocalMed, Inc 
182 Hem Research, Inc. 229 Locus Pharmaceuticals, Inc. 
183 Hybrigenics SA 230 Luxtron Corporation 
184 I-Cube, Inc. 231 MacroNex, Inc. 
185 Icoria, Inc.  232 Martek Biosciences Corporation 
186 IDEC Pharmaceuticals Corp 233 Matrix Semiconductor, Inc. 
187 IKOS Systems, Inc 234 Mech-El Industries, Inc. 
188 Illumina, Inc. 235 MediaQ, Inc. 
189 Imalux Corporation 236 Mediopia International Co Ltd 
190 ImmuLogic Pharmaceutical Corp 237 Mellanox Technologies, Inc. 
191 Immunicon Corporation 238 Message Pharmaceuticals, Inc. 
192 Immunomed Corporation 239 Metabolex, Inc. 
193 Immusol, Inc 240 MetaProbe LLC 
194 In2Gen Co., Ltd  241 Metris Therapeutics, Ltd. 
195 Incara  242 Micro Linear Corporation 
196 InfiMed Therapeutics, Inc. 243 Micro Technology, Inc. 
197 InGenuity Systems, Inc. 244 Microbeam, Inc. 
198 Innergy Power Corp. 245 Microfabrica, Inc. 
199 Innov Holding Company 246 Microgenics Corporation 
200 Integrated Device Technology 247 Micron Custom Manufacturing Inc. 
201 Integrated Micromachines, Inc. 248 Microscale Company, Ltd. 
202 Integrated Telecom Express, Inc. 249 Millennium Systems, Inc. 
203 Intellon Corporation 250 Molecular Biosystems, Inc. 
204 Interactive Silicon, Inc. 251 Molecular Devices Corp 
205 Interamics, Inc. 252 Molecular Genetics, Inc. 
206 InterMune, Inc. 253 Monoclonal Antibodies, Inc. 
207 International Biotechnologies Inc. 254 Morrow Electronics, Inc. 
208 International Canine Genetics 255 Mosaic Systems, Inc. 
209 International Microelectronic 256 MultiLink Technology Corp. 
210 Invitron Corporation 257 Myco Pharmaceuticals 
211 iPhotonics, Inc. 258 Mycogen Corporation 
212 Ista Pharmaceuticals, Inc. 259 MystiCom, Ltd. 
213 JGKB Photonics, Inc. 260 Nanogen, Inc. 
214 Kaylex, Inc. 261 Navarro Networks 
215 Kelsius, Inc. 262 nCHIP, Inc. 
216 Kinetek Systems, Inc. 263 NEC Eluminant Technologies, Inc. 
217 KOR Electronics, Inc. 264 NeoRx Corporation 
218 Koronis Pharmaceuticals 265 Neose Technologies, Inc. 
219 Lamina Ceramics, Inc. 266 Ness Display Corporation 
220 Level One Communications, Inc. 267 NetEffect, Inc. 
221 Life Technologies, Inc. 268 NeuroControl Corporation 
222 LifeSpan BioSciences, Inc. 269 Neurocrine Biosciences, Inc. 
223 LifeSpex, Inc. 270 NeXagen, Inc. 
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271 Nitgen Technologies 318 Quake Technologies, Inc. 
272 Norak Biosciences, Inc. 319 Quantum Bridge Communications 
273 Nova Pharmaceutical Corp 320 Quantum Effect Devices, Inc 
274 Novalux, Inc. 321 Quidel Corporation 
275 Novellus Systems, Inc 322 Renalogics  
276 November 323 Renalogies  
277 NPS Pharmaceuticals, Inc. 324 Replicon NeuroTherapeutics, Inc 
278 NxtWave Communications 325 Repligen Corporation 
279 Ocean Genetics 326 RF Solutions, Inc 
280 Omex Corporation 327 RiboGene, Inc.  
281 Oncodiagnostics, Inc. 328 Rigel Pharmaceuticals, Inc 
282 Oncor, Inc. 329 Saber Equipment Corp. 
283 Optillion, Inc. 330 Safer, Inc.  
284 Opto-Electronic Center 331 SandCraft, Inc. 
285 Orchid Biosciences, Inc. 332 Saratoga Semiconductor Corp 
286 Oren Semiconductor Inc 333 Security Tag Systems 
287 Ortel Corporation 334 Sekonix Company, Ltd. 
288 OSI Pharmaceuticals, Inc. 335 Semiconductor Manufacturing Corp. 
289 Pacific Lithium Limited  336 Sensym Inc. 
290 PacketLight Networks, Ltd. 337 Shaman Pharmaceuticals, Inc. 
291 Panelvision Corporation 338 ShareWave, Inc. 
292 Paradigm Technology, Inc. 339 Sheldahl, Inc. 
293 Paradygm Science & Technologie 340 Sherwood Enterprises, Inc. 
294 Passave Technologies, Inc 341 SiByte, Inc. 
295 Peak Systems 342 SICOR, Inc. 
296 Peptor, Ltd. 343 Silicon Light Machines 
297 Perlegen Sciences, Inc. 344 Silicon Power Cube  
298 Phaethon Communications, Inc. 345 Silicon Wave, Inc. 
299 Phospho-Energetics, Inc. 346 SkyTune Corporationa 
300 PhotoBioChem NV 347 Sonics, Inc. 
301 Photodyne, Inc. 348 Sphinx Pharmaceuticals Corp 
302 Picolight, Inc.  349 Spiration, Inc. 
303 PinPoint Corp 350 Standard MEMS, Inc. 
304 Planar Systems, Inc. 351 Sterix Ltd 
305 Plastic Logic, Ltd. 352 StratumOne Communications, Inc 
306 Pliant Systems, Inc. 353 Substrate Technologies, Inc. 
307 Pluto Technologies International,Inc. 354 Sungene Technologies Corp 
308 PMC-Sierra, Inc. 355 Sunyang Tech Co., Ltd. 
309 Power Integrations, Inc. 356 Support Technologies, Inc. 
310 Powerline GES Pty Ltd 357 Suprex Corporation 
311 Procept, Inc.  358 Surface Mounted Technology Corp 
312 Proconics International, Inc. 359 SVO Enterprises Corporation 
313 ProCyte Corporation 360 Symphony Pharmaceuticals, Inc. 
314 ProQuip, Inc. 361 Synaptic Pharmaceutical Corp 
315 Provac, Inc. 362 Synbiotics Corporation 
316 PSI Star Corporation 363 Synergen, Inc. 
317 PTC Therapeutics, Inc. 364 Synergy Semiconductor Corp 
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365 Synopsys, Inc. 412 Zhone Technologies 
366 Syntro Corporation 413 Zight Corporation 
367 Tamul Multimedia Company, Ltd. 414 Zolo Technologies, Inc. 
368 Telecruz Technology, Inc.  415 Zoran Corporation 
369 Telios Pharmaceuticals, Inc.  416 Zylin Corporation 
370 Telmos, Inc. 417 Zynaxis, Inc. 
371 Tensilica, Inc.   418 Zyomyx, Inc. 
372 TerraGen Discovery   
373 Tessera Technologies, Inc.   
374 Test Systems, Inc.   
375 Therion Biologics Corporation    
376 Thesys Memory Products Corp   
377 TissueInformatics, Inc.   
378 Touch Activated Switch Arrays   
379 Transgenics, Inc.   
380 Transmeta Corporation   
381 Trega Biosciences, Inc.   
382 Trine Pharmaceuticals, Inc.   
383 Triplex Pharmaceutical Corp   
384 Trophix Pharmaceuticals, Inc.    
385 Tropic Networks, Inc.     
386 U.S. Genomics, Inc.   
387 Ultra Diagnostics Corporation    
388 Ultro Lighting International Pte   
389 Unistructure, Inc.    
390 Unitive Electronics, Inc.   
391 Variagenics, Inc.   
392 Vascular Architects, Inc.   
393 VaxGen, Inc.   
394 Vega Vista, Inc   
395 Verax Corporation   
396 Versicor, Inc.    
397 Vitelic Corporation    
398 Vitesse Semiconductor Corp   
399 VLSI Technology, Inc.   
400 VTC, Inc.   
401 WaferScale Integration, Inc   
402 WAVICS, Inc.   
403 Xcat, Inc.   
404 XCellsyz, Ltd.   
405 XDI Innovations   
406 Xenogen Corporation   
407 Xenova Group PLC   
408 Xilinx, Inc.   
409 XOMA Corporation   
410 Xytronyx, Inc.   
411 ZBD Displays Ltd   
 
 
      Appendix B 
   102
APPENDIX B 


















3Com Ventures  3577 3571,7376,7379 Silicon Wave, Inc. 3674 Provides silicon ASIC solutions for communication equipment. 7373 0.25 
Abbott Laboratories  2834 2833,3821,5047 Aronex Pharmaceuticals, Inc. 2836 Develops anti-infective and cancer therapeutics. 3356 0.75 
Abbott Laboratories  2834 2833,3821,5047 LocalMed, Inc 8731 Develops innovative catheter systems to deliver therapeutics agents. 2836 0 
Abbott Laboratories  2834 2833,3821,5047 Metabolex, Inc. 2834 Develops and discovers new drugs for type 2 diabetes. 
3823,3845,3
825 1 
Abbott Laboratories  2834 2833,3821,5047 RiboGene, Inc.  2834 Develops therapeutic compounds designed to combat infections. 7373 1 
Acma Australia Pty Ltd.  5045 6719,7379,7372,5722 Harwal Electrical Industries Pty Ltd 3573 
Designs and manufactures 
switchboard installations. 5139 0 
ADC Telecommunications, 
Inc. 3661 3669,7372,7379 PacketLight Networks, Ltd. 3674 Develops optical systems. 8731 0.5 
Affymetrix, Inc.  8731 / Eos Biotechnology, Inc. 2936 Develops therapeutic antibody based drugs. 3826 0 
Affymetrix, Inc.  8731 / Orchid Biosciences, Inc. 8071 Develops computer micro-engineering technology for drug design. 8731 0.25 
Affymetrix, Inc.  8731 / Perlegen Sciences, Inc. 2836 Provides genetics research. 7379 0 





Genetics Institute, Inc. 2836 Develops recombinant DNA human pharmaceutical products. 8731 0 
Altera Corporation 3674 7372 I-Cube, Inc. 3674 Develops several types of CMOS integrated circuits. 5139 1 
Altera Corporation 3674 / Tensilica, Inc.   3629 Develops application-tailored microprocessors. 7371,6794 0.5 
Amena-Retevision Movil SA  2833 / Advancell 2835 Develops in vitro cellular technology for the pharmaceutical industry. 
2899,3821,3
826,8731 0.75 
Amena-Retevision Movil SA  2833 / XCellsyz, Ltd. 2835 Produces novel human cell based technologies for drug discovery. 5065 0.75 
American Cyanamid  8071 / Cytogen Corporation 2834 Develops biomedical systems for imaging and treating cancers. 2836 0 
American Cyanamid  8071 / Ecogen, Inc. 2834 Developing microbial and viral biological pest controls. 3087 0 
American Cyanamid  8071 / Embrex, Inc 2836 Develops technology of poultry embryo growth stimulants. 3087 0 
American Cyanamid  8071 / XOMA Corporation 2836 Develops genetically-engineered monoclonal antibodies. 
5045,5065,3
672,7372 0 




Calient Networks 3832 Develops intelligent, all-photonic switching systems and software. 2835 0 




Quidel Corporation 2835 Manufactures and markets medical diagnotic test kits. 7373 0 




Silicon Power Cube  3674 Manufactures high power solid state switching modules. 7373 0 
American Hospital Supply 
Corp. 2835 / Bio-Diagnostics, Inc. 2835 
Develops instrumentation to analyze 
certain blood chemistries. 3569,3821 1 




,4841 Advanced Power Technology, Inc 3674 
Manufactures semiconductors for high 






,4841 Aetna Communication Laboratories 3832 







,4841 Level One Communications, Inc. 3661 
Designs and markets specialty 




,4841 Microbeam, Inc. 3674 
Manufactures scientific instruments 






,4841 Pliant Systems, Inc. 3832 
Manufactures and markets fiber optic 






,4841 ShareWave, Inc. 3674 
Develops semiconductor technology 






,4841 Unistructure, Inc.  3573 
Manufactures multi-layer printed circuit 
assemblies. 7371,6794 0 
Analog Devices Enterprises  3674 / Altera Corporation 3674 Manufactures semi-custom erasable programmable logic devices. 3577 1 
Analog Devices Enterprises  3674 / Axsun Technologies, Inc 3674 Manufactures optical components for the telecommunications industry. 3569,3821 1 
Analog Devices Enterprises  3674 / Bipolar Integrated Technology Inc. 3674 Designs VLSI integrated circuits. 2835 1 
Analog Devices Enterprises  3674 / GigaBit Logic, Inc. 3674 Manufactures ultra high-speed gallium arsenide integrated circuits. 5139 1 
Analog Devices Enterprises  3674 / Photodyne, Inc. 3825 Manufactures fiber optic testing equipment and other products. 7379 0.25 
Analog Devices Enterprises  3674 / Test Systems, Inc. 3811 Makes loaded and bare-board testers. 7371,6794 0.25 
Analogic Corp.  3825 7382,3577,7011 Telmos, Inc. 3674 Manufactures ICs using DMOs, CMOs and precision analog arrays. 2834 0.25 
Anschutz Investment 6282 / Chromatis Networks, Inc. 3669 Develops an automated intelligent 2879 0 
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Company  microscope system. 
Anschutz Investment 
Company  6282 / Tropic Networks, Inc.   3832 
Operates as an optical networking 
company. 7371,6794 0 
Anschutz Investment 
Company  6282 / Zolo Technologies, Inc. 3832 
Develops and manufactures optical 
networking subsystems. 3661,3229 0 
Asachi Keiki Co. Ltd. 3390 / Crystal Semiconductor Corp 3674 Develops integrated circuits with analog/digital functions. 3566,5065 0.25 
Asachi Keiki Co. Ltd. 3390 / Luxtron Corporation 3822 
Manufactures ultra-sensitive 




Asahi Chemical Industry 
Co., Ltd. 2899 5039,2834 Circe Biomedical, Inc. 2834 
Develops bioartificial organs and 
biomedical systems. 3827 0.5 
Asahi Chemical Industry 
Co., Ltd. 2899 5039,2834 Crystal Semiconductor Corp 3674 
Develops integrated circuits with 
analog/digital functions. 3566,5065 0 
AT&T 4813 7389,7375,8999,7379 Paradigm Technology, Inc. 3674 
Develops advanced semiconductor 
devices for high-speed RAMs. 8731 0 
August Systems Corp. 3825 / Micron Custom Manufacturing Inc. 3573 Operates as an electronics manufacturing services provider. 
3823,3845,3
825 0.25 




Benchmarq Microelectronics, Inc. 3500 
Designs, tests, & markets integrated 
circuits and semiconductor 
components. 
3569,3821 0 
Becton, Dickinson & Co.  3841 3842,3826,3845 Applied Biosystems, Inc. 3826 Develops genetic machinery and chemical products. 2836,8731 0.5 
Becton, Dickinson & Co.  3841 3842,3826,3845 Luxtron Corporation 3822 
Manufactures ultra-sensitive 




Becton, Dickinson & Co.  3841 3842,3826,3845 Nanogen, Inc. 3826 Develops proprietary DNA sequencing technology from the Salk Institute. 3841 0.5 
Becton, Dickinson & Co.  3841 3842,3826,3845 OSI Pharmaceuticals, Inc. 2834 Develops products for the detection, monitoring and treatment of cancer. 8731 0 
Becton, Dickinson & Co.  3841 3842,3826,3845 Quidel Corporation 2835 Manufactures and markets medical diagnotic test kits. 7373 0 
Becton, Dickinson & Co.  3841 3842,3826,3845 Sensym Inc. 3674 Manufactures low-cost pressure sensors. 7373 0.25 
BIOMEC Inc. 2899 / Imalux Corporation 5047 Develops medical imaging equipment and devices. 5139 0 
BIOMEC Inc. 2899 / NeuroControl Corporation 3842 Develops FES technology to restore paralyzed muscles and limbs. 2836,8731 0 
BMW Technologies Inc. 3711 3751 Dolch American Instruments 3674 Manufactures logic analyzers for complex microprocessor architectures. 3087 0.25 
Boehringer Mannheim Corp  2834 / XOMA Corporation 2836 Develops genetically-engineered monoclonal antibodies. 
5045,5065,3
672,7372 0.75 
Borg-Warner Security Corp. 3714 3585 PMC-Sierra, Inc. 3674 Manufactures standard and application-specific integrated circuits. 
3613,3577,3
823 0.25 
Bristol-Myers Company 2834 2844,5122,3842 Procept, Inc.  2843 Develops immunotherapeutic and diagnostic pharmaceuticals. 
3613,3577,3
823 1 







BRM Capital 6172 / Passave Technologies, Inc 3573 
Develops digital signal processing 
(DSP) cores for semiconductor 
industry. 
8731 0 
BSI Industries 2891 / Agensys, Inc. 8732 Develops targeted cancer therapeutics. 
2899,3821,3
826,8731 0 
C. Itoh & Co. Ltd. 5171 5172 Repligen Corporation 2856 Produces recombinant proteins. 7373 0 
Cabletron Systems, Inc. 3661 7376 CentrePath  7373 
Designs fiber optic networking 
products addressing bandwidth 
bottlenecking. 
2879 0 
Canon, Inc.  3579 3555,3861 Energy Conversion Devices, Inc 3674 Develops technologies involving amorphous semiconductors. 
8731,3499,3
827,3674 0.25 




ShareWave, Inc. 3674 
Develops semiconductor technology 
for wireless home networking 
products. 
7373 0 
Centocor Corporation 2834 / Apollon, Inc.  2836 Develops and commercializes nucleic acid based vaccines. 2836,8731 0.75 
Centocor Corporation 2834 / ChromaVision Medical Systems Inc. 3827 Develops an automated intelligent microscope system. 2879 0 
Centocor Corporation 2834 / Variagenics, Inc. 2836 Develops and commercializes pharmacogenomics products. 7371,6794 0.75 
ChevronTexaco Venture 





Illumina, Inc. 3826 Develops tools for the large-scale analysis of genetic variation & function 5139 0 
ChevronTexaco Venture 














Xenogen Corporation 8731 Develops biochemical reporters that monitor biological events. 2835 0 
CIBC Bank, CIBC 
Resourcing  6021 
6022,6029,6081
,6082 Variagenics, Inc. 2836 
Develops and commercializes 
pharmacogenomics products. 7371,6794 0 
Cisco Systems, Inc.   3661 / Acelo Semiconductor, Inc.  3674 Creates semiconductors for fiber optic telecommunications. 
3827,7389,3
577 0.5 
Cisco Systems, Inc.   3661 / BaySpec, Inc. 3229 Designs, manufactures and markets fiber-optic components and modules. 3569,3821 0.25 
Cisco Systems, Inc.   3661 / CENiX, Inc. 3679 Designs and manufactures high-speed optoelectronic interfaces. 2879 0.5 
Cisco Systems, Inc.   3661 / Cidra Corporation 8711 Designs and manufactures optical components and modules for 3827 0 
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networks. 
Cisco Systems, Inc.   3661 / Integrated Micromachines, Inc. 3679 
Develops high performance 
components for optical switching 
applications. 
3674 0.5 
Cisco Systems, Inc.   3661 / iPhotonics, Inc. 8711 Provides outsourced services for fiber optic system and subsystem OEMs. 8731 0 
Cisco Systems, Inc.   3661 / Lamina Ceramics, Inc. 3573 Manufactures ceramic printed circuit boards based on a metal substrate. 8731 0.25 
Cisco Systems, Inc.   3661 / LightLogic, Inc. 3663 Develops optoelectronic components and subsystems. 8731 0.75 
Cisco Systems, Inc.   3661 / MystiCom, Ltd. 3573 
Develops digital signal processing 
(DSP) cores for semiconductor 
industry. 
3841 0.25 
Cisco Systems, Inc.   3661 / Navarro Networks 3674 Designs high-performance VLSI integrated circuits 3841 0.25 
Cisco Systems, Inc.   3661 / Novalux, Inc. 3669 Manufactures photonic systems for semiconductor manufacturing. 8731 0.75 
Cisco Systems, Inc.   3661 / Optillion, Inc. 3674 Develops and manufactures fibre-optic ethernet transceivers. 8731 0.75 
Cisco Systems, Inc.   3661 / Phaethon Communications, Inc. 3674 Develops Fiber Optic networking systems. 7379 0.75 
Cisco Systems, Inc.   3661 / Picolight, Inc.  3832 Produces and sells fiber-optic components. 3699 0.25 
Cisco Systems, Inc.   3661 / Quake Technologies, Inc. 3674 Develops physical layer chips for high speed optical networking. 7373 0.5 
Cisco Systems, Inc.   3661 / Quantum Effect Devices, Inc 3571 Manufactures microprocessors for embedded systems applications. 7373 0.25 
Cisco Systems, Inc.   3661 / SandCraft, Inc. 3571 Develops and markets superscalar microprocessors for communications. 7373 0.25 
Cisco Systems, Inc.   3661 / ShareWave, Inc. 3674 
Develops semiconductor technology 
for wireless home networking 
products. 
7373 0.5 
Cisco Systems, Inc.   3661 / SiByte, Inc. 3571 Development and manufacturing of microprocessor solutions. 7373 0.75 
Cisco Systems, Inc.   3661 / StratumOne Communications, Inc 3669 Develops integrated semiconductor technology. 8731 0.75 
Cisco Systems, Inc.   3661 / Tensilica, Inc.   7371 Develops application-tailored microprocessors. 6794 0 
Cisco Systems, Inc.   3661 / Vega Vista, Inc 7371 Operates a fabless semiconductor company. 6794 0 
Cisco Systems, Inc.   3661 / Zhone Technologies 5045 





Comcast Interactive Capital 4841 7375 Quantum Bridge Communications 3663 Provides carrier class Fiber to the Premises (FTTP) equipment. 7373 0 




Candescent Technologies Corp. 3830 Licenses technology for high-definition flat panel displays. 
3675,3672,3
676 0.25 




Intellon Corporation 3573 Develops integrated circuits, subsystems and development tools. 3674,3669 0.75 




Transmeta Corporation 3571 Manufactures and designs VLSI chips for wireless mobile devices. 7371,6794 0.75 
Comstellar Technologies, 
Inc.  5160 / Ashvattha Semiconductor, Inc. 5065 
Provides integrated radio frequency 
chips. 8071 0.25 
Conexant Systems, Inc. 3674 3661 Tensilica, Inc.   3629 Develops application-tailored microprocessors. 7371,6794 0.5 
Control Data Corporation 3670 / Micro Technology, Inc. 3674 Manufactures high performance peripheral controller devices. 
3823,3845,3
825 0.75 
Control Data Corporation 3670 / VTC, Inc. 3674 Manufactures analog semiconductors for the disk drive industry. 5065 0.75 
Cooper Development Co. 3851 3841,3827 XOMA Corporation 3672 Develops genetically-engineered monoclonal antibodies. 3672,7372 0.25 
Cowen Biotech Ltd. 2836 / Repligen Corporation 2856 Produces recombinant proteins. 7373 0.5 
CP Ventures Inc. 3624 2821,2221,3469 Austek Microsystems, Ltd. 3620 Manufactures custom semiconductors and circuit board subsystems. 3569,3821 0.75 
CPC International Inc. 7380 / Syntro Corporation 2834 Develops biotechnology for animal health and specialty chemicals. 2834 0 
CPT Holdings Inc. 7379 / Xcat, Inc. 3800 Manufactures integrated logic and fault simulation accelerator systems. 5065 0 
Crossroad Systems 3577 3572 NetEffect, Inc. 3674 Develops chips for networking and storage applications. 2836,8731 0.25 
Crystal Systems Solutions 
Ltd. 7371 / Sonics, Inc. 3674 
Develops communication subsystems 
to connect Intellectual Property cores. 7373 0 
Cypress Semiconductor 
Corp. 3674 / Alvesta Corporation 3832 
Designs and manufactures full-duplex, 
10Gb/s optical transceivers. 3577 0.25 
Cypress Semiconductor 
Corp. 3674 / Silicon Light Machines 3679 
Develops light valve technology for 
use in projection displays. 7373 0.75 
DAMAC Ventures 6799 / Blaze Network Products, Inc. 3832 Develops optical transceiver products and optical sub-assemblies. 2835 0 
DAMAC Ventures 6799 / Chameleon Systems, Inc. 3674 




DAMAC Ventures 6799 / Cidra Corporation 8711 
Designs and manufactures optical 
components and modules for 
networks. 
3827 0 
DAMAC Ventures 6799 / PinPoint Corp 5063 Develops devices used for tracking personnel within healthcare facilities. 3699 0 
DAMAC Ventures 6799 / Silicon Wave, Inc. 3674 Provides silicon ASIC solutions for communication equipment. 7373 0 
DAMAC Ventures 6799 / Standard MEMS, Inc. 3674 Manufactures Micro Electro Mechanical Systems (MEMS) for high 8731 0 
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technology. 
Data General Corporation 3575 3577,3669 Actel Corporation  3674 
Manufactures programmable 




Data General Corporation 3575 3577,3669 Power Integrations, Inc. 3674 Develops integrated circuits to interface and control high voltages. 
3613, 
3577,3823 0.25 
Dekalb Agriresearch 2836 / Life Technologies, Inc. 3826 Produces research enzymes for the genetic engineering market. 8731 0 
Diagnostic Products Corp. 3842 3841,2835 Monoclonal Antibodies, Inc. 2835 Develops hybridoma cell lines and manufactures monoclonal antibodies. 3841 0 
Digital Equipment Corp. 3571 3577,7373,3572 Synergy Semiconductor Corp 3679 Manufactures high-performance ECL and BICMOS products. 2834 0.5 





Alchemia Pty., Ltd. 8731 Develops a new technology for the manufacture of carbohydrates. 5122 0 





Alien Technology Corporation  3573 Develops electronic display technology. 3577 0 





AmberWave Systems Corporation  7379 Supplies strained silicon technology for the semiconductor industry. 3577 0 





Collaborative Research, Inc 8737 Develops biotechnology products in the medical, agricul. & indus. fields. 3827 0.25 





Dionex Corporation 3826 
Manufactures ion chromatography 
systems used for ID of ionic 
contaminants. 
3087 0.25 





DNA Research Innovations, Ltd. 3826 Develops automated DNA extraction instuments. 3087 0 





Epicyte Pharmaceutical, Inc. 2836 
Develops medical therapies for 
diseases affecting mucous 
membranes. 
3826 0 





Genetics Institute, Inc. 2836 Develops recombinant DNA human pharmaceutical products. 8731 0 





Graffinity Pharmaceutical Design 
GmbH 2834 
Develops chemical microarrays for 
use in post genomic drug discovery. 5139 0 





JGKB Photonics, Inc. 3674 Operates as a fabless optical component company. 8731 0 





Plastic Logic, Ltd. 3573 Develops plastic circuits for mass applications. 
3613,3577,3
823 0 





PSI Star Corporation 3679 Develops etching processes for printed circuit boards. 2844 0 





XDI Innovations 3674 
Develops specially engineered 
electronic products and 
semiconductors. 
5065 0 





ZBD Displays Ltd 3679 Develops liquid crystal display technology. 
5045,5065,3
672,7372 0 





Greyhawk Systems, Inc. 3573 Manufactures high information content, large area displays. 5139 0 





Hem Research, Inc. 8731 
Dvlps Ampligen, potentially 
therapeutic agent for treatment of 
AIDS, cancer 
5139 0 





Molecular Biosystems, Inc. 3845 Engages in applied molecular biology R&D of diagnostic products. 3825 0 
Eastman Kodak Co, Inc. 3861 3577 Be Here Corporation 3569 Develops panoramic still-image camera lens system. 3821 0.25 
Eastman Kodak Co, Inc. 3861 3577 Cytogen Corporation 2834 Develops biomedical systems for imaging and treating cancers. 2836 0 
Eastman Kodak Co, Inc. 3861 3577 NeoRx Corporation 2835 Develops antibody agents for use in the treatment of cancer. 2836, 8731 0 
Elan Corporation PLC 3861 5122 Acorda Therapeutics, Inc. 3861 Develops therapeutic products to restore spinal cord functionality. 
2899,3821,3
826,8731 1 
Elan Corporation PLC 3861 5122 Athersys Inc. 3861 Develops therapeutic products. 3569, 3821 1 
Elan Corporation PLC 3861 5122 Beyond Genomics, Inc. 3861 Develops a systems biology platform. 3569, 3821 1 
Elan Corporation PLC 3861 5122 Incara  3861 Develops catalytic antioxidant compounds for cancer therapies. 5139 1 
Electrolux Corporation 7372 6719,4899 Touch Activated Switch Arrays 3100 
Develops a unique system of controls 
which eliminates mechanical 
components 
7371, 6794 0 
Electro-Science Corp. 2810 / Electronic Systems Products, Inc. 3861 
Manufactures radio communications 
equipment, simulation components, 
etc. 
3087 0 
Electro-Science Corp. 2810 / Immunomed Corporation 2834 Develops immunological drugs for the veterinary industry. 5139 0.5 
ELF Technologies 2999 / Advanced Power Technology, Inc 3674 Manufactures semiconductors for high power and high frequency control. 
2899,3821,3
826,8731 0 
ELF Technologies 2999 / Agridyne Technologies, Inc.  721 Develops botanical insecticides and plant growth enhancement products. 8731,5122 0 
ELF Technologies 2999 / Angenics, Inc. 2835 Develops in vitro monoclonal antibody diagnostic tests. 2836,8731 0 
ELF Technologies 2999 / Crop Genetics International Corp. 721 Produces improved plant products 3566,5065 0 
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using DNA technologies. 
ELF Technologies 2999 / Embrex, Inc 2836 Develops technology of poultry embryo growth stimulants. 3087 0 
ELF Technologies 2999 / Enzytech, Inc 2834 Develops value-added products for healthcare, food and chemicals. 3826 0 
ELF Technologies 2999 / Kinetek Systems, Inc. 3826 Develops separation systems for the biotechnology industry. 8731 0 
ELF Technologies 2999 / Martek Biosciences Corporation 2865 
Develops nutritionals and 




ELF Technologies 2999 / Microgenics Corporation 5951 Develops medical diagnostic test kits for clinical laboratories. 
3823,3845,3
825 0 
ELF Technologies 2999 / Saber Equipment Corp. 3600 Develops novel integrated fuel dispensing systems. 7373 0 
ELF Technologies 2999 / Safer, Inc.  721 
Manufactures non-toxic, 
non-petrochemical insecticides and 
fungicides. 
7373 0 
ELF Technologies 2999 / Shaman Pharmaceuticals, Inc. 3800 Develops pharmaceuticals by isolating active compounds in tropical plants. 7373 0 
ELF Technologies 2999 / Sphinx Pharmaceuticals Corp 2835 Develops lipid-based diagnostics and therapeutics for various diseases. 7373 0 
ELF Technologies 2999 / Telios Pharmaceuticals, Inc.  3826 
Develops products to aid 
cardiovascular wound and tissue 
healing. 
2834 0 
Eli Lilly & Company 2834 2833,2869,8099 Agouron Pharmaceuticals, Inc. 2834 Develops pharmaceuticals for the health care and food industries. 8731,5122 1 
Eli Lilly & Company 2834 2833,2869,8099 Athena Neurosciences, Inc. 2834 Develops diagnostics and therapeutics for neurological disorders. 3569,3821 1 
Eli Lilly & Company 2834 2833,2869,8099 BI, Inc. 2750 Mfrs. electronic identification systems and components. 3569,3821 0.25 
Eli Lilly & Company 2834 2833,2869,8099 Glycomed, Inc. 2834 Develops therapeutic drugs based on complex carbohydrates. 5139 1 
Eli Lilly & Company 2834 2833,2869,8099 Kelsius, Inc. 3826 Developing biological sensors for in vivo and in vitro purposes. 8731 0 
Eli Lilly & Company 2834 2833,2869,8099 NeXagen, Inc. 2834 
Develops a new class of 
pharmaceuticals based on RNA 
molecules. 
2836,8731 1 
Eli Lilly & Company 2834 2833,2869,8099 Verax Corporation 3826 Manufactures proteins and continuous fermentation systems. 7371,6794 0 
Elron Technologies 7372 6719,4899 Oren Semiconductor Inc 3674 Develops digital-TV demodulation ICs for US and worldwide markets. 8731 0 
Elron Technologies 7372 6719,4899 Zoran Corporation 3674 Designs digital signal processing (DSP) chips and system processors. 7372 0 
Ericsson Business 
Innovation AB. 3661 / Dialog Semiconductor GmbH 3674 
Manufactures mixed signal Application 
specific Integrated Circuits (ASIC). 7371 0.5 
Evans and Sutherland 7372 3674  Mosaic Systems, Inc. 3674 
Designs electrically programmable 
silicon semiconductors. 3841 0 
Evans and Sutherland 7372 3674  VLSI Technology, Inc. 3674 
Manufactures customized very large 
scale integrated CMOS 
semiconductors. 
5065 0 





Epid 3573 A low-cost flat panel display to replace CRTs. 3826 0 





Erndex 3674 Manufactures photo diodes. 3826 0 





Kaylex, Inc. 3830 Developing liquid crystal displays. 8731 0 















Microgenics Corporation 3823 Develops medical diagnostic test kits for clinical laboratories. 3845,3825 0 
Farley Inc. 6531 / Exelixis, Inc. 8731 
Develops pre-clinical models to 
assess and validate human gene 
function. 
3826 0 
Fenwick & West LLP 3674 / FormFactor, Inc. 3679 
Develops microsprings used to 
interconnect electronic packages to 
PCB's. 
3826 0.5 
Fenwick & West LLP 3674 / Transmeta Corporation 3571 Manufactures and designs VLSI chips for wireless mobile devices. 7371,6794 0.25 
Flextronics International 
Ltd. 3672 3679 Celetronix  3679 
Provides electronic and optical 
manufacturing services. 3845 0.75 
Flextronics International 
Ltd. 3672 3679 Unitive Electronics, Inc. 3679 
Develops advanced semiconductor 
wafer processing and packaging 
technologies 
7371,6794 0.75 
Foster Industries, Inc. 3651 / International Microelectronic 8711 Manufactures custom semiconductor integrated circuits. 3674 0 
Foster Industries, Inc. 3651 / Lightwave Technologies, Inc. 8731 Manufactures optical fiber cable for the telecommunications industry. 3832 0 
Foster Industries, Inc. 3651 / LipoGen, Inc.  2835 Develops liposome-based diagnostic test products. 8731 0 
Foster Industries, Inc. 3651 / Suprex Corporation 8731 Develops supercritical fluid chromatography instruments (SFC). 3800,5065 0 
Fuji Bank, Limited 6029 / Telecruz Technology, Inc.  3573 Designs and manufactures integrated circuits for the interactive TV market. 2834 0 
Fujitsu Ltd. 3571 3674 Anamartic Ltd. 3571 Manufactures semiconductor-based 2836,8731 1 
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storage systems. 
Fujitsu Ltd. 3571 3674 Vitesse Semiconductor Corp 3674 Designs communications integrated circuits for network equipment. 5065 0.25 
G.D. Searle Division 3823 / Biotechnology Development Corp. 3826 
Provides medical equipment, 
disposables, technology & consulting 
services. 
2835 0.75 
Genentech Corporatio 2834 / Glycomed, Inc. 2834 Develops therapeutic drugs based on complex carbohydrates. 5139 1 
Genentech Corporatio 2834 / InterMune, Inc. 2834 Develops products to treat pulmonary and infectious diseases and cancer. 8731 1 
Genentech Corporatio 2834 / Telios Pharmaceuticals, Inc.  8731 
Develops products to aid 
cardiovascular wound and tissue 
healing. 
2834 0 
Genentech Corporatio 2834 / VaxGen, Inc. 2834 Tests and markets HIV vaccine. 7371,6794 1 
Genentech Corporatio 2834 / Verax Corporation 3826 Manufactures proteins and continuous fermentation systems. 7371,6794 0 
Genentech Corporatio 2834 / Xenova Group PLC 2834 Designs and develops novel small molecule drugs from natural sources. 2835 1 
General Atom/Toshiba 
Corp. 3669 3679 Applied Superconetics 3560 
Mfrs. superconducting magnetics for 
magnetic resonance imaging systems. 3600 0.25 





Sherwood Enterprises, Inc. 3560 Manufacture complex cable systems and sub-assemblies. 7373 0.5 
General Instrument 
Corporation 3674 3629 Cybernetic Data Products, Inc. 4899 
Manufactures moving message 
displays and visual communication 
systems. 
3566,5065 0 
General Motors 3711 3713,6141,6331,6159,6163 Agility Communications, Inc.  4813 




General Signal Corporation 3541 / Electron Beam Corp. 3699 
Mfrs electron-beam lithography 
equipment for semiconductor 
processing. 
3087 0.25 
General Signal Corporation 3541 / Zylin Corporation 3541 Designs digital signal processing (DSP) chips and system processors. 7372 1 
Getty OIL Company 2070 / Synergen, Inc. 2834 Develops specialty chemicals through genetic engineering. 2834 0.25 





Repligen Corporation 2856 Produces recombinant proteins. 7373 0 
Glyko Biomedical, Ltd. 2860 / BioMarin Pharmaceutical, Inc. 2835 Develops and commercializes carbohydrate enzyme therapeutics. 2835 0.25 
Gould Inc. 3692 0723 Altus Corporation  3692 Produces lithium-thionyl chloride power cells. 3577 1 
Guidant Corporation 3845 3841 CardioFocus, Inc. 8731 Develops photonic medical devices that treats cardiovascular diseases. 3845 0 
Guidant Corporation 3845 3841 Spiration, Inc. 3841 Develops devices for the treatment of pulmonary diseases. 8731 0.75 
Harris Corporation 3669 3679 Cross-Check Technology, Inc. 3825 Provides testability solutions for semiconductor designs. 3566,5065 0.25 
Harris Corporation 3669 3679 NxtWave Communications 3577 Manufactures digital modulation and de-modulation integrated circuits. 8731 0.25 
Harris Corporation 3669 3679 Peak Systems 3577 Develops ion implant monitors for the semiconductor industry. 7379 0.25 
Harris Corporation 3669 3679 Synopsys, Inc. 3577 Develops high level design automation software. 2834 0.25 
Heizer Corporation 3674 / Omex Corporation 3573 Develops laser-based optical document storage systems. 8731 0.25 




Caliper Technologies Corp. 3826 Manufactures systems for biochemical analysis. 
3675,3672,3
676 0.25 
Hillman  5084 5072,5039,8711,7389 Agile Therapeutics, Inc.  2834 
Develops novel transdermal products 




Corporation 2834 / Berlex Biosciences  2834 
Develops human/animal health 
products and vaccines. 3569, 3821 1 
Hoechst Celanese 
Corporation 2834 / Celgene Corporation 2834 
Develops biocatalysts for the 
production of fine chemicals. 2879 1 
Hoechst Celanese 
Corporation 2834 / Nova Pharmaceutical Corp 2834 
Develops therapeutic drugs focusing 
on central nervous system disorders. 8731 1 
Hybritech Incorporated 0723 / Gen-Probe, Inc.  2835 Manufactures medical products based on DNA probe technology. 3826 0 
Hyundai Venture 
Investment Corp. 6799 / Cellontech Co Ltd 2835 
Operates in the biotechnology 
industry. 2879 0 
Hyundai Venture 
Investment Corp. 6799 / Daehan Bio Link Company, Ltd. 721 
Supplies specific pathogen free (SPF) 
laboratory animals. 2836 0 
Hyundai Venture 
Investment Corp. 6799 / Focus Company Ltd. 3679 Manufactures electronic components. 3826 0 
Hyundai Venture 
Investment Corp. 6799 / FST Inc. (FKA: Fine Semiconduc 3674 
Manufactures and supplies pellicle to 
its clients. 3826 0 
Hyundai Venture 
Investment Corp. 6799 / Genomine, Inc. 8071 Develops edible vaccine. 5139 0 
Hyundai Venture 
Investment Corp. 6799 / In2Gen Co., Ltd  2836 
Provides preventive and diagnosis 




Investment Corp. 6799 / Innergy Power Corp. 3600 
Develops and manufactures 




Investment Corp. 6799 / Mediopia International Co Ltd 3674 





Investment Corp. 6799 / Microscale Company, Ltd. 3674 
Supplies flip chip bumping services to 




Investment Corp. 6799 / Nitgen Technologies 3674 
Designs and develops fingerprint 
recognition applications. 2836,8731 0 
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Hyundai Venture 
Investment Corp. 6799 / Sunyang Tech Co., Ltd. 3699 
Operates as a semiconductor 
equipment maker. 8731,5065 0 





Credence Systems Corp. 3825 
Manufactures Automatic Test 
Equipment (ATE) for LSI/VLSI 
semiconductors. 
3566,5065 0.25 





MultiLink Technology Corp. 3674 Designs and manufactures integrated circuits, modules, and boards. 3841 0.25 
Infotechnology 2834 / American Bionetics, Inc. 2830 Develops instrumentation and supplies for biotechnology industry. 3577 0.75 
Infotechnology 2834 / Associated Biomedic Systems, Inc. 2836 Develops T-cell growth factor and immune interferon technologies. 8071 0.75 
Infotechnology 2834 / Clinical Sciences, Inc. 2835 Produces immunodiagnostic reagents and reagent systems. 3827 0.75 
Infotechnology 2834 / Compulaser, Inc. 3573 
Manufactures computer-controlled 
laser production tools and laser 
systems. 
3827 0 
Infotechnology 2834 / Environmental Processing Inc 7397 Tests and conditions semiconductor circuits. 
8731,3499,3
827,3674 0 
Infotechnology 2834 / Flight Dynamics, Inc. 5088 Dvlps display systems sold in varying configurations to commercial airlines 3826 0 
Innova Corp 3841  Besco Inc. 3670 
Developed proprietary ceramic 
pressure transducers to digitize 
signals. 
3821,3829 0.25 
Innova Corp 3841  Focus Semiconductor Systems, Inc. 3826 Manufactures chemical vapor deposition systems for IC production. 3674 0.5 
Innova Corp 3841  Luxtron Corporation 3822 
Manufactures ultra-sensitive 




Institution of Immunology 2836 / IDEC Pharmaceuticals Corp 2836 Develops biopharmaceuticals to treat cancer and immune disorders. 5139 1 
Integrated Device 
Technology Inc. 3674 / Quantum Effect Devices, Inc 3571 
Manufactures microprocessors for 
embedded systems applications. 7373 0.25 
Intelligent Systems 
Corporation 7372 8243,8093,3821 AtheroGenics, Inc. 2834 
Operates a biopharmaceutical 




Corporation 7372 8243,8093,3821 Renalogies  8731 
Develops drugs for treatment of kidney 
diseases. 7373 0 
Intelligent Systems 
Corporation 7372 8243,8093,3821 RF Solutions, Inc 2834 
Develops pharmaceuticals to treat 
kidney disease. 7373 0 
Invacare Corporation 8731 / NeuroControl Corporation 3674 Provides broadband wireless products for the telecommunications industry. 7373 0 
Itochu Corporation 5099 5199 NEC Eluminant Technologies, Inc. 3842 Develops FES technology to restore paralyzed muscles and limbs. 2836,8731 0 





Aclara BioSciences Inc.  3674 Develops systems for the passive optical network. 3841 0 





Acorda Therapeutics, Inc. 2835 Develops electronically-controlled microfluidics technology. 
2899,3821,3
826,8731 0.75 





Allos Therapeutics, Inc.  2835 Develops therapeutic products to restore spinal cord functionality. 
2899,3821,3
826,8731 0.75 





Aphton Corporation 2835 Develops and commercializes small molecular drugs. 3577 0.75 





Bio Logicals, Inc. 8731 Engaged in products to enhance capabilities of the immune system. 2836,2834 0 





British Bio-Technology Group PLC 7391 Develops synthesis capabilities and pilot production of cloned products. 3569,3821 0 





Cambridge Biotechnology 7391 Develops and manufactures reagents and pharmaceuticals. 2835 0.75 





Critical Therapeutics, Inc. 3672 Produces painkillers and obesity treatments. 3675,3676 0 





Cyrano Sciences, Inc. 7391 Develops therapeutic products for critical care medicine. 3566,5065 0 





Cytogen Corporation 3826 Develops electronic sensor capable of identifying a spectrum of odors. 3566,5065 0.75 





DigiLens, Inc.  2834 Develops biomedical systems for imaging and treating cancers. 2836 0 




Enzo Biochem 3674 Designs, manufactures and markets polymer optical components. 7371 0 
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41 





Epicyte Pharmaceutical, Inc. 3826 
Research commercial products and 
processes based on genetic 
engineering. 
3826 0.75 





Genaissance Pharmaceuticals, Inc. 2836 
Develops medical therapies for 
diseases affecting mucous 
membranes. 
3826 0 





Gliatech, Inc. 8071 Operates as a pharmaceutical company. 3826 0 





Immunicon Corporation 3841 Develops neural regeneration pharmaceuticals and devices. 5139 0.75 





Koronis Pharmaceuticals 2835 Develops affinity ferrofluids in combination with magnetic separation. 5139 0.75 





LifeSpex, Inc. 2835 
Develops technologies for the 
prevention and treatment of viral 
diseases. 
8731 0.75 





Locus Pharmaceuticals, Inc. 2835 Develops in-vivo medical diagnostic and therapeutic applications. 8731 0.75 





Metris Therapeutics, Ltd. 3821 Develops a process to calculate the architecture of a protein's pocket. 8731 0 





Neose Technologies, Inc. 2835 Develops therapies for benign gynecological diseases. 
3823,3845,3
825 0.75 





Neurocrine Biosciences, Inc. 8731 Discovers and develops complex carbohydrates. 2836 0 





Peptor, Ltd. 2836 Develops drugs to treat nervous and immune system disorders. 8731 0.75 





PhotoBioChem NV 3841 
Discovers and developes novel 
therapies for the treatment of 
diseases. 
7379 0 





Replicon NeuroTherapeutics, Inc 3841 Develops drugs to help protect against infectious diseases. 7379 0 





Rigel Pharmaceuticals, Inc 8071 
Operates as a biopharmaceutical 
company focused on the use of 
replicons. 
7373 0 





Sterix Ltd 8731 Provides intracellular combinatorial biochemistry research services. 7373 0 





Trega Biosciences, Inc. 8731 Develops and discovers steriod derivatives. 8731 0 





Trine Pharmaceuticals, Inc. 2835 Develops novel, small molecule drug therapies. 7371,6794 0.75 





Trophix Pharmaceuticals, Inc.  2835 Operates a drug development company. 7371,6794 0.75 





U.S. Genomics, Inc. 2836 Develops pharmaceutical products for neurodegenerative diseases. 7371,6794 0.75 





Vascular Architects, Inc. 2836 Operates a genomic informatics company. 7371,6794 0.75 
Kanematsu-Gosho Ltd. 5065 / Benzing Technologies, Inc. 7371 Develops, manufactures, and markets endovascular surgery products. 5047,6794 0 
Kebo LAB AB 3678 / Oncor, Inc. 3674 Manufactures cleaning systems for semiconductor fabrication equipment. 3569,3821 0.75 
Kimball Manufacturing 2521 2434,2517,3672,3674 Applied Micro Circuits Corp. 8731 
Develops DNA/RNA probes and 
hybridization systems for cancer 
detection. 
2835 0 
Kopvenco Inc. ( Koppers 
Co.) 2819 2869,3569,3743 Ecogen, Inc. 3674 
Manufactures semicustom bipolar and 
BICMOS gate array integrated circuits. 2836,8731 0 
Kopvenco Inc. ( Koppers 
Co.) 2819 2869,3569,3743 Engenics, Inc. 3674 
Developing microbial and viral 
biological pest controls. 3087 0 
Kopvenco Inc. ( Koppers 2819 2869,3569,3743 Eotec Corporation 3826 Engages principally in developing 8731,3499,3 0 
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Co.) continuous fermentation processes. 827,3674 
Kopvenco Inc. ( Koppers 
Co.) 2819 2869,3569,3743 Genex Corporation 3832 
Manufactures specialty single-mode, 
large-core, multi-mode fibers. 3826 0 
Kyocera International, Inc. 3674 / Micro Linear Corporation 3674 Develops recombinant DNA technology to commercial products. 5139 1 
Kyocera International, Inc. 3674 / Vitelic Corporation  3573 Manufactures analog/digital semi-custom and custom IC circuits. 
3823,3845,3
825 0.25 
Kyocera International, Inc. 3674 / WaferScale Integration, Inc 3674 Develops very large scale integration (VLSI) semiconductor products. 7371,6794 1 
Kyocera International, Inc. 3674 / Xilinx, Inc. 3674 Develops non-volatile programmable memory and semi-custom ICs. 5065 1 
LG Electronics 3651 3652,3661 Bermai, Inc.  5045 Develops and manufactures digital programmable logic devices 
5065,3672,7
372 0 
LG Electronics 3651 3652,3661 Tessera Technologies, Inc. 3674 Develops semiconductor technology for the broadband wireless industry. 3569,3821 0.5 
Litton Industries 2891 / PMC-Sierra, Inc. 3674 Develops semiconductor packaging technology for electronic products. 7371,6794 0 
Lotus Development 
Corporation 2891 / Genoptix, Inc. 3674 
Manufactures standard and 
application-specific integrated circuits. 
3613,3577,3
823 0 
LSI Logic Corporation 3674 3672,5065,7371,3572,5045 Adaptive Silicon, Inc 3821 
Provides genetic testing and 
identification services. 5139 0.25 
LSI Logic Corporation 3674 3672,5065,7371,3572,5045 IKOS Systems, Inc 3821 





Development Co. 2860 / Altus Corporation  3573 
Manufactures PC-based logic 
validation systems for ASIC testing. 5139 0 
Lubrizol Business 
Development Co. 2860 / Chemgen, Inc. 2869 
Produces lithium-thionyl chloride 
power cells. 3577 0.75 
Lubrizol Business 
Development Co. 2860 / Creative BioMolecules, Inc. 2048 
Developing proprietary bioprocess and 
fermentation processes. 2879 0.25 
Lubrizol Business 
Development Co. 2860 / Genentech, Inc. 2834 
Develops human growth factors 
through genetic engineering. 3566,5065 0.75 
Lubrizol Business 
Development Co. 2860 / GLC Associates 2860 
Develops commercial products with 
genetic engineering techniques. 8731 1 
Lubrizol Business 
Development Co. 2860 / Mycogen Corporation 2048 
Mfrs specialty and fine chemicals 
produced via biocatalysis. 5139 0.25 
Lubrizol Business 
Development Co. 2860 / Ocean Genetics 2860 
Develops synthetic bio-pesticides for 
large crop protection. 3841 1 
Lubrizol Business 
Development Co. 2860 / Sungene Technologies Corp 2865 
Develops marine biotechnology 
products and research procedures. 8731 0.75 
Lubrizol Business 
Development Co. 2860 / SVO Enterprises Corporation 2869 
Specializes in genetic modification of 
cereal and oil seed crops. 8731,5065 0.75 
Lubrizol Business 
Development Co. 2860 / Syntro Corporation 2048 
Develops and produces unique 
vegetable oils and derivatives. 8731,5065 0.25 
Manufacturers Life 
Insurance Co. 6311 6321,6324,6399 PTC Therapeutics, Inc. 2834 
Develops biotechnology for animal 
health and specialty chemicals. 2834 0 
Manufacturers Life 
Insurance Co. 6311 6321,6324,6399 TissueInformatics, Inc. 8731 
Operates a biopharmaceutical 
company. 2844 0 
Marion Merrill Dow 8090 / SICOR, Inc. 8731 Operates as a bioinformatics company. 7371,6794 0.25 
Martin Marietta 
Investments, Inc. 1422 1423,1442,3297 Agridyne Technologies, Inc.  2834 




Marubeni Corporation 5113 5111 Substrate Technologies, Inc. 5122 Develops botanical insecticides and plant growth enhancement products. 8731 0.5 
Matsushita Electric 
Corporation 3639 3679 Tensilica, Inc.   3674 
Develops and manufactures integrated 
circuit (IC) substrates. 8731,5065 0.5 
MCM Capital Group, Inc. 6199 / NeuroControl Corporation 3629 Develops application-tailored microprocessors. 7371,6794 0 
MedImmune  2836 2834 Applied Molecular Evolution, Inc. 3842 Develops FES technology to restore paralyzed muscles and limbs. 2836,8731 0 
Medtronic, Inc. 3845 3841,3842 Advanced Tissue Sciences, Inc 8731 Develops technologies to improve the production of human antibodies. 2836,8731 0 
Medtronic, Inc. 3845 3841,3842 Cepheid, Inc. 8731 Provides biological research services. 2899,3821,3826,8731 0 
Medtronic, Inc. 3845 3841,3842 Vascular Architects, Inc. 3842 Develops fast, integrated systems for DNA probe essays. 2879 0.75 
Merck & Co. 2834 5122 Crop Genetics International Corp. 5047 Develops, manufactures, and markets endovascular surgery products. 7371,6794 0 
Merck & Co. 2834 5122 ImmuLogic Pharmaceutical Corp 2834 Produces improved plant products using DNA technologies. 3566,5065 1 
Microsoft Corporation 7372 3577,7375,8999 Matrix Semiconductor, Inc. 7380 Develops pharmaceuticals for treatment of infectious diseases. 5139 0.5 
Microsoft Corporation 7372 3577,7375,8999 Pluto Technologies International,Inc. 7380 Developed three-dimensional integrated circuits. 
3823,3845,3
825 0.5 
Microsoft Corporation 7372 3577,7375,8999 ShareWave, Inc. 7380 Develops computer-based video storage and networking solutions. 
3613,3577,3
823 0.5 
Microwave Technology 3679 3559 KOR Electronics, Inc. 7373 
Develops semiconductor technology 
for wireless home networking 
products. 
7373 0 






Mosaic Systems, Inc. 2860 Designs electronic systems for government and defense contractors. 8731 0 






Panelvision Corporation 2860 Designs electrically programmable silicon semiconductors. 3841 0 
Mitsui & Co.  5099 / Array Biopharma, Inc 3679 Manufactures thin film, flat panel display screens. 8731 0 
Mitsui & Co.  5099 / Crysteco, Inc. 8731 Develops new small molecule drugs. 8071 0 
Mitsui & Co.  5099 / Gain Electronics 5065 Manufactures highly doped silicon wafers. 3566 0.5 
Mitsui & Co.  5099 / Genome Networks, Inc. 2819 Mfrs gallium arsenide (GAAS) 3826 0 
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integrated circuit/custom designed 
gate arrays 
Mitsui & Co.  5099 / Graviton, Inc. 8731 Develops drugs for large pharmaceutical companies. 5139 0 
Mitsui & Co.  5099 / Norak Biosciences, Inc. 3674 
Provides internet-based monitoring 
and info management systems 
services. 
5139 0 
Mitsui & Co.  5099 / Powerline GES Pty Ltd 8731 Develops drugs using a single universal fluorescent assay. 2836,8731 0 
Molex, Inc. 3678 3679,3496 Sheldahl, Inc. 3674 Designs, develops and manufactures power electronic products. 
3613,3577,3
823 0.75 
Monsanto Corp. 2879 8731 Asyst Technologies, Inc. 3674 Develops semiconductors for automotive and consumer electronics. 7373 0 
Monsanto Corp. 2879 8731 Biogen, Inc. 3559 Wholesales mini-environment systems used primarily in cleanrooms. 3569,3821 0 
Monsanto Corp. 2879 8731 Invitron Corporation 7699 Develops pharmaceuticals for human healthcare through gentic engineering. 5085 0 
Monsanto Corp. 2879 8731 Novellus Systems, Inc 8731 Operates large-scale mammalian cell culture systems. 8731 0 
National Bank of Canada 6021 6022,6029,6081,6082 AltaRex Corp.  3573 
Manufactures semiconductor chemical 
vapor deposition equipment. 8731 0 
National Distillers 2790 / Cetus Corporation 2836 Uses antibody based therapeutics for treatment of late stage cancers. 3577 0.25 
National Iron and Steel Mill 2790 / PMC-Sierra, Inc. 2836 Develops anticancer therapeutics and applications of gene probe technology. 2879 0.25 
National Semiconductor 3674 5065,3679,7373 Fairchild Semiconductor Int¡¯l Inc. 3679 Manufactures standard and application-specific integrated circuits. 
3613, 3577, 
3823 0.75 
National Semiconductor 3674 5065,3679,7373 MediaQ, Inc. 3674 Manufactures semiconductors devices and photographic equipment. 3826 1 
National Semiconductor 3674 5065,3679,7373 Sensym Inc. 3679 Provides silicon system solutions for consumer appliances. 
3823, 3845, 
3825 0.75 
Neoplux Capital 6798 / DNA Link, Inc. 3674 Manufactures low-cost pressure sensors. 7373 0 
Neoplux Capital 6798 / Sekonix Company, Ltd. 2836 Operates in medical genetics research in Korea. 3087 0 
Neoplux Capital 6798 / Tamul Multimedia Company, Ltd. 3674 Develops and produces plastic optic devices and components. 7373 0 
Nissho Electronics 3845 / Agility Communications, Inc.  3600 
Develops multimedia and 
communication LSI and their 
application system. 
2834 0.25 




Corporation 4899 / Aerie Networks, Inc 3800 
Develops therapeutics for cancer 




Corporation 4899 / CentrePath  4813 





Corporation 4899 / FiberNet Telecom Group, Inc. 4813 
Designs fiber optic networking 
products addressing bandwidth 
bottlenecking. 
2879 0.25 
Northern Pacific Capital 
Corp. 6282 / Morrow Electronics, Inc. 3674 
Provides optical fiber network inside 
class-A commercial buildings. 3826 0 
Northern Telecom Ltd. 4899 / Micro Linear Corporation 4813 Manufactures marine electronics equipment. 3841 0.25 
NYNEX Technology 
Investments 6282 / Pliant Systems, Inc. 3674 
Manufactures analog/digital 
semi-custom and custom IC circuits. 
3823,3845,3
825 0 
Olin Corporation 3341 3482,3483,3589 International Biotechnologies Inc. 3832 Manufactures and markets fiber optic systems for phone companies. 
3613,3577,3
823 0.25 
Oracle  7372 7371 Genomics Collaborative, Inc. 7380 Manufactures product systems for molecular biology research. 8731 0.5 
Oracle  7372 7371 InGenuity Systems, Inc. 7380 Provides DNA and Genetic Research services. 5139 0.5 
Otsuka Pharmaceutical Co 2834 / Ista Pharmaceuticals, Inc. 2836 Conducts gene research in order to develop gene-related drugs. 5139 0.75 
Otsuka Pharmaceutical Co 2834 / Phospho-Energetics, Inc. 8731 Develops contact lens to restore visual acuity. 8731 0 
Oxford Instruments Group 
PLC 3826 6719,3823 DNA Plant Technology 8731 
Manufactures nuclear resonance 
spectrum analysis devices. 7379 0 
Oxford Instruments Group 
PLC 3826 6719,3823 Panelvision Corporation 721 
Develops improved varieties of crop, 
industrial and consumer products. 3087 0 
Pacific Telecom 3651 3669 Support Technologies, Inc. 3679 Manufactures thin film, flat panel display screens. 8731 0.5 
Pacific Telecom 3651 3669 Thesys Memory Products Corp 3825 Manufactures automatic systems and printed circuit board test equipment. 8731,5065 0.25 
Pacnat Company 3825 / Applied Microsystems Corp. 3674 Manufactures low-cost add-on semiconductor memories for PCs. 7371,6794 0.25 
Pernovo Corp. (Perstorp 3825 / Creative BioMolecules, Inc. 3674 
Manufactures and supplies 
microprocessor development test 
tools. 
2836,8731 0.25 
Pfizer Inc 2834 2835,2048 Immusol, Inc 2836 Develops human growth factors through genetic engineering. 3566,5065 0.5 
Pfizer Inc 2834 2835,2048 Myco Pharmaceuticals 2836 Develops and discovers biologically relevant therapeutic drugs. 5139 0.5 
Philips Venture Capital 
Fund B.V. 3639 3651,3679 Be Here Corporation 721 
Develops drugs derived from fungi and 
related organisms. 3841 0 
Philips Venture Capital 
Fund B.V. 3639 3651,3679 MystiCom, Ltd. 3861 
Develops panoramic still-image 
camera lens system. 3569,3821 0.25 
Philips Venture Capital 
Fund B.V. 3639 3651,3679 ShareWave, Inc. 3674 
Develops digital signal processing 
(DSP) cores for semiconductor 
industry. 
3841 0.5 
Polaroid Corporation 3861 / Zight Corporation 3674 
Develops semiconductor technology 
for wireless home networking 
products. 
7373 0.25 
Proctor & Gamble 2841 2676,2033,2844 Vector Pharmaceuticals, Inc. 3679 Develops high-resolution color 5045,5065,3 0 
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Purdue Pharma L.P. 2834 / AltaRex Corp.  2836 Develops live viral vaccines to be used in immunization programs. 3569,3821 0.75 
Questec Enterprises, Inc.  2990 / Innov Holding Company 2836 Uses antibody based therapeutics for treatment of late stage cancers. 3577 0.25 
Questec Enterprises, Inc.  2990 / Proconics International, Inc. 3674 Manufactures mass flow controllers for integrated circuits. 5139 0 
Raychem Corporation 3699 / Interamics, Inc. 3699 Manufactures a highly refined silicon wafer transfer system. 
3613,3577,3
823 1 
Raychem Corporation 3699 / Luxtron Corporation 3679 Mfrs co-fired custom ceramic multi-layer interconnect products. 3674,3669 0.5 
RCA 3823 / Planar Systems, Inc. 3822 
Manufactures ultra-sensitive 




RCA 3823 / WaferScale Integration, Inc 3823 Manufactures electroluminescent (EL) components. 
3613,3577,3
823 1 
RCT BioVentures NE LLC 8731 / InfiMed Therapeutics, Inc. 8900 Develops non-volatile programmable memory and semi-custom ICs. 5065 0.25 
RCT BioVentures NE LLC 8731 / MetaProbe LLC 8731 Develops protein and peptide formulated products. 5139 1 
Renaissance Tech. 5045 7372 Crystalvision Inc. 3573 Develops liquid crystal display flat panel for PCs. 3566,5065 0 
Repligen Corp. 2836 8071,8731 Glycan Pharmaceuticals Inc 2835 Operates as a development-stage biotechnology company. 
3823,3845,3
825 0.75 
Rhone Poulenc 2836 / Biomedical Diagnostics 2834 Develop pharmaceuticals based on carbohydrate technology. 5139 0.75 
Rhone Poulenc 2836 / EntoMed SA 2834 Develops and markets biological diagnostic tools. 2835 0.75 
Rhone Poulenc 2836 / Hybrigenics SA 8731 Develops insect-derived antimicrobial peptides. 
3499,3827,3
674 0 
Rockwell International 3679 3812,3674,5045,3845 Micro Linear Corporation 3679 
Develops biotechnology and 
bioinformatics products. 5139 1 
Rodal Corp. 3576 / Cetus Corporation 3674 Manufactures analog/digital semi-custom and custom IC circuits. 
3823,3845,3
825 0.25 
Rohm and Haas Company. 2821 2869,2099,3672,2879 Advanced Genetic Sciences, Inc  2836 
Develops anticancer therapeutics and 
applications of gene probe technology. 2879 0.5 
SAIC Venture Capital Corp. 6099 / Agilix Corporation  721 Develops genetically engineered agricultural products. 
2899,3821,3
826,8731 0 
SAIC Venture Capital Corp. 6099 / DigiLens, Inc.  8731 Develops functional genomics and proteomics platform technologies. 
2899,3821,3
826,8731 0 
SAIC Venture Capital Corp. 6099 / LifeSpan BioSciences, Inc. 3674 Designs, manufactures and markets polymer optical components. 7371 0 
Sandoz Ltd. 2834 / Agridyne Technologies, Inc.  8732 Operates as a genomics company. 8731 0 
Schering-Plough Corp. 2834 2841,5122 Accelrys, Inc.  721 Develops botanical insecticides and plant growth enhancement products. 8731,5122 0 
Schering-Plough Corp. 2834 2841,5122 Biogen, Inc. 2836 Develops pharmaceutical and chemical libraries. 
3827,7389,3
577 0.75 
Schering-Plough Corp. 2834 2841,5122 Molecular Devices Corp 2836 Develops pharmaceuticals for human healthcare through gentic engineering. 5085 0.75 
Schering-Plough Corp. 2834 2841,5122 ProCyte Corporation 2836 Develops test delivery systems using silicon sensor technology. 3841 0.75 
Schlumberger Limited 2084 2085 Contrex, Inc. 2834 Develops Iamin, a synthetic product which aids in wound healing. 2844 0.25 
Schlumberger Limited 2084 2085 GE Novasensor Inc. 3823 Manufactures integrated circuit wafer inspection systems. 3566,5065 0 
Seagate Technology Inc 3572 3577 Mosaic Systems, Inc. 3600 Supplies silicon-based sensors. 3826 0.25 
Sensormatic Electronics 
Corp. 3669 7382 Datavision, Inc. 3577 
Designs electrically programmable 
silicon semiconductors. 3841 0.25 
Sepracor Inc. 2834 8731 Versicor, Inc.  2836 Manufactures centrally-monitored, interactive alarm systems. 7371 0.75 
Shanghai Industrial 
Holdings Ltd. 3560 
6719,4499,2834
,2131,3714 Semiconductor Manufacturing Corp. 3600 
Develops infectious disease 
therapeutic drugs. 7371,6794 0.25 
Shanghai Land Holdings 
Ltd. 6531 6719 Ness Display Corporation 3699 
Operates a holding company that 
establishes semiconductor facilities. 7373 0 
Shanghai Land Holdings 
Ltd. 6531 6719 WAVICS, Inc. 3600 
Manufactures and develops Organic 
Light-Emitiing Diode Displays (OLED). 2836,8731 0 
Sharp Corporation 3663 / Greyhawk Systems, Inc. 3571 Operates as a fabless semiconductor company. 5065 0.25 
Sharp Corporation 3664 / WaferScale Integration, Inc 3573 Manufactures high information content, large area displays. 5139 0.25 
Shaw Ventures Ltd. 3498 1623,3322,5085,8999 360networks, Inc.  3674 
Develops non-volatile programmable 
memory and semi-custom ICs. 5065 0.25 
Shinsho Corporation 5051 / ProQuip, Inc. 3669 Develops high-bandwidth fiber optic communication infrastructures. 
3827,7389,3
577 0 
Siemens Corporation 3613 3621,3844 Graviton, Inc. 3825 
Manufactures automatic test 
equipment for rigid disk media and 
disk drives. 
2844 0 
Siemens Venture Capital 
GmbH 6799 3621,3844 Agility Communications, Inc.  3674 
Provides internet-based monitoring 
and info management systems 
services. 
5139 0 
Siemens Venture Capital 
GmbH 6799 3621,3844 Graviton, Inc. 4813 




Siemens Venture Capital 
GmbH 6799 3621,3844 Interactive Silicon, Inc. 3674 
Provides internet-based monitoring 
and info management systems 
services. 
5139 0 
Siemens Venture Capital 
GmbH 6799 3621,3844 LightLogic, Inc. 3674 
Manufactures semiconductors and 
software for better system 
performance. 
3674,3669 0 
Siemens Venture Capital 
GmbH 6799 3621,3844 November 3663 
Develops optoelectronic components 
and subsystems. 8731 0 
Siemens Venture Capital 
GmbH 6799 3621,3844 Zight Corporation 8071 
Develops biotechnology for use within 
molecular medicine. 8731 0 
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Sigma Resources 7389 / Saratoga Semiconductor Corp 3679 Develops high-resolution color displays. 
5045,5065,3
672,7372 0 
SISIR International Pte Ltd. 3823 / Pacific Lithium Limited  3573 Manufactures standard and custom semiconductor chips. 7373 0.25 
SISIR International Pte Ltd. 3823 / Ultro Lighting International Pte 3692 Develops technologies and products for the lithium based market. 8731 0.25 
Smith Kline Beecham Corp. 2834 8071 Amgen, Inc.  2836 Designs and develops electronic ballasts. 7371,6794 0.75 
Smith Kline Beecham Corp. 2834 8071 Applied Biotechnology, Inc. 2836 Develops and markets molecular biology-based products. 2836,8731 0.75 
Smith Kline Beecham Corp. 2834 8071 British Bio-Technology Group PLC 2836 Develops cancer diagnostics, therapeutics and animal vaccines. 2836,8731 0.75 
Smith Kline Beecham Corp. 2834 8071 Corixa Corporation 2834 Develops and manufactures reagents and pharmaceuticals. 2835 1 
Smith Kline Beecham Corp. 2834 8071 Cytotech, Inc. 2834 Develops cellular-mediated immunity as a treatment for cancer. 3566,5065 1 
Smith Kline Beecham Corp. 2834 8071 Gliatech, Inc. 721 Supplies specific pathogen free (SPF) laboratory animals. 2836 0 
Smith Kline Beecham Corp. 2834 8071 International Canine Genetics 3841 Develops neural regeneration pharmaceuticals and devices. 5139 0 
Smith Kline Beecham Corp. 2834 8071 MacroNex, Inc. 2834 Developing methods to improve the genetic purity of purebred dogs. 8731 1 
Smith Kline Beecham Corp. 2834 8071 Message Pharmaceuticals, Inc. 2834 
Develops peptides targeted at 




Smith Kline Beecham Corp. 2834 8071 NPS Pharmaceuticals, Inc. 2835 
Develops technology for drug 




Smith Kline Beecham Corp. 2834 8071 Ocean Genetics 2834 Discovers small molecule drugs. 8731 1 
Smith Kline Beecham Corp. 2834 8071 Provac, Inc. 2834 Develops marine biotechnology products and research procedures. 8731 1 
Smith Kline Beecham Corp. 2834 8071 Sphinx Pharmaceuticals Corp 2836 
Develops vaccines, 
immunotherapeutics and diagnostic 
tests. 
2844 0.75 
Smith Kline Beecham Corp. 2834 8071 Symphony Pharmaceuticals, Inc. 2835 Develops lipid-based diagnostics and therapeutics for various diseases. 7373 0.75 
Smith Kline Beecham Corp. 2834 8071 Synaptic Pharmaceutical Corp 3834 Develops therapeutics to regulate ion flow. 8731,5065 0 
Smith Kline Beecham Corp. 2834 8071 Synbiotics Corporation 2836 
Develops therapeutic products for 
treatment of nervous system 
disorders. 
8731,5065 0.75 
Smith Kline Beecham Corp. 2834 8071 TerraGen Discovery 2835 
Mnfrs biomedical products use in 
human and veterinary healthcare 
fields. 
2834 0.75 
Smith Kline Beecham Corp. 2834 8071 Therion Biologics Corporation  2834 Terragen investigates therapeutic properties of microorganisms. 7371,6794 1 
Smith Kline Beecham Corp. 2834 8071 Transgenics, Inc. 2836 Develops pharmaceuticals for vaccines for cancer. 7371,6794 0.75 
Smith Kline Beecham Corp. 2834 8071 Triplex Pharmaceutical Corp 752 
Conducts research at Princeton 
University focusing on transgenic 
mice. 
7371,6794 0 
Smith Kline Beecham Corp. 2834 8071 Ultra Diagnostics Corporation  2834 Develops pharmaceutical compounds that bind to cellular DNA. 7371,6794 1 
Smith Kline Beecham Corp. 2834 8071 Zynaxis, Inc. 2835 Produces non-isotopic immunoassays for human in-vitro diagnosic testing. 7371,6794 0.75 
Sony Corporation 3651 3679 Dixy Company Ltd. 3679 Develops therapeutic delivery systems and diagnostic products. 7372 0.5 
Sony Corporation 3651 3679 SandCraft, Inc. 3679 Designs, mfrs low cost gas plasma displays for industrial, military, etc. 3087 0.5 
Sony Corporation 3651 3679 Transmeta Corporation 3571 Develops and markets superscalar microprocessors for communications. 7373 0.25 
Sony Corporation 3651 3679 Vitelic Corporation  3571 Manufactures and designs VLSI chips for wireless mobile devices. 7371,6794 0.25 
Standard Microsystems 
Corp. 3674 / Surface Mounted Technology Corp 3670 
Develops very large scale integration 
(VLSI) semiconductor products. 7371,6794 0.75 
Standard OIL  3821 / Analog Devices, Inc.  3573 
Produces printed circuit boards & 
provides semiconductor assembly 
services. 
8731,5065 0.25 
Standard OIL  3821 / Energy Conversion Devices, Inc 3670 Manufactures precision integrated circuits. 2836,8731 0.25 
Standard OIL  3821 / General Ionex Corporation 3674 Develops technologies involving amorphous semiconductors. 
8731,3499,3
827,3674 0.25 
Standard OIL  3821 / GigaBit Logic, Inc. 3674 Custom producer of ion beam instruments/ion accelerator products. 8731 0.25 
Standard OIL  3821 / International Microelectronic 3674 Manufactures ultra high-speed gallium arsenide integrated circuits. 5139 0.25 
Standard OIL of California 3821 / Cetus Corporation 3674 Manufactures custom semiconductor integrated circuits. 8731 0 
Sumitomo Cement 
Company, Ltd. 3241 / Ortel Corporation 2836 
Develops anticancer therapeutics and 
applications of gene probe technology. 2879 0 
Sumitomo Corporation 5099 / Argonaut Technologies, Inc. 3811 Manufactures linear fiber optic products. 8731 0 
Sumitomo Corporation 5099 / Atheros Communications, Inc 3826 Develops instruments and chemicals for medicinal chemistry use. 3356 0 
Sumitomo Corporation 5099 / Galileo Pharmaceuticals, Inc. 3674 Manufactures 802.11A wireless LAN chipsets and software. 3569,3821 0 
Sumitomo Corporation 5099 / GES Pharmaceutical Inc 3834 Develops products for the treatment and prevention of ischemia. 3826 0 
Sumitomo Corporation 5099 / nCHIP, Inc. 2836 Develops neuro-transmitter re-uptake genes for rational drug design. 5139 0 
Sumitomo Corporation 5099 / SkyTune Corporationa 3679 Designs and manufactures advanced silicon circuit board packages. 3841 0 
Sumitomo Corporation 5099 / Zyomyx, Inc. 3670 Manufactures audio/video integrated 7373 0 
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circuits for the PC market. 
Sumitomo Metal Industries 3312 / Mosaic Systems, Inc. 2835 Develops protein biochips to identify inhibitors. 7372 0 
Sun Microsystems, Inc. 3571 7373,7371,7372,3575,3572 Graviton, Inc. 3674 
Designs electrically programmable 
silicon semiconductors. 3841 0.25 
Sun Microsystems, Inc. 3571 7373,7371,7372,3575,3572 Lineo, Inc. 3674 
Provides internet-based monitoring 
and info management systems 
services. 
5139 0.25 
Sun Microsystems, Inc. 3571 7373,7371,7372,3575,3572 Mellanox Technologies, Inc. 3674 
Develops, markets and sells 
embedded Linux system software. 8731 0.25 
Syntex Corporation 2836 / American Bionetics, Inc. 8742 Develops semiconductors to address bandwidth bottlenecking. 
3823,3845,3
825 0 
Syntex Corporation 2836 / Genelabs Technologies, Inc. 2830 Develops instrumentation and supplies for biotechnology industry. 3577 0.75 
Syntex Corporation 2836 / Genetic Systems Diagnostics Partners 2835 
Develops diagnostic and research 
products for biotechnology. 3826 0.75 
Syntex Corporation 2836 / Xytronyx, Inc. 2835 Engaged in monoclonal antibody technology research. 8731 0.75 
Sysorex 2790 / Integrated Device Technology 2835 Develops biotechnological products for veterinary medicine. 
5045,5065,3
672,7372 0.25 
Tandem Computers, Inc. 3670 / Anamartic Ltd. 3674 Manufacturers VLSI semiconductors utilizing enhanced CMOS technology. 3674 0.75 
Tandem Computers, Inc. 3670 / Clinicor, Inc. 3573 Manufactures semiconductor-based storage systems. 2836,8731 0.25 
Tata Enterprises  3571 5045,7372 Agridyne Technologies, Inc.  3834 
Provides commercial research 
services to drug and medical 
companies. 
3827 0.25 
Taub-Tech Ventures 3571 / GigaBit Logic, Inc. 3834 Develops botanical insecticides and plant growth enhancement products. 8731,5122 0.25 
TDK Corporation 3679 3652 Atheros Communications, Inc 3679 Manufactures ultra high-speed gallium arsenide integrated circuits. 5139 1 
TDK Corporation 3679 3652 Silicon Wave, Inc. 3679 Manufactures 802.11A wireless LAN chipsets and software. 3569,3821 1 
Technology Asia Ventures 
Sdn Bhd 6799 7359 GeneMedix PLC 3674 
Provides silicon ASIC solutions for 
communication equipment. 7373 0 
Teck Research Inc. 1041 1044,1021,1031 Oncodiagnostics, Inc. 2834 Develops and manufactures a range of high value therapeutic proteins 3826 0 
Tektronix Development Co 3825 3823,3826 ATEQ Corp. 3679 
Producer of biotech genetic 
engineering systems; and serum 
pharmaceuticals. 
8731 0.25 
Tektronix Development Co 3825 3823,3826 Credence Systems Corp. 3569 Develops photolithography equipment for IC fabrication. 3821 0.25 
Telefonica 4899 / California Micro Devices, Inc. 3825 
Manufactures Automatic Test 
Equipment (ATE) for LSI/VLSI 
semiconductors. 
3566,5065 0 
Tellabs Inc. 3661 7373,3669 Agility Communications, Inc.  3674 Manufactures high performance electronic components. 
3675,3672,3
676 0.5 
Tellabs Inc. 3661 7373,3669 Calient Networks 4813 Develops products for the telecommunications industry. 
2899,3821,3
826,8731 0 
Tellabs Inc. 3661 7373,3669 PMC-Sierra, Inc. 3832 Develops intelligent, all-photonic switching systems and software. 2835 0.25 
Tenax Corporation 3577 / Mech-El Industries, Inc. 3674 Manufactures standard and application-specific integrated circuits. 
3613,3577,3
823 0.25 





NxtWave Communications 3600 Manufactures digital modulation and de-modulation integrated circuits. 8731 0 
TI Ventures 6799 / APEX Semiconductor, Inc. 3699 Manufactures automatic semiconductor bonding equipment. 
3823,3845,3
825 0 
TI Ventures 6799 / ARC International PLC  3674 Develops DRAM and embedded DRAM products. 2836,8731 0 
TI Ventures 6799 / AuthenTec, Inc. 3571 Develops integrated solutions for system-on-chip (SoC) design. 3356 0 
TI Ventures 6799 / MystiCom, Ltd. 3674 Provides silicon solutions to the biometric and security markets. 3569,3821 0 
TI Ventures 6799 / Zight Corporation 3573 
Develops digital signal processing 
(DSP) cores for semiconductor 
industry. 
3841 0 




Applied Micro Circuits Corp. 3679 Develops high-resolution color displays. 
5045,5065,3
672,7372 0 




Millennium Systems, Inc. 3674 Manufactures semicustom bipolar and BICMOS gate array integrated circuits. 2836,8731 0 
Tosco Corporation 3674 5541,5411 Amgen, Inc.  3825 Developed a portable testing device used in the repair of microprocessors. 
3823,3845,3
825 0.25 
Trident Microsystems, Inc. 3674 3577 Integrated Telecom Express, Inc. 3825 Develops and markets molecular biology-based products. 2836,8731 0.25 




C.P. Clare Corporation 3674 Designs, distributes and sells computer semiconductors. 3674 0.25 
TVI Corporation 3812 / Biopure Corporation 3674 Develops signal electromagnetic and semiconductor switches and relays. 2835 0.25 
Ultramar PLC 1311 / Agricultural Genetics Company 2836 Develops oxygen therapeutic for the healthcare markets. 2835 0 
United Computer and 
Technology 3679 / Cambridge BioTech Corporation 3836 
Operates as a research company to 
apply molecular biology to plant 
breeding 
8731,5122 0.25 
United Computer and 
Technology 3679 / Codata Systems Corporation 3836 
Develops diagnostics, therapeutics & 
vaccines using monoclonal antibody. 3672,3676 0.25 
United Computer and 
Technology 3679 / Security Tag Systems 3836 
Manufactures computerized fire 
detection systems for large buildings. 3827 0.25 
Velocity Capital 6799 / Silicon Wave, Inc. 3800 Manufactures reusable electronic tags 7373 0 
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Management LLC for preventing shoplifters. 
VentureBank@PNC 6799 / iPhotonics, Inc. 3674 Provides silicon ASIC solutions for communication equipment. 7373 0 
Votorantim Venture Capital 
Ltd 6799 / Alellyx Applied Genomics 8711 
Provides outsourced services for fiber 
optic system and subsystem OEMs. 8731 0 
Wang Development and 
Investment Corp. 6799 / Applied Optoelectronics Technology 2834 
Operates a biotechnology company in 
Brazil. 8731,5122 0 
Wang Development and 
Investment Corp. 6799 / Paradygm Science & Technologie 5063 
Manufactures automatic test 
equipment for optoelectronic 
components. 
2836,8731 0 
Weston Investment Co. 6799 / Agridyne Technologies, Inc.  3800 Manufactures spectrometers for use during surgery. 8731 0 
Williams Communications 
Group 4899 / Icoria, Inc.  721 
Develops botanical insecticides and 
plant growth enhancement products. 8731,5122 0 




Agility Communications, Inc.  4831 Develops functional genomics products focusing on agriculture. 5139 0 










1. Source of information on Firms are mainly from Osiris Database, as well as Lexis/Nexis Academic Database 
2. Sources of information on Company are mainly from  SDC and CorpTech database, as well as Lexis/Nexis Academic and www.selectory.com 
(Dun & Bradstreet Database) 
3. The variable "market relatedness" is based on the overlaps of 4-digit Primary Standard Industry Codes (SIC) of the investors and investees. The 
variable receives values 1, 0.75, 0.5 or 0.25 if the firm and company have the same SIC code on four, three, two or one digit level, respectively. If 
the firm and company have totally different SIC code, then it receives a value of 0.  
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100 Agricultural Production-Crops 1 Agricultural Production Crops 
200 Agricultural Prod-Livestock & Animal Specialties 2 Agriculture production livestock and animal specialties 
700 Agricultural Services 7 Agricultural Services 
800 Forestry 8 Forestry 
900 Fishing, Hunting and Trapping 9 Fishing, hunting, and trapping 
1000 Metal Mining 10 Metal Mining 
1040 Gold and Silver Ores 10 Metal Mining 
1090 Miscellaneous Metal Ores 10 Metal Mining 
1221 Bituminous Coal & Lignite Mining 12 Coal Mining 
1311 Crude Petroleum & Natural Gas 13 Oil And Gas Extraction 
1381 Drilling Oil & Gas Wells 13 Oil And Gas Extraction 
1382 Oil & Gas Field Exploration Services 13 Oil And Gas Extraction 
1389 Oil & Gas Field Services, NEC 13 Oil And Gas Extraction 
1400 Mining & Quarrying of Nonmetallic Minerals (No Fuels) 14 Mining And Quarrying Of Nonmetallic Minerals, Except Fuels 
1520 General Bldg Contractors - Residential Bldgs 15 Building Construction General Contractors And Operative Builders 
1531 Operative Builders 15 Building Construction General Contractors And Operative Builders 
1540 General Bldg Contractors - Nonresidential Bldgs 15 Building Construction General Contractors And Operative Builders 
1600 Heavy Construction Other Than Bldg Const - Contractors 16 Heavy Construction Other Than Building Construction Contractors 
1623 Water, Sewer, Pipeline, Comm & Power Line Construction 16 Heavy Construction Other Than Building Construction Contractors 
1700 Construction - Special Trade Contractors 17 Construction Special Trade Contractors 
1731 Electrical Work 17 Construction Special Trade Contractors 
2000 Food and Kindred Products 20 Food And Kindred Products 
2011 Meat Packing Plants 20 Food And Kindred Products 
2013 Sausages & Other Prepared Meat Products 20 Food And Kindred Products 
2015 Poultry Slaughtering and Processing 20 Food And Kindred Products 
2020 Dairy Products 20 Food And Kindred Products 
2024 Ice Cream & Frozen Desserts 20 Food And Kindred Products 
2030 Canned, Frozen & Preservd Fruit, Veg & Food Specialties 20 Food And Kindred Products 
2033 Canned, Fruits, Veg, Preserves, Jams & Jellies 20 Food And Kindred Products 
2040 Grain Mill Products 20 Food And Kindred Products 
2050 Bakery Products 20 Food And Kindred Products 
2052 Cookies & Crackers 20 Food And Kindred Products 
2060 Sugar & Confectionery Products 20 Food And Kindred Products 
2070 Fats & Oils 20 Food And Kindred Products 
2080 Beverages 20 Food And Kindred Products 
2082 Malt Beverages 20 Food And Kindred Products 
2086 Bottled & Canned Soft Drinks & Carbonated Waters 20 Food And Kindred Products 
2090 Miscellaneous Food Preparations & Kindred Products 20 Food And Kindred Products 
2092 Prepared Fresh or Frozen Fish & Seafoods 20 Food And Kindred Products 
2100 Tobacco Products 21 Tobacco Products 
2111 Cigarettes 21 Tobacco Products 
2200 Textile Mill Products 22 Textile Mill Products 
2211 Broadwoven Fabric Mills, Cotton 22 Textile Mill Products 
2221 Broadwoven Fabric Mills, Man Made Fiber & Silk 22 Textile Mill Products 
2250 Knitting Mills 22 Textile Mill Products 
2253 Knit Outerwear Mills 22 Textile Mill Products 
2273 Carpets & Rugs 22 Textile Mill Products 
2300 Apparel & Other Finishd Prods of Fabrics & Similar Matl 23 Apparel And Other Finished Products Made From Fabrics And Similar Materials 
2320 Men's & Boys' Furnishgs, Work Clothg, & Allied Garments 23 Apparel And Other Finished Products Made From Fabrics And Similar Materials 
2330 Women's, Misses', and Juniors Outerwear 23 Apparel And Other Finished Products Made From Fabrics And Similar Materials 
2340 Women's, Misses', Children's & Infants' Undergarments 23 Apparel And Other Finished Products Made From Fabrics And Similar Materials 
2390 Miscellaneous Fabricated Textile Products 23 Apparel And Other Finished Products Made From Fabrics And Similar Materials 
2400 Lumber & Wood Products (No Furniture) 24 Lumber And Wood Products, Except Furniture 
2421 Sawmills & Planting Mills, General 24 Lumber And Wood Products, Except Furniture 
2430 Millwood, Veneer, Plywood, & Structural Wood Members 24 Lumber And Wood Products, Except Furniture 
2451 Mobile Homes 24 Lumber And Wood Products, Except Furniture 
2452 Prefabricated Wood Bldgs & Components 24 Lumber And Wood Products, Except Furniture 
2510 Household Furniture 25 Furniture And Fixtures 
2511 Wood Household Furniture, (No Upholstered) 25 Furniture And Fixtures 
2520 Office Furniture 25 Furniture And Fixtures 
2522 Office Furniture (No Wood) 25 Furniture And Fixtures 
2531 Public Bldg & Related Furniture 25 Furniture And Fixtures 
2540 Partitions, Shelvg, Lockers, & of fice & Store Fixtures 25 Furniture And Fixtures 
2590 Miscellaneous Furniture & Fixtures 25 Furniture And Fixtures 
2600 Papers & Allied Products 26 Paper And Allied Products 
2611 Pulp Mills 26 Paper And Allied Products 
2621 Paper Mills 26 Paper And Allied Products 
2631 Paperboard Mills 26 Paper And Allied Products 
2650 Paperboard Containers & Boxes 26 Paper And Allied Products 
2670 Converted Paper & Paperboard Prods (No Contaners/Boxes) 26 Paper And Allied Products 
2673 Plastics, Foil & Coated Paper Bags 26 Paper And Allied Products 
2711 Newspapers: Publishing or Publishing & Printing 27 Printing, Publishing, And Allied Industries 
2721 Periodicals: Publishing or Publishing & Printing 27 Printing, Publishing, And Allied Industries 
2731 Books: Publishing or Publishing & Printing 27 Printing, Publishing, And Allied Industries 
2732 Book Printing 27 Printing, Publishing, And Allied Industries 
2741 Miscellaneous Publishing 27 Printing, Publishing, And Allied Industries 
2750 Commercial Printing 27 Printing, Publishing, And Allied Industries 
2761 Manifold Business Forms 27 Printing, Publishing, And Allied Industries 
2771 Greeting Cards 27 Printing, Publishing, And Allied Industries 
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2780 Blankbooks, Looseleaf Binders & Bookbindg & Relatd Work 27 Printing, Publishing, And Allied Industries 
2790 Service Industries For The Printing Trade 27 Printing, Publishing, And Allied Industries 
2800 Chemicals & Allied Products 28 Chemicals And Allied Products 
2810 Industrial Inorganic Chemicals 28 Chemicals And Allied Products 
2820 Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) 28 Chemicals And Allied Products 
2821 Plastic Materials, Synth Resins & Nonvulcan Elastomers 28 Chemicals And Allied Products 
2833 Medicinal Chemicals & Botanical Products 28 Chemicals And Allied Products 
2834 Pharmaceutical Preparations 28 Chemicals And Allied Products 
2835 In Vitro & In Vivo Diagnostic Substances 28 Chemicals And Allied Products 
2836 Biological Products, (No Disgnostic Substances) 28 Chemicals And Allied Products 
2840 Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics 28 Chemicals And Allied Products 
2842 Specialty Cleaning, Polishing and Sanitation Preparations 28 Chemicals And Allied Products 
2844 Perfumes, Cosmetics & Other Toilet Preparations 28 Chemicals And Allied Products 
2851 Paints, Varnishes, Lacquers, Enamels & Allied Prods 28 Chemicals And Allied Products 
2860 Industrial Organic Chemicals 28 Chemicals And Allied Products 
2870 Agricultural Chemicals 28 Chemicals And Allied Products 
2890 Miscellaneous Chemical Products 28 Chemicals And Allied Products 
2891 Adhesives & Sealants 28 Chemicals And Allied Products 
2911 Petroleum Refining 29 Petroleum Refining And Related Industries 
2950 Asphalt Paving & Roofing Materials 29 Petroleum Refining And Related Industries 
2990 Miscellaneous Products of Petroleum & Coal 29 Petroleum Refining And Related Industries 
3011 Tires & Inner Tubes 30 Rubber And Miscellaneous Plastics Products 
3021 Rubber & Plastics Footwear 30 Rubber And Miscellaneous Plastics Products 
3050 Gaskets, Packg & Sealg Devices & Rubber & Plastics Hose 30 Rubber And Miscellaneous Plastics Products 
3060 Fabricated Rubber Products, NEC 30 Rubber And Miscellaneous Plastics Products 
3080 Miscellaneous Plastics Products 30 Rubber And Miscellaneous Plastics Products 
3081 Unsupported Plastics Film & Sheet 30 Rubber And Miscellaneous Plastics Products 
3086 Plastics Foam Products 30 Rubber And Miscellaneous Plastics Products 
3089 Plastics Products, NEC 30 Rubber And Miscellaneous Plastics Products 
3100 Leather & Leather Products 31 Leather And Leather Products 
3140 Footwear, (No Rubber) 31 Leather And Leather Products 
3211 Flat Glass 32 Stone, Clay, Glass, And Concrete Products 
3220 Glass & Glassware, Pressed or Blown 32 Stone, Clay, Glass, And Concrete Products 
3221 Glass Containers 32 Stone, Clay, Glass, And Concrete Products 
3231 Glass Products, Made of Purchased Glass 32 Stone, Clay, Glass, And Concrete Products 
3241 Cement, Hydraulic 32 Stone, Clay, Glass, And Concrete Products 
3250 Structural Clay Products 32 Stone, Clay, Glass, And Concrete Products 
3260 Pottery & Related Products 32 Stone, Clay, Glass, And Concrete Products 
3270 Concrete, Gypsum & Plaster Products 32 Stone, Clay, Glass, And Concrete Products 
3272 Concrete Products, Except Block & Brick 32 Stone, Clay, Glass, And Concrete Products 
3281 Cut Stone & Stone Products 32 Stone, Clay, Glass, And Concrete Products 
3290 Abrasive, Asbestos & Misc Nonmetallic Mineral Prods 32 Stone, Clay, Glass, And Concrete Products 
3310 Steel Works, Blast Furnaces & Rolling & Finishing Mills 33 Primary Metal Industries 
3312 Steel Works, Blast Furnaces & Rolling Mills (Coke Ovens) 33 Primary Metal Industries 
3317 Steel Pipe & Tubes 33 Primary Metal Industries 
3320 Iron & Steel Foundries 33 Primary Metal Industries 
3330 Primary Smelting & Refining of Nonferrous Metals 33 Primary Metal Industries 
3334 Primary Production of Aluminum 33 Primary Metal Industries 
3341 Secondary Smelting & Refining of Nonferrous Metals 33 Primary Metal Industries 
3350 Rolling Drawing & Extruding of Nonferrous Metals 33 Primary Metal Industries 
3357 Drawing & Insulating of Nonferrous Wire 33 Primary Metal Industries 
3360 Nonferrous Foundries (Castings) 33 Primary Metal Industries 
3390 Miscellaneous Primary Metal Products 33 Primary Metal Industries 
3411 Metal Cans 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3412 Metal Shipping Barrels, Drums, Kegs & Pails 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3420 Cutlery, Handtools & General Hardware 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3430 Heating Equip, Except Elec & Warm Air; & Plumbing Fixtures 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3433 Heating Equipment, Except Electric & Warm Air Furnaces 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3440 Fabricated Structural Metal Products 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3442 Metal Doors, Sash, Frames, Moldings & Trim 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3443 Fabricated Plate Work (Boiler Shops) 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3444 Sheet Metal Work 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3448 Prefabricated Metal Buildings & Components 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3451 Screw Machine Products 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3452 Bolts, Nuts, Screws, Rivets & Washers 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3460 Metal Forgings & Stampings 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3470 Coating, Engraving & Allied Services 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3480 Ordnance & Accessories, (No Vehicles/Guided Missiles) 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3490 Miscellaneous Fabricated Metal Products 34 Fabricated Metal Products, Except Machinery And Transportation Equipment 
3510 Engines & Turbines 35 Industrial And Commercial Machinery And Computer Equipment 
3523 Farm Machinery & Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
3524 Lawn & Garden Tractors & Home Lawn & Gardens Equip 35 Industrial And Commercial Machinery And Computer Equipment 
3530 Construction, Mining & Materials Handling Machinery & Equip 35 Industrial And Commercial Machinery And Computer Equipment 
3531 Construction Machinery & Equip 35 Industrial And Commercial Machinery And Computer Equipment 
3532 Mining Machinery & Equip (No Oil & Gas Field Mach & Equip) 35 Industrial And Commercial Machinery And Computer Equipment 
3533 Oil & Gas Field Machinery & Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
3537 Industrial Trucks, Tractors, Trailors & Stackers 35 Industrial And Commercial Machinery And Computer Equipment 
3540 Metalworkg Machinery & Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
3541 Machine Tools, Metal Cutting Types 35 Industrial And Commercial Machinery And Computer Equipment 
3550 Special Industry Machinery (No Metalworking Machinery) 35 Industrial And Commercial Machinery And Computer Equipment 
3555 Printing Trades Machinery & Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
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3559 Special Industry Machinery, NEC 35 Industrial And Commercial Machinery And Computer Equipment 
3560 General Industrial Machinery & Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
3561 Pumps & Pumping Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
3562 Ball & Roller Bearings 35 Industrial And Commercial Machinery And Computer Equipment 
3564 Industrial & Commercial Fans & Blowers & Air Purifing Equip 35 Industrial And Commercial Machinery And Computer Equipment 
3567 Industrial Process Furnaces & Ovens 35 Industrial And Commercial Machinery And Computer Equipment 
3569 General Industrial Machinery & Equipment, NEC 35 Industrial And Commercial Machinery And Computer Equipment 
3570 Computer & of fice Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
3571 Electronic Computers 35 Industrial And Commercial Machinery And Computer Equipment 
3572 Computer Storage Devices 35 Industrial And Commercial Machinery And Computer Equipment 
3575 Computer Terminals 35 Industrial And Commercial Machinery And Computer Equipment 
3576 Computer Communications Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
3577 Computer Peripheral Equipment, NEC 35 Industrial And Commercial Machinery And Computer Equipment 
3578 Calculating & Accounting Machines (No Electronic Computers) 35 Industrial And Commercial Machinery And Computer Equipment 
3579 Office Machines, NEC 35 Industrial And Commercial Machinery And Computer Equipment 
3580 Refrigeration & Service Industry Machinery 35 Industrial And Commercial Machinery And Computer Equipment 
3585 Air-Cond & Warm Air Heatg Equip & Comm & Indl Refrig Equip 35 Industrial And Commercial Machinery And Computer Equipment 
3590 Misc Industrial & Commercial Machinery & Equipment 35 Industrial And Commercial Machinery And Computer Equipment 
3600 Electronic & Other Electrical Equipment (No Computer Equip) 36 
Electronic And Other Electrical Equipment And Components, Except Computer 
Equipment 
3612 Power, Distribution & Specialty Transformers 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3613 Switchgear & Switchboard Apparatus 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3620 Electrical Industrial Apparatus 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3621 Motors & Generators 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3630 Household Appliances 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3634 Electric Housewares & Fans 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3640 Electric Lighting & Wiring Equipment 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3651 Household Audio & Video Equipment 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3652 Phonograph Records & Prerecorded Audio Tapes & Disks 36 
Electronic And Other Electrical Equipment And Components, Except Computer 
Equipment 
3661 Telephone & Telegraph Apparatus 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3663 Radio & Tv Broadcasting & Communications Equipment 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3669 Communications Equipment, NEC 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3670 Electronic Components & Accessories 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3672 Printed Circuit Boards 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3674 Semiconductors & Related Devices 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3677 Electronic Coils, Transformers & Other Inductors 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3678 Electronic Connectors 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3679 Electronic Components, NEC 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3690 Miscellaneous Electrical Machinery, Equipment & Supplies 36 
Electronic And Other Electrical Equipment And Components, Except Computer 
Equipment 
3695 Magnetic & Optical Recording Media 36 Electronic And Other Electrical Equipment And Components, Except Computer Equipment 
3711 Motor Vehicles & Passenger Car Bodies 37 Transportation Equipment 
3713 Truck & Bus Bodies 37 Transportation Equipment 
3714 Motor Vehicle Parts & Accessories 37 Transportation Equipment 
3715 Truck Trailers 37 Transportation Equipment 
3716 Motor Homes 37 Transportation Equipment 
3720 Aircraft & Parts 37 Transportation Equipment 
3721 Aircraft 37 Transportation Equipment 
3724 Aircraft Engines & Engine Parts 37 Transportation Equipment 
3728 Aircraft Parts & Auxiliary Equipment, NEC 37 Transportation Equipment 
3730 Ship & Boat Building & Repairing 37 Transportation Equipment 
3743 Railroad Equipment 37 Transportation Equipment 
3751 Motorcycles, Bicycles & Parts 37 Transportation Equipment 
3760 Guided Missiles & Space Vehicles & Parts 37 Transportation Equipment 
3790 Miscellaneous Transportation Equipment 37 Transportation Equipment 
3812 Search, Detection, Navagation, Guidance, Aeronautical Sys 38 
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And 
Optical Goods; Watches And Clocks 
3821 Laboratory Apparatus & Furniture 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3822 Auto Controls For Regulating Residential & Comml Environments 38 
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And 
Optical Goods; Watches And Clocks 
3823 Industrial Instruments For Measurement, Display, and Control 38 
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And 
Optical Goods; Watches And Clocks 
3824 Totalizing Fluid Meters & Counting Devices 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3825 Instruments For Meas & Testing of Electricity & Elec Signals 38 
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And 
Optical Goods; Watches And Clocks 
3826 Laboratory Analytical Instruments 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3827 Optical Instruments & Lenses 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
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3829 Measuring & Controlling Devices, NEC 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3841 Surgical & Medical Instruments & Apparatus 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3843 Dental Equipment & Supplies 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3844 X-Ray Apparatus & Tubes & Related Irradiation Apparatus 38 
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And 
Optical Goods; Watches And Clocks 
3845 Electromedical & Electrotherapeutic Apparatus 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3851 Ophthalmic Goods 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3861 Photographic Equipment & Supplies 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3873 Watches, Clocks, Clockwork Operated Devices/Parts 38 Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks 
3910 Jewelry, Silverware & Plated Ware 39 Miscellaneous Manufacturing Industries 
3911 Jewelry, Precious Metal 39 Miscellaneous Manufacturing Industries 
3931 Musical Instruments 39 Miscellaneous Manufacturing Industries 
3942 Dolls & Stuffed Toys 39 Miscellaneous Manufacturing Industries 
3944 Games, Toys & Children's Vehicles (No Dolls & Bicycles) 39 Miscellaneous Manufacturing Industries 
3949 Sporting & Athletic Goods, NEC 39 Miscellaneous Manufacturing Industries 
3950 Pens, Pencils & Other Artists' Materials 39 Miscellaneous Manufacturing Industries 
3960 Costume Jewelry & Novelties 39 Miscellaneous Manufacturing Industries 
3990 Miscellaneous Manufacturing Industries 39 Miscellaneous Manufacturing Industries 
4011 Railroads, Line-Haul Operating 40 Railroad Transportation 
4013 Railroad Switching & Terminal Establishments 40 Railroad Transportation 
4100 Local & Suburban Transit & Interurban Hwy Passenger Trans 41 Local And Suburban Transit And Interurban Highway Passenger Transportation 
4210 Trucking & Courier Services (No Air) 42 Motor Freight Transportation And Warehousing 
4213 Trucking (No Local) 42 Motor Freight Transportation And Warehousing 
4220 Public Warehousing & Storage 42 Motor Freight Transportation And Warehousing 
4231 Terminal Maintenance Facilities For Motor Freight Transport 42 Motor Freight Transportation And Warehousing 
4400 Water Transportation 44 Water Transportation 
4412 Deep Sea Foreign Transportation of Freight 44 Water Transportation 
4512 Air Transportation, Scheduled 45 Transportation By Air 
4513 Air Courier Services 45 Transportation By Air 
4522 Air Transportation, Nonscheduled 45 Transportation By Air 
4581 Airports, Flying Fields & Airport Terminal Services 45 Transportation By Air 
4610 Pipe Lines (No Natural Gas) 46 Pipelines, Except Natural Gas 
4700 Transportation Services 47 Transportation Services 
4731 Arrangement of Transportation of Freight & Cargo 47 Transportation Services 
4812 Radiotelephone Communications 48 Communications 
4813 Telephone Communications (No Radiotelephone) 48 Communications 
4822 Telegraph & Other Message Communications 48 Communications 
4832 Radio Broadcasting Stations 48 Communications 
4833 Television Broadcasting Stations 48 Communications 
4841 Cable & Other Pay Television Services 48 Communications 
4899 Communications Services, NEC 48 Communications 
4900 Electric, Gas & Sanitary Services 49 Electric, Gas, And Sanitary Services 
4911 Electric Services 49 Electric, Gas, And Sanitary Services 
4922 Natural Gas Transmission 49 Electric, Gas, And Sanitary Services 
4923 Natural Gas Transmisison & Distribution 49 Electric, Gas, And Sanitary Services 
4924 Natural Gas Distribution 49 Electric, Gas, And Sanitary Services 
4931 Electric & Other Services Combined 49 Electric, Gas, And Sanitary Services 
4932 Gas & Other Services Combined 49 Electric, Gas, And Sanitary Services 
4941 Water Supply 49 Electric, Gas, And Sanitary Services 
4950 Sanitary Services 49 Electric, Gas, And Sanitary Services 
4953 Refuse Systems 49 Electric, Gas, And Sanitary Services 
4955 Hazardous Waste Management 49 Electric, Gas, And Sanitary Services 
4961 Steam & Air-Conditioning Supply 49 Electric, Gas, And Sanitary Services 
4991 Cogeneration Services & Small Power Producers 49 Electric, Gas, And Sanitary Services 
5000 Wholesale-Durable Goods 50 Wholesale Trade-durable Goods 
5010 Wholesale-Motor Vehicles & Motor Vehicle Parts & Supplies 50 Wholesale Trade-durable Goods 
5013 Wholesale-Motor Vehicle Supplies & New Parts 50 Wholesale Trade-durable Goods 
5020 Wholesale-Furniture & Home Furnishings 50 Wholesale Trade-durable Goods 
5030 Wholesale-Lumber & Other Construction Materials 50 Wholesale Trade-durable Goods 
5031 Wholesale-Lumber, Plywood, Millwork & Wood Panels 50 Wholesale Trade-durable Goods 
5040 Wholesale-Professional & Commercial Equipment & Supplies 50 Wholesale Trade-durable Goods 
5045 Wholesale-Computers & Peripheral Equipment & Software 50 Wholesale Trade-durable Goods 
5047 Wholesale-Medical, Dental & Hospital Equipment & Supplies 50 Wholesale Trade-durable Goods 
5050 Wholesale-Metals & Minerals (No Petroleum) 50 Wholesale Trade-durable Goods 
5051 Wholesale-Metals Service Centers & of fices 50 Wholesale Trade-durable Goods 
5063 Wholesale-Electrical Apparatus & Equipment, Wiring Supplies 50 Wholesale Trade-durable Goods 
5064 Wholesale-Electrical Appliances, Tv & Radio Sets 50 Wholesale Trade-durable Goods 
5065 Wholesale-Electronic Parts & Equipment, NEC 50 Wholesale Trade-durable Goods 
5070 Wholesale-Hardware & Plumbing & Heating Equipment & Supplies 50 Wholesale Trade-durable Goods 
5072 Wholesale-Hardware 50 Wholesale Trade-durable Goods 
5080 Wholesale-Machinery, Equipment & Supplies 50 Wholesale Trade-durable Goods 
5082 Wholesale-Construction & Mining (No Petro) Machinery & Equip 50 Wholesale Trade-durable Goods 
5084 Wholesale-Industrial Machinery & Equipment 50 Wholesale Trade-durable Goods 
5090 Wholesale-Misc Durable Goods 50 Wholesale Trade-durable Goods 
5094 Wholesale-Jewelry, Watches, Precious Stones & Metals 50 Wholesale Trade-durable Goods 
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5099 Wholesale-Durable Goods, NEC 50 Wholesale Trade-durable Goods 
5110 Wholesale-Paper & Paper Products 51 Wholesale Trade-non-durable Goods 
5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries 51 Wholesale Trade-non-durable Goods 
5130 Wholesale-Apparel, Piece Goods & Notions 51 Wholesale Trade-non-durable Goods 
5140 Wholesale-Groceries & Related Products 51 Wholesale Trade-non-durable Goods 
5141 Wholesale-Groceries, General Line 51 Wholesale Trade-non-durable Goods 
5150 Wholesale-Farm Product Raw Materials 51 Wholesale Trade-non-durable Goods 
5160 Wholesale-Chemicals & Allied Products 51 Wholesale Trade-non-durable Goods 
5171 Wholesale-Petroleum Bulk Stations & Terminals 51 Wholesale Trade-non-durable Goods 
5172 Wholesale-Petroleum & Petroleum Products (No Bulk Stations) 51 Wholesale Trade-non-durable Goods 
5180 Wholesale-Beer, Wine & Distilled Alcoholic Beverages 51 Wholesale Trade-non-durable Goods 
5190 Wholesale-Miscellaneous Nondurable Goods 51 Wholesale Trade-non-durable Goods 
5200 Retail-Building Materials, Hardware, Garden Supply 52 Building Materials, Hardware, Garden Supply, And Mobile Home Dealers 
5211 Retail-Lumber & Other Building Materials Dealers 52 Building Materials, Hardware, Garden Supply, And Mobile Home Dealers 
5271 Retail-Mobile Home Dealers 52 Building Materials, Hardware, Garden Supply, And Mobile Home Dealers 
5311 Retail-Department Stores 53 General Merchandise Stores 
5331 Retail-Variety Stores 53 General Merchandise Stores 
5399 Retail-Misc General Merchandise Stores 53 General Merchandise Stores 
5400 Retail-Food Stores 54 Food Stores 
5411 Retail-Grocery Stores 54 Food Stores 
5412 Retail-Convenience Stores 54 Food Stores 
5500 Retail-Auto Dealers & Gasoline Stations 55 Automotive Dealers And Gasoline Service Stations 
5531 Retail-Auto & Home Supply Stores 55 Automotive Dealers And Gasoline Service Stations 
5600 Retail-Apparel & Accessory Stores 56 Apparel And Accessory Stores 
5621 Retail-Women's Clothing Stores 56 Apparel And Accessory Stores 
5651 Retail-Family Clothing Stores 56 Apparel And Accessory Stores 
5661 Retail-Shoe Stores 56 Apparel And Accessory Stores 
5700 Retail-Home Furniture, Furnishings & Equipment Stores 57 Home Furniture, Furnishings, And Equipment Stores 
5712 Retail-Furniture Stores 57 Home Furniture, Furnishings, And Equipment Stores 
5731 Retail-Radio, Tv & Consumer Electronics Stores 57 Home Furniture, Furnishings, And Equipment Stores 
5734 Retail-Computer & Computer Software Stores 57 Home Furniture, Furnishings, And Equipment Stores 
5735 Retail-Record & Prerecorded Tape Stores 57 Home Furniture, Furnishings, And Equipment Stores 
5810 Retail-Eating & Drinking Places 58 Eating And Drinking Places 
5812 Retail-Eating Places 58 Eating And Drinking Places 
5900 Retail-Miscellaneous Retail 59 Miscellaneous Retail 
5912 Retail-Drug Stores and Proprietary Stores 59 Miscellaneous Retail 
5940 Retail-Miscellaneous Shopping Goods Stores 59 Miscellaneous Retail 
5944 Retail-Jewelry Stores 59 Miscellaneous Retail 
5945 Retail-Hobby, Toy & Game Shops 59 Miscellaneous Retail 
5960 Retail-Nonstore Retailers 59 Miscellaneous Retail 
5961 Retail-Catalog & Mail-Order Houses 59 Miscellaneous Retail 
5990 Retail-Retail Stores, NEC 59 Miscellaneous Retail 
6021 National Commercial Banks 60 Depository Institutions 
6022 State Commercial Banks 60 Depository Institutions 
6029 Commercial Banks, NEC 60 Depository Institutions 
6035 Savings Institution, Federally Chartered 60 Depository Institutions 
6036 Savings Institutions, Not Federally Chartered 60 Depository Institutions 
6099 Functions Related To Depository Banking, NEC 60 Depository Institutions 
6111 Federal & Federally-Sponsored Credit Agencies 61 Non-depository Credit Institutions 
6141 Personal Credit Institutions 61 Non-depository Credit Institutions 
6153 Short-Term Business Credit Institutions 61 Non-depository Credit Institutions 
6159 Miscellaneous Business Credit Institution 61 Non-depository Credit Institutions 
6162 Mortgage Bankers & Loan Correspondents 61 Non-depository Credit Institutions 
6163 Loan Brokers 61 Non-depository Credit Institutions 
6172 Finance Lessors 61 Non-depository Credit Institutions 
6189 Asset-Backed Securities 61 Non-depository Credit Institutions 
6199 Finance Services 61 Non-depository Credit Institutions 
6200 Security & Commodity Brokers, Dealers, Exchanges & Services 62 Security And Commodity Brokers, Dealers, Exchanges, And Services 
6211 Security Brokers, Dealers & Flotation Companies 62 Security And Commodity Brokers, Dealers, Exchanges, And Services 
6221 Commodity Contracts Brokers & Dealers 62 Security And Commodity Brokers, Dealers, Exchanges, And Services 
6282 Investment Advice 62 Security And Commodity Brokers, Dealers, Exchanges, And Services 
6311 Life Insurance 63 Insurance Carriers 
6321 Accident & Health Insurance 63 Insurance Carriers 
6324 Hospital & Medical Service Plans 63 Insurance Carriers 
6331 Fire, Marine & Casualty Insurance 63 Insurance Carriers 
6351 Surety Insurance 63 Insurance Carriers 
6361 Title Insurance 63 Insurance Carriers 
6399 Insurance Carriers, NEC 63 Insurance Carriers 
6411 Insurance Agents, Brokers & Service 64 Insurance Agents, Brokers, And Service 
6500 Real Estate 65 Real Estate 
6510 Real Estate Operators (No Developers) & Lessors 65 Real Estate 
6512 Operators of Nonresidential Buildings 65 Real Estate 
6513 Operators of Apartment Buildings 65 Real Estate 
6519 Lessors of Real Property, NEC 65 Real Estate 
6531 Real Estate Agents & Managers (For Others) 65 Real Estate 
6532 Real Estate Dealers (For Their Own Account) 65 Real Estate 
6552 Land Subdividers & Developers (No Cemeteries) 65 Real Estate 
6770 Blank Checks 67 Holding And Other Investment Offices 
6792 Oil Royalty Traders 67 Holding And Other Investment Offices 
6794 Patent Owners & Lessors 67 Holding And Other Investment Offices 
6795 Mineral Royalty Traders 67 Holding And Other Investment Offices 
6798 Real Estate Investment Trusts 67 Holding And Other Investment Offices 
6799 Investors, NEC 67 Holding And Other Investment Offices 
7000 Hotels, Rooming Houses, Camps & Other Lodging Places 70 Hotels, Rooming Houses, Camps, And Other Lodging Places 
7011 Hotels & Motels 70 Hotels, Rooming Houses, Camps, And Other Lodging Places 
7200 Services-Personal Services 72 Personal Services 
7310 Services-Advertising 73 Business Services 
7311 Services-Advertising Agencies 73 Business Services 
7320 Services-Consumer Credit Reporting, Collection Agencies 73 Business Services 
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7330 Services-Mailing, Reproduction, Commercial Art & Photography 73 Business Services 
7331 Services-Direct Mail Advertising Services 73 Business Services 
7340 Services-To Dwellings & Other Buildings 73 Business Services 
7350 Services-Miscellaneous Equipment Rental & Leasing 73 Business Services 
7359 Services-Equipment Rental & Leasing, NEC 73 Business Services 
7361 Services-Employment Agencies 73 Business Services 
7363 Services-Help Supply Services 73 Business Services 
7370 Services-Computer Programming, Data Processing, Etc. 73 Business Services 
7371 Services-Computer Programming Services 73 Business Services 
7372 Services-Prepackaged Software 73 Business Services 
7373 Services-Computer Integrated Systems Design 73 Business Services 
7374 Services-Computer Processing & Data Preparation 73 Business Services 
7377 Services-Computer Rental & Leasing 73 Business Services 
7380 Services-Miscellaneous Business Services 73 Business Services 
7381 Services-Detective, Guard & Armored Car Services 73 Business Services 
7384 Services-Photofinishing Laboratories 73 Business Services 
7385 Services-Telephone Interconnect Systems 73 Business Services 
7389 Services-Business Services, NEC 73 Business Services 
7500 Services-Automotive Repair, Services & Parking 75 Automotive Repair, Services, And Parking 
7510 Services-Auto Rental & Leasing (No Drivers) 75 Automotive Repair, Services, And Parking 
7600 Services-Miscellaneous Repair Services 76 Miscellaneous Repair Services 
7812 Services-Motion Picture & Video Tape Production 78 Motion Pictures 
7819 Services-Allied To Motion Picture Production 78 Motion Pictures 
7822 Services-Motion Picture & Video Tape Distribution 78 Motion Pictures 
7829 Services-Allied To Motion Picture Distribution 78 Motion Pictures 
7830 Services-Motion Picture Theaters 78 Motion Pictures 
7841 Services-Video Tape Rental 78 Motion Pictures 
7900 Services-Amusement & Recreation Services 79 Amusement And Recreation Services 
7948 Services-Racing, Including Track Operation 79 Amusement And Recreation Services 
7990 Services-Miscellaneous Amusement & Recreation 79 Amusement And Recreation Services 
7997 Services-Membership Sports & Recreation Clubs 79 Amusement And Recreation Services 
8000 Services-Health Services 80 Health Services 
8011 Services-Offices & Clinics of Doctors of Medicine 80 Health Services 
8050 Services-Nursing & Personal Care Facilities 80 Health Services 
8051 Services-Skilled Nursing Care Facilities 80 Health Services 
8060 Services-Hospitals 80 Health Services 
8062 Services-General Medical & Surgical Hospitals, NEC 80 Health Services 
8071 Services-Medical Laboratories 80 Health Services 
8082 Services-Home Health Care Services 80 Health Services 
8090 Services-Misc Health & Allied Services, NEC 80 Health Services 
8093 Services-Specialty Outpatient Facilities, NEC 80 Health Services 
8111 Services-Legal Services 81 Legal Services 
8200 Services-Educational Services 82 Educational Services 
8300 Services-Social Services 83 Social Services 
8351 Services-Child Day Care Services 83 Social Services 
8600 Services-Membership or ganizations 86 Membership Organizations 
8700 Services-Engineering, Accounting, Research, Management 87 Engineering, Accounting, Research, Management, And Related Services 
8711 Services-Engineering Services 87 Engineering, Accounting, Research, Management, And Related Services 
8731 Services-Commercial Physical & Biological Research 87 Engineering, Accounting, Research, Management, And Related Services 
8734 Services-Testing Laboratories 87 Engineering, Accounting, Research, Management, And Related Services 
8741 Services-Management Services 87 Engineering, Accounting, Research, Management, And Related Services 
8742 Services-Management Consulting Services 87 Engineering, Accounting, Research, Management, And Related Services 
8744 Services-Facilities Support Management Services 87 Engineering, Accounting, Research, Management, And Related Services 
8880 American Depositary Receipts 88 Private Households 
8888 Foreign Governments 88 Private Households 
8900 Services-Services, NEC 89 Miscellaneous Services 
9721 International Affairs 97 National Security And International Affairs 
9995 Non-Operating Establishments 99 Nonclassifiable Establishments 
    
    
Note: 1.SIC descriptions are taken from http://www.sec.gov/info/edgar/siccodes.htm 
 2.Group descriptions are from http://www.osha.gov/pls/imis/sic_manual.html 
 
